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Abstract
Personalised medicine for cancer treatment promises benefits for patient
survival and effective use of medical resources. This goal requires the development
of predictive models for the identification and implementation of biomarkers for the
prediction of patient survival given treatment options. This thesis addresses research
questions in this area.
The systematic review detailed in Chapter 2 investigates the literature con-
cerning the prediction of resistance to chemotherapy for ovarian cancer patients using
statistical methods and gene expression measurements. The range of models used by
studies in the systematic review highlights the popularity of traditional models, such
as Cox proportional hazards, with few more complex models being utilised.
In Chapters 3 and 4, new methods are presented for modelling right-censored
survival data. Due to the nature of biomedical data, the methods used need to be
flexible and adequately account for high dimensional, noisy data. Gaussian processes
fulfil these requirements and were hence used for the development of three Gaussian
process models for right-censored survival data. Chapter 3 details these models, and
they are applied to synthetic and cancer data in Chapter 4. In all cases the Gaussian
processes for survival were found to equal or outperform all comparison models, as
measured by concordance index.
Given the application to molecular cancer data, it was expected that the
data would be high dimensional. Two feature selection methods are investigated in
Chapter 5 for use with Gaussian processes to address this.
In Chapter 6 a program is developed for the analysis of the data produced
by a test for cancer mutations using qPCR. The automated program was designed
to isolate the analysis from the user and produce results and reports for clinical
use. It is observed that this approach of automated analysis would be suitable for
application to any form of clinical test or complex predictive model without the
requirement of user guidance.
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Chapter 1
Introduction
The thesis presented here addresses research questions relating to personalised
medicine for cancer and the application of tools to predict patient survival in a
clinical setting. Gaussian process models developed to infer survival outcomes are
introduced, implemented and tested. These models are investigated in the context
of oncology patient survival, using molecular and clinical data. Also introduced are
two feature selection techniques applied to Gaussian processes for use with these
high-dimensional data. Additionally, a published systematic review is presented,
investigating the prediction of treatment response in ovarian cancer, and a program
for the analysis of qPCR-based mutation testing data for clinical use is detailed.
1.1 Oncogenesis
The average rate of cancer incidence in England was 595.8 per 100 000 people in
2015 [44], with an average 5-year age-standardised mortality rate of 59% for patients
diagnosed between 2010 and 2014 and followed up to 2015 [10]. In the Cancer
Registration Statistics bulletin [44] released by the Office for National Statistics in
2017, it was observed that although on average ‘cancer mortality rates have generally
decreased over time, despite the increase in cancer incidence’, this trend is not
observed across all cancer types. For example, whereas breast and prostate cancer
mortality rates have fallen, this trend is not found for lung cancer in women, pancreas
and larynx in men [2]. For breast and prostate cancer, increase in incidence and
decrease in mortality both may be attributed in part to improvement in diagnostic
tools: the national breast screening program for women aged 50 to 70, and more
widespread use of the prostate-specific antigen test in older men [43]. Additionally,
it is observed that response to breast cancer treatment may be dependent on ER
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and HER2 status, and treatments are recommended to differ based on this [112]. It
is therefore clear that the development of diagnostic and treatment-specific tools is
of great importance to the decrease in cancer mortality rates.
Cancer is characterised by uncontrolled replication of cells [82]. In a ‘normal’
cell, there are a range of processes that monitor and control the vital cellular
mechanisms such as growth, division, and metabolism. These control processes
prevent the cell from unconstrained responses that, whilst beneficial for the individual
cell and its descendents, may be deleterious to the organism as a whole. When these
processes are hindered, therefore, the cell may undergo unrestrained growth, for
example [159]. It is interesting that, given deactivation of genetic stability control
processes, mutations become more common, often resulting in the deactivation of
further processes [93].
The causes of cancer are still a highly active research area, but it is generally
accepted that DNA mutations play a key role in oncogenesis [23]. Cellular proteins
are produced from amino acids and peptides using DNA as a template. Any damage
in this template, therefore, will result in changes in the proteins produced. Depending
on the magnitude of the change, the protein may become non-functional, or the
function may change. It is thought that, due to mutations, cancerous cells have DNA
that does not code for the original proteins, causing alterations in cellular processes
and changes in rates of cell growth, replication, and death. For example, the loss of
function of proteins involved in important monitoring processes may allow cells to
grow and replicate uncontrollably.
There are types of genes, known as oncogenes and tumour-suppressor genes,
that are particularly important in oncogenesis [82]. Oncogenes are identified as
those that, when activated, promote cancer. These genes are usually inactive or
active at a low level but when they are activated, for example via a change of
function mutation or somatic copy number mutation, they produce cancer-promoting
products or overexpress normal products. Many oncogenes, for example RAS [95],
start as proto-oncogenes and perform a cellular function before activation to become
an oncogene. Tumour suppressor genes code for proteins involved in inhibitory
pathways that control the cell cycle or apoptosis. Mutations in these genes may lead
to loss of function in proteins and hence lack of regulation. For example, p53, a
gene coding for a protein strongly linked to cell cycle arrest and apoptosis, conveys
protection against the proliferation of cancerous cells and is found to be mutated in
a large proportion of tumour types [143].
The genetic locations of any mutations present in the genome are therefore
of interest, as knowledge of the ‘turned off’ processes may allow patterns in tumour
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Figure 1.1: An outline of personalised medicine. The patient population is expected
to have varying disease characteristics. For each patient, disease and patient-specific
measurements are taken and passed to the model. The model makes predictions
which may be used to make actionable recommendations for treatment guidance.
development to be predicted.
1.2 Personalised medicine for cancer
Cancer is highly heterogeneous, both in development and treatment response [97].
This is partially due to the high variation in mutations present in different cancers,
and even within tumours, and presents challenges for treatment [97]. Personalised
medicine proposes that, following testing, treatments should be selected based on
tumour-specific characteristics [65]. Currently, the NHS is starting to phase in
mutation testing for a small range of cancers, for example non-small-cell lung cancer
[108, 106, 111] and metastatic melanoma [110, 109], but this is limited in terms
of both tests and the available treatment choices. However, the NHS Personalised
Medicine Strategy is aiming for personalised medicine in cancer to be started to be
implemented by 2020 [1], presenting the need for tests and analysis tools capable of
much higher throughput and complex analysis. Figure 1.1 shows a diagram depicting
the application of personalised medicine.
Prognosis is defined as the ‘likely outcome or course of a disease; the chance of
recovery or recurrence’ [5]. Prognostic models and biomarkers are therefore those that
predict patient survival using relevant clinical and non-clinical information. These
models, however, do not take treatments and interventions into account. Models and
biomarkers predicting survival, given a certain therapy are referred to as predictive.
Prognostic models are a special case of predictive models, given no treatment.
For example, consider two biomarkers: prostate specific antigen (PSA) as
a biomarker for prostate cancer survival, and EGFR mutation status for survival
following erlotinib maintenance treatment for advanced non–small-cell lung cancer
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[13]. In the first case, PSA expression is used as a prognostic biomarker whereby high
expression predicts short survival times, but does not influence treatment choice. By
contrast, in the second case the presence or absence of an EGFR mutation is used as
a predictive biomarker whereby the presence predicts better response to erlotinib, but
the survival estimate is also dependent on the treatment. Considering the discrete
case for simplicity, for the prognostic biomarker there are only two possible cases
– biomarker positive or biomarker negative – whereas for the predictive biomarker
there are four, due to the binary nature of both the biomarker and treatment use.
In this way, predictive biomarkers are capable of incorporating more information
than prognostic biomarkers when utilised for treatment selection.
Similarly, models may be prognostic or predictive. Clinically, the two model
types are often used differently [160]. Prognostic models are often based on non-
disease-related information and used at an early time point to predict patient survival
or disease progression. Measurements used in these models may include factors such
as age or whether a patient smokes. Predictions using these models may provide
assistance when considering options such as watchful waiting or surgery [160]. By
contrast, predictive models can be used to predict patient survival under the influence
of a treatment or intervention. For example, the Mammaprint
TM
gene signature
[146] uses the expression of 70 genes and HER status to predict breast cancer patient
likelihood of metastasis and the utility of chemotherapy.
1.3 Prediction of response to cancer treatment
Resistance to chemotherapy is a well documented response, and treatment plans
usually account for this eventuality when recommending therapies [28]. For advanced
stage ovarian cancer, for example, NICE recommends platinum-based first-line
treatment either alone or in combination with paclitaxel [105]. However, dependent
on the response to platinum-based therapy, second line treatments are more varied,
as treatment of a platinum-resistant tumour with platinum-based therapy would not
be successful.
There are two key proposed mechanisms by which cancers become treatment
resistant. First, as therapies are designed to kill tumour cells, there is an element of
clonal selection. It is suggested that, given a group of tumour cells with a variety
of mutations, those that survive chemotherapy will later form the tumour present
at second-line treatment [56]. For example, in BRCA mutated cancer, a second
BRCA mutation has been seen to restore BRCA functionality and improve DNA
repair, counteracting the mechanism of action of platinum-based treatments [94].
4
For treatments such as anti-estrogen treatment for breast cancer, loss of estrogen
receptors has been observed, removing the drug target and hence preventing cell
death [79].
An alternative route of chemotherapy resistance is through changes in gene
expression, for example via altered epigenetics, allowing the up and down-regulation
of pathways relating to cell survival [56]. There are a range of mechanisms by which
protection may be inferred, including increased DNA repair, increased drug pumps
and detox, reduction in drug target, decreased apoptosis, and increased proliferation
[54].
It is expected that knowledge of mutations and gene expression levels may
allow the prediction of patient response to chemotherapy. If this is the case, treatment
pathways may be personalised and treatments to which patient response would not
be optimal may be avoided, greatly improving survival and patient quality of life.
1.4 Statistical modelling and machine learning
Given the volume of data often available about a given cancer patient, there is
great potential value in developing tools that can produce clinically actionable
recommendations. These tools should be capable of taking in data and producing a
personalised recommendation for a patient, enabling clinical decisions to be made.
These tools would involve the application of a statistical or mathematical model,
allowing underlying trends in the data to be identified and utilised for prediction.
In this context, statistical models may be very useful; given potentially noisy
data and assuming a given probability distribution, they may predict likely outcomes
[99]. For example, given data and outcomes X and y, a linear regression formulation
calculates the optimum model parameters β such that the fit is optimised and hence
the relationship is decided to be y = Xβ +  [104], where  is Gaussian noise. For
this model, the relationship is pre-determined to be linear, errors are assumed to
be uncorrelated and normally distributed, as are the covariates, as well as further
assumptions.
In contexts with small numbers of variables, and where the underlying data-
generating mechanisms are thought to be understood, well-defined models such as
linear regression have great utility. However, these models do not generalise well to
situations where relationships between variables are not known or are complex. In
the context of molecular cancer data and similar biological measurements, models
capable of more complex relationships between variables and outcome are therefore
required.
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Figure 1.2: a) Functions randomly drawn from a GP prior. b) Functions randomly
drawn from a GP posterior, given data X. Data points are marked as dots, the
predicted mean is marked as a dotted line. The shaded area represents the 95%
confidence interval (2 standard deviations from the predicted mean). Based on
Figure 2.2 from Rasmussen and Williams [127].
Many machine learning methods offer flexibility and the ability to identify
patterns in data [104]. Additionally, as with some statistical models, the predictions
produced by some machine learning methods may be probabilistic. This has the
benefit of allowing the confidence in the predicted values to be determined, which
would clearly be of use in clinical contexts. Models such as Gaussian processes
provide the benefits of both statistical and machine learning techniques, and hence
are particularly suitable for use with complex, noisy medical data.
Gaussian processes consider the function f(x) as coming from the space of
functions relating features to outcome, y = f(x) + , subject to a prior constraining
f(x) to have certain qualities, such as smoothness and stationarity [127]. Given the
data, they provide a posterior distribution on the possible functions. In this way, the
properties of the possible functions may be used to predict the posterior mean and
variance for given test x∗ values. For Gaussian processes the prior is determined by
the choice of covariance and mean functions, and the associated hyperparameters.
Given two data points x1 and x2, the covariance and mean functions define how
similar the values of the function, f(x1) and f(x2), must be.
The effect of conditioning the prior using the data X may be seen in Figure 1.2,
where functions drawn randomly from the prior and posterior are shown.
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Figure 1.3: Illustration of right-censored survival times. Censored times are marked
with dots, uncensored times as crosses. The unknown true survival times for the
censored samples will be further to the right than the censored times; the censored
times act as minimum values for the true times.
1.5 Modelling and predicting survival outcomes
Medical studies involving patients often produce survival data. Generally, all patients
enter the study at a measurable time, t0, and the required measurements are recorded
as the study progresses. The patients are monitored for the occurrence of a pre-
defined event, examples of which could be death, disease progression or relapse. If
this event occurs, the time at which this happens is recorded for each patient, te.
These times are referred to as survival times. Traditionally, when incorporated into
a model these survival times are given the label y and are also known as targets.
The measured variables, also known as features, are assigned the label X.
It is common in studies involving patients for a number of patients to drop out
before the end of the study. This may be due to a variety of reasons and results in the
patient being lost to follow-up for the remainder of the study time. Data X for these
patients will normally have already been collected, so the data are not discarded; the
survival time is instead considered to be right-censored. A right-censored survival
time is the time at which the patient was last seen, and provides a lower bound for
the unknown date of event occurrence, tc ≤ te. Censored survival data are depicted
in Figure 1.3.
For a data set containing multiple patients, survival data therefore consists
of survival times y, measured variables X, and whether each patient underwent the
event, e.
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Currently in the literature there are many commonly used models for survival
data. The most popular of these, Cox proportional hazards regression [29], relies
on the assumption that the risk of outcome is proportional to the exponential of a
linear combination of the covariates [40]. This assumption allows the proportionality
constant, the baseline hazard, to be disregarded. This approach is sensible when con-
sidering hazard ratios, as the baseline hazard will cancel. However, when attempting
to use Cox proportional hazards regression predictively, the baseline hazard may
become problematic to estimate. Other popular methods include accelerated failure
time models [163] and gradient boosted machines [138].
Whilst these models are well researched and frequently used, in the context
of medical molecular data it becomes increasingly necessary for machine learning
techniques to be available for survival data. Gaussian processes provide a range
of existing, well researched approaches and techniques for modelling data from a
range of contexts. Regression and classification are routinely applied for real and
categorical outcomes. Due to their flexibility, ability to work with high dimensional
data, and inherent ability to account for noisy data, Gaussian processes would be
an ideal tool for medical research data analysis. However, Gaussian processes for
survival data are a lesser researched topic.
An approach to Gaussian processes for survival data is considered here in
Chapter 3. Given the form of right-censored survival data, it is sensible to consider
censored times as partially missing outcomes, with the censored time acting as a
lower bound on the possible values. Gaussian processes are therefore used to place a
prior on the space of functions relating features to outcomes, with the aim of inferring
the missing values. This approach attempts to predict the underlying, non-censored
outcomes using information from both the uncensored and censored samples.
1.6 Cancer patient data and measurements
As medical data, the measurements relevant in cancer research involve various clinical
features. Research is usually separated by the primary tumour site, as it is well
observed that cancers in different sites progress very differently [70]. Stage and
grade are often reported, and both are used as measures of tumour progression.
Cancer stage takes into account tumour size and location, whether lymph nodes are
involved, and whether the primary tumour has metastasised [4]. For most cancers,
stages range from 1 to 4, with some also having stage 0. Tumour grade is a measure
of the level of similarity between the tumour tissue and normal cells for the site,
where the normal cells are well-differentiated [6]. It is expected that as the cancer
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progresses cells will undergo anaplasia, whereby they revert to an undifferentiated
state. Undifferentiated cells are known to grow and divide faster, and hence would
lead to faster tumour growth and metastasis [6]. Other measurements of interest
include age, previous treatments, and relevant site-specific biomarker levels, such as
BRCA1/BRCA2, HER2, CA-125, PSA and CEA.
Mutation analysis is highly relevant in cancer research. This requires a
method of sequencing, to identify the order of bases that make up the DNA of the
genes of interest. Two common techniques are next generation sequencing, and
the quantitative polymerase chain reaction (qPCR). Next generation sequencing
provides a platform to generate large amounts of sequence data without requiring
prior knowledge of likely mutations. By contrast, qPCR methods are more targeted,
with a list of mutations being tested, but are often faster and cheaper to run.
Gene expression is often also of interest in cancer studies and involves measur-
ing the levels of mRNA within cells. Due to the central dogma - DNA is transcribed
to mRNA, which is translated to proteins - measuring the levels of mRNA allows
the required levels of protein to be inferred [83]. As cancer cells up-regulate pro-
cesses that aid their survival and down-regulate those that would impose control
mechanisms, the levels of expression of a wide range of genes are expected to be
abnormal in cancer cells [132]. It is therefore reasonable to expect that knowledge
of gene expression may provide information on the status and likely trajectory of
cancer development and response to treatment. Gene expression is often measured
via qPCR, with common commercial kits providing measurements of around 20 000
genes [36]. These data are therefore very high dimensional.
1.7 Feature selection
Due to the often high-dimensionality of cancer data, feature selection is often applied.
This method involves the identification of important and informative features, and
the removal of those that are deemed unnecessary.
Although the addition of features would be expected to increase the infor-
mation available, the inclusion of many dimensions of data into a model may cause
computational and statistical issues, due to the ‘curse of dimensionality’ [17]: as the
number of features increases the volume of the feature space grows exponentially,
and the samples become increasingly sparse, and often unevenly distributed though
the space. Moreover, the inclusion of additional features inherently adds noise, which
for features with little predictive value may outweigh the added signal. Therefore,
in order to obtain better predictions, it may be useful to remove non-informative
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features, reducing the dimensionality of the data set.
Feature selection procedures fall into three categories [58]: filter, wrapper
and embedded. Filter methods act as a preprocessing step, implemented before
the chosen model, and result in the removal of unwanted features to reduce the
dimensionality of data input to the model. Filtering procedures include statistical
tests for correlation between feature and outcome, and retaining a pre-defined set of
features thought to be informative by mechanistic insight.
Wrapper methods consist of the identification of a series of feature subsets, and
repeated model fitting using these feature subsets. Model fit is assessed using a chosen
score, such as Akaike information criterion (AIC), Bayesian information criterion
(BIC) or correlation between predictions and true values, and the suitability of the
feature set is recorded. These methods may use any model for the underlying fitting.
Popular wrapper methods include stepwise feature selection, genetic algorithms and
simulated annealing. Wrapper methods are often found to be computationally costly,
due to the repeated application of the model.
Finally, embedded methods are incorporated into the model itself. These
methods include l1-regularization techniques such as elastic net penalisation for gener-
alised linear models [45], decision trees such as Random Forest [20] and the automatic
relevance determination kernel for Gaussian processes [127]. Embedded methods
require that the whole data set is passed to the model, and hence dimensionality
reduction is not usually possible. However, the embedded feature selection typically
increases the model complexity, which brings with it challenges for computation and
inference.
One simple form of feature selection is the identification of a set of interesting
features before data interrogation, using prior knowledge of the real-life context. For
medical data, this could be the underlying disease mechanisms or known responses to
treatment. In Chapter 4, two gene lists are specified using biological knowledge from
literature. The first was composed of genes identified as mechanistically relevant
to chemoresistance in ovarian cancer. The second consists of genes found to be
predictive by two or more studies identified during a systematic review of the
literature concerning the prediction of resistance to chemotherapy in ovarian cancer
using gene expression, shown in Chapter 2. These gene sets were used in Chapter 4
for feature selection of high dimensional gene expression data sets prior to model
fitting.
For Gaussian processes, emphasis is often placed on the computational de-
pendence on the number of samples. However, computational complexity is also
typically dependent on the number of dimensions, though the covariance function. It
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is therefore important that the number of dimensions be reduced, both to alleviate
the curse of dimensionality and improve run time.
Feature selection for Gaussian processes is not a widely studied area and
there are few general methods for feature selection with Gaussian processes. The
automatic relevance determination (ARD) covariance function is a highly used ap-
proach to feature selection [127]. This covariance function involves a hyperparameter
per feature, and by varying these hyperparameters the relationship between each
feature and the response may be changed. However, due to the large number of
hyperparameters this method may be prone to overfitting. Many alternative methods
implement modifications of a spike-and-slab prior (notably described by George and
McCulloch [49]) on the ARD covariance function [89, 135, 136], with the aim of
setting features as constant. Other techniques tend to employ Gaussian processes
as a component of a more complex feature selection procedure [122, 123, 26]. It
is therefore of interest to investigate feature selection in the context of Gaussian
processes.
In Chapter 5, two feature selection methods for Gaussian processes are inves-
tigated. The first method, an embedded method, takes the form of a modification
of the ARD kernel. This method utilises prior knowledge of feature similarity and
relevance to group features and reduces the resulting number of model hyperparam-
eters. The second method acts as a wrapper to allow Bayesian model averaging
using randomly selected feature subsets. The resulting models are used to produce
ensemble predictions, greatly reducing the computational requirements compared to
the full, all-features model.
1.8 Thesis chapters
The chapters of this thesis are as follows:
Chapter 2 details a published systematic review into the literature concerning
the prediction of resistance to chemotherapy in ovarian cancer using gene expression
measurements.
Chapter 3 introduces three Gaussian process models designed to model
censored survival times as partially missing outcomes, using covariates to place
Gaussian process priors on the space of all functions relating covariates to outcome.
These models are implemented and investigated using synthetic and molecular data
sets in Chapter 4. They are observed to have equal or superior predictive ability
compared to commonly used alternative models.
Two feature selection procedures for Gaussian processes are introduced and
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implemented in Chapter 5. The two methods are tested using synthetic and molecular
data sets and again compared to suitable alternative models. These methods were
observed to have equal predictive ability to the comparison models.
Chapter 6 describes an interactive analysis program developed to analyse data
produced by DNA-expression-based cancer mutation testing, and produce reports for
clinical use detailing the mutations observed. This program applies traditional q-PCR
analysis techniques, and these are carried out in a stand-alone manner, allowing the
analysis to be carried out reliably and without the requirement of knowledge of the
process.
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Chapter 2
Systematic Review: Prediction
of resistance to chemotherapy in
ovarian cancer
This chapter presents a systematic review that investigates the literature concerning
the prediction of resistance to chemotherapy in ovarian cancer using gene expression
measurements. Following data compilation, some analysis was then conducted to
assess the reliability, applicability and conclusions of the included studies, both on a
study-by-study basis and as meta-analysis.
A version of this work has been published as [92]:
Katherine L Lloyd, Ian A Cree, and Richard S Savage. Prediction of resistance to
chemotherapy in ovarian cancer: a systematic review. BMC Cancer, 15(1): 117,
2015.
Ian Cree and Richard Savage conceived and planned the study. Literature
searches and analysis were carried out by Katherine Lloyd.
2.1 Introduction
2.1.1 Systematic Review
When starting research into a new topic, it is vital to gain a comprehensive view of
the existing literature. The benefits of this approach are two-fold. Firstly, this allows
the breadth and thoroughness of existing research into the topic of interest to be seen.
In this way, gaps in the literature and hence prospective research areas become clear.
Secondly, a thorough investigation of the existing literature provides an opportunity
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to assess the success of existing studies. It is important that study effectiveness,
bias and limitations are acknowledged when compiling conclusions based on existing
literature. In addition, knowledge of the strengths and shortcomings of previous
work should also guide the defining of a research area.
Rather than a general literature review, here it was decided that a systematic
review was appropriate, as this format allows a narrow question to be investigated
thoroughly. Due to the availability of publication databases, comprehensive literature
searches are also increasingly feasible and simple to perform.
When carrying out a systematic review, a basic set of steps are followed. This
structured approach allows the results to be reproducible and hence provides support
to conclusions drawn following meta-analysis. As listed by Khan et al. [80], the five
steps are:
• Framing the question
• Identifying relevant publications
• Assessing study quality
• Summarising the evidence
• Interpreting the findings
Following the identification of a focused, definable research question, search
terms for the databases of choice are developed. These terms are modified to provide
a list of papers that is hoped to be complete and exhaustive, without becoming too
general. Once the searches are carried out, the list of papers is then filtered, by
reading and checking that the search criteria are fulfilled. For speed, this is often
carried out twice, initially using abstracts and again using full articles. Any papers
found not to fulfil the search criteria are rejected and discounted from further analysis.
The gathered papers are then assessed in detail. Methodological aspects and results
are compiled for analysis, both on a paper-by-paper basis and as meta-analysis,
allowing conclusions to be drawn. Acknowledgement of possible bias and limitations
of studies are also important here, as this will affect the confidence put in results
and conclusions.
2.1.2 Research Question
Gene expression based tools for the prediction of patient prognosis after surgery or
chemotherapy are currently available for some cancers. For example, MammaPrint R©
uses the expression of 70 genes to predict the likelihood of metastasis in breast cancer
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[146]. Similarly, the Oncotype DX R© assay uses the expression of a panel of 21 genes
to predict recurrence after treatment of breast cancer [7]. The Oncotype DX assay
is also available for colon [8] and prostate cancers [9]. The development of a similar
tool for ovarian cancer could greatly improve patient prognosis and quality of life
by guiding chemotherapy choices. The prediction of cancer prognosis using gene
signatures is a popular research field, within which a wide variety of approaches have
been considered.
For ovarian cancer in the UK, the standard of care for first-line chemotherapy
treatment recommended by the National Institute for Health and Care Excellence
(NICE) is ‘paclitaxel in combination with a platinum-based compound or platinum-
based therapy alone’ [105]. This uniform approach ignores the complexity of ovarian
cancer histologic types, particularly as there is evidence to suggest differences in
response [55, 166].
Improvement in survival has been poor in ovarian cancer. Between 1971 and
2007 there was a 38% increase in relative 10-year survival in breast cancer, whereas
the increase in ovarian cancer was 17% [2]. This difference in progress is likely to
be due, at least in part, to the lack of tools with which to predict chemotherapy
response in ovarian cancer.
The computational and statistical approaches employed in studies predicting
chemotherapy response vary greatly. One popular method is Cox proportional
hazards regression. This model assumes that the hazard of death is proportional
to the exponential of a linear predictor formed of the explanatory variables. This
model has the advantage that, unlike many other regression techniques, it can model
right-censored data such as that found in medical studies where patients leave before
the end of the study period [40]. This technique is therefore often used in medical
contexts, sometimes to the exclusion of other more suitable techniques. Other popular
modelling techniques include linear models, support vector machines, hierarchical
clustering, principal components analysis and the formation of scoring algorithms.
Models of survival data may be predictive or prognostic. For prognostic
models the emphasis is on the prediction of patient survival time with no reference
to treatment. Predictive models, on the other hand, take into account treatment and
predict survival time given a chosen therapeutic intervention [160]. This distinction
is subtle and, clearly, prognostic models may be formulated as predictive models
given no treatment. However, in practice the difference is contextually important.
At diagnosis or following an intervention, prognostic models with an emphasis on
non-clinical covariates may be used to predict patient survival and disease progression
[167]. However, following tests and treatment, predictive models utilising test results
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and clinical disease assessments may be of use to tailor interventions and aid treatment
selection. In the context of patient response to chemotherapy, given the varying
biological processes and mechanisms of action involved, predictive models are much
more likely to be effective, predicting patient response given a chosen treatment.
The aim of this review is to investigate the literature surrounding the predic-
tion of chemotherapy response in ovarian cancer using gene expression. It has been
observed, for example by Gillet et al. [53], that gene signatures obtained from cancer
cell lines are not always relevant to in vivo studies, and that cell lines are inaccurate
models of chemosensitivity [31]. The search was therefore restricted to studies involv-
ing human tissue in order to ensure that the resulting gene signatures are applicable
in a clinical setting. It was also specified that the study must involve patients who
have undergone chemotherapy treatment, so that the effects of resistance may be
investigated.
A PRISMA checklist was completed for this document and may be found in
Appendix Figure A.2.
2.2 Methods
2.2.1 Search Methodology
The aim of this review is to investigate the literature on the prediction of chemoresis-
tance in patients with ovarian cancer. Therefore, the six most important requirements
identified were:
• Concerned with (specifically) ovarian cancer
• Patients were treated with chemotherapy
• Gene expression was measured for use in predictions
• Predictions are related to a measure of chemoresistance (e.g. response rates,
progression-free survival)
• Measurements were taken on human tissue (not cell lines)
• The research aim is to develop a diagnostic tool or predict response
A PubMed search was carried out on 6th August 2014 to identify studies
fulfilling the above requirements. The search terms may be found in Appendix
Table A.1. This search resulted in 78 papers.
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2.2.2 Filtering
During reading, each abstract or full text was assessed as to whether it was appropriate
for the research question and those not found to be suitable were excluded. The
search results were filtered twice, once based on abstracts and once based on full
texts. An overview of the filtering process may be found in Figure 2.1. For the
abstract-based filtering, papers were excluded if the six essential criteria were not
all met, if the paper was a review article or if the paper was non-English language.
This resulted in 48 papers remaining. For the full-text-based filtering, exclusion was
due to not fulfilling the search criteria or papers that were not available. 42 papers
were remaining after full-text-based filtering.
2.2.3 Data Extraction
Data was extracted from each paper using a pre-defined table created for the purpose,
with a number of well-defined fields of information to be extracted. Extraction was
carried out in duplicate with a wash-out period of 3 months to avoid bias. The
wash-out period, a period of time between two extractions by the same investigator,
is intended to allow the second round of extraction to be approached fresh, to mimic
extraction by two independent investigators. Variables extracted were:
• Author
• Year
• Journal
• Number of samples
• Number of genes measured
• Study end-point
• Tissue source
• Percentage cancerous tissue
• Gene or protein expression measurement technique
• Sample histological types
• Sample histological stages
• Patient prior chemotherapy
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Figure 2.1: PRISMA search filtering flow diagram. The initial search results were
filtered using titles and abstracts and, later, the full text to ensure the search criteria
were fulfilled. Following filtering the number of papers included reduced from 78 to
42.
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• Modelling techniques applied
• Whether the model accounts for heterogeneity in patient chemotherapy
• Whether the model was prognostic or predictive
• Whether the model was validated
• Model predictive ability including any metrics or statistics
• Genes found to be predictive
2.2.4 Bias Analysis
Bias in the studies selected for the systematic review was assessed according to
QUADAS-2 [164], a tool for the quality assessment of diagnostic accuracy studies.
For each paper, this tool assesses the risk of bias and the applicability of the study
to the research question being investigated by the systematic review. There are
four topics: patient selection, index test, reference standard, and flow and timing.
Each topic is considered for risk of bias and applicability and assigned a rating of
‘high risk’, ‘low risk’ or ‘unclear’. Patient selection is concerned with randomness,
representativeness and exclusions. The index test is the test of interest to the review
and the reference standard is the current test used for this purpose. Flow and timing
considers the timing of the study, when tests were carried out and which patients
received which tests. For each paper, results should be considered across the topics,
with a paper only being considered low risk if all topics have achieved this status.
Levels of evidence were also assessed according to the CEBM 2011 Levels of
Evidence [3]. This system ranks studies and clinical trials using several factors to
assess the strength of their evidence. Different types of studies are considered to
provide different strengths of evidence and are assigned levels of 1 to 5 accordingly,
with 1 providing the strongest evidence. For example, systematic reviews and random
controlled trials are considered to provide strong evidence, whereas case-control
studies provide much less.
Results of these analyses may be found in Appendix Figure A.3. Briefly, the
majority of studies were considered to be low risk, with six studies judged to have
unclear risk for at least one domain and seven studies judged to be high risk for at
least one domain. Thirty-six studies were judged to have evidence of level 2, with the
remaining six having evidence of level 3. These levels of risk and evidence suggest
that the majority of conclusions drawn from these studies are representative and
applicable to the review question.
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2.2.5 Gene Set Enrichment
Gene set enrichment analysis (GSEA) was applied to the gene sets reported by the
studies selected for this review.
GSEA is a technique by which large sets of genes are assessed for their func-
tional associations with known biological processes. This is often used to investigate
links to disease phenotypes, for example. GSEA uses pre-existing relational databases
of classifications to categorise genes, such as the Kyoto Encyclopedia of Genes and
Genomes (KEGG) database. An enrichment score is calculated for each category
in the database, showing to what extent it is represented in the provided set of
genes, compared to the full population of genes included in the chosen database.
For example, if genes associated with the cell cycle are relatively more common in
the gene set than in all genes, this category will have a larger enrichment score and
be considered over-represented. The hypergeometric test is used to assess whether
a particular category has been observed statistically significantly more often than
for a random sample drawn from the set of all genes. This test is applied for each
category, and hence a p-value correction is required to adjust for multiple testing.
Analysis was performed using the R package HTSanalyzeR [162]. Where
reported by studies included in the review, gene sets were extracted and combined
according to the chemotherapy treatments applied to patients in each study. The
two groups assessed were those studies where all patients were treated with platinum
and taxane in combination, ‘platinum and taxane’, and those studies where patients
were given treatments other than platinum and taxane, ‘other treatments’. The
‘other treatments’ group includes those given platinum as a single agent. Any studies
reporting treatments from both groups were excluded, as were studies that did not
report the chemotherapy treatments used. Using functions from the HTSanalyzeR
package, KEGG terms were identified for each gene and gene set collection analysis
was carried out, which applies hypergeometric tests and gene set enrichment analysis.
A p-value cut-off of 0.0001 was used. Enrichment maps were then plotted, using
the 30 most significant KEGG terms. P-values were adjusted using the Benjamini-
Hochberg correction [18]. On the enrichment maps, each node represents a set of
genes related to the named KEGG term, and the size of the node is determined by
the number of genes present related to that term. The edges link related gene sets,
and their thickness represents a measure of similarity between the two sets of genes,
according to a weighted Kolmogorov–Smirnov-like statistic. The nodes are coloured
according to the p-value reported for the hypergeometric test for that term, and
darker colour represents greater significance.
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2.3 Results
Appendix Tables A.1, A.2, A.4, A.3 A.5 and A.6 detail some key information
regarding the studies included in the review. Table A.1 contains the number of
samples analysed, the number of genes considered for the model, and the resulting
genes retained as the predictive gene signature. Table A.2 provides information
about the tissue used for gene expression measurements and whether the studies
assessed the percent neoplastic tissue before measurement, and Table A.4 details
the gene expression measurement techniques used. Table A.3 contains the reported
histological types and stages of the samples processed by each study. Table A.5
provides information on chemotherapy treatments undergone by patients, whether
the model was prognostic or predictive, and whether the model was validated using
either an independent set of samples or cross validation. Table A.6 lists the outcome
to be predicted, the modelling techniques applied, and the predictive ability of the
resulting model.
2.3.1 Tissue Source
For studies involving RNA extraction the tissue source is an important consideration,
as RNA degradation and fragmentation could affect the results of techniques involving
amplification. This is a notable issue in formalin fixed paraffin embedded (FFPE)
tissue, due to the cross-linking of genetic material and proteins [102]. Of the 42
papers included in this review, the majority used fresh-frozen biopsy tissue. The
numbers of each tissue source may be found in Table 2.1, and the tissue source used
by individual papers may be found in Appendix Table A.2. Nine papers did not
use an RNA source directly as secondary data was used. Data sources were mostly
other studies or data repositories, such as the TCGA dataset. Two studies did not
specify the source tissue though extraction and expression measurement methods
were detailed.
The majority of papers in this review used fresh-frozen tissue. This choice
was likely made to minimise RNA degradation and hence improve measurement
accuracy. Due to the risk of RNA degradation because of long storage times and the
fixing process applied to FFPE tissue, it is often expected that FFPE tissue will be
irreversibly cross-linked and fragmented. However, following investigation into RNA
integrity when extracted from paired FFPE and fresh-frozen tissue, Rentoft et al.
[129] found that for most samples up- and down-regulation of four genes was found to
be the same whether measured in FFPE or fresh-frozen tissue. They concluded that,
if samples were screened to ensure RNA quality, FFPE material can successfully
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Table 2.1: Numbers of studies using various mRNA sources.
mRNA Source Number of studies
FFPE tissue 12
Fresh-frozen tissue 22
Fresh-frozen effusion 2
Fresh tissue 1
Blood 1
Not used 9
Not specified 2
provide RNA for gene expression measurement.
The use of fresh-frozen tissue in a research setting is not unusual, as can be
seen from the fact that this tissue type was most popular in this review. However,
for translational research expected to lead to a clinical test, this is not as reasonable.
FFPE tissue is much more readily available, due to simpler acquisition and storage,
and tissue is already taken for histological analysis. Therefore a model capable of
using data obtained from FFPE tissue is much more likely to be applicable in a
clinical setting.
Another important consideration is the proportion of neoplastic cells in the
sample. For each paper the reported proportion may be seen in Appendix Table A.2.
Of the 42 papers, 14 reported that the proportion of cancerous cells was measured.
This was usually done using hematoxylin and eosin stained histologic slides. It is
important for the gene expression measurement that the tissue used contains a high
proportion of neoplastic cells, and hence it is important that this pre-analytical
variable is controlled. Of the studies in this review, those reporting the percentage
cancerous cells were evenly distributed between FFPE and fresh-frozen tissues.
2.3.2 Gene or Protein Expression Quantification
Of the studies highlighted by this review, there were four main techniques applied
for gene or protein expression measurement: Probe-target hybridization microarrays,
quantitative PCR, reverse transcription end-point-PCR, and immunohistochemical
staining. Of these methods only immunohistochemistry measures protein expression,
via classification of the level of staining, and the other methods quantify gene
expression via measurement of mRNA copy number.
Methods involving probe-target hybridization are available commercially, and
19 of the 42 studies utilised these. For example the Affymetrix R© Human U133A 2.0
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GeneChip and the Agilent R© Whole Human Genome Oligo Microarray were both
used by multiple studies. Additionally, 7 studies used custom-made probe-target
hybridization arrays. Probe-target hybridisation arrays generally measure thousands
of genes and hence can provide a wealth data per sample. TaqMan R© microfluidic
arrays or quantitative-PCR were used by 16 studies. These techniques are typically
used for smaller panels of genes. The TaqMan R© arrays, for example, may contain
up to 384 genes per array. These methods are more targeted and hence the price per
sample is usually lower.
Immunohistochemistry is a more labour-intensive technique, requiring staining
for each gene considered, and hence was mostly only used by studies using small
numbers of genes. This technique, which is semi-quantitative due to the scoring
systems employed, also suffers from a lack of standardisation of procedures. Of the
11 papers using this technique, the maximum number of genes analysed was seven,
and the mean number of genes assessed was 2.8. Although these studies provide
useful information regarding the correlation of particular genes with outcome, the
small numbers of genes is likely to result in an incomplete gene signature and low
predictive power.
Several of the papers utilising quantifiable techniques used an alternative
method or replicates to obtain a measure of the assay variability. Five papers
involving commercial or custom microarrays also used reverse transcription PCR
(RT-PCR) to measure the expression of a small number of genes for comparison and
one study used samples run in duplicate to calculate the coefficient of variation. Of
the studies using TaqMan microfluidic arrays, two used samples run in duplicate to
obtain the coefficient of variation. However, even fewer papers reported a metric
representing the level of variability found. Two studies reported a coefficient of
variation; Glaysher et al. [54] reported CoV = 2% = 0.02 for TaqMan arrays and
Hartmann et al. [63] reported CoV = 0.2 for their custom microarray.
Another two reported Spearman’s ρ or Pearson’s r coefficients of correlation
between microarray and RT-PCR results. Both coefficients represent the correlation
between two variables, here two alternative mRNA measurement techniques. These
coefficients may take values between -1 and 1, with 1 representing perfect positive
correlation, 0 being no correlation, and -1 being perfect negative correlation. However,
they differ in that Pearson’s r assesses linear correlation, whereas Spearman’s ρ
measures monotonic correlation. Yoshihara et al. [170] gave Pearson’s r values
ranging from 0.5 to 0.8, and Crijns et al. [32] gave Spearman’s ρ values between -0.6
and -0.9. Comparing these values to the possible ranges, both studies appear to have
good correlation between techniques.
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2.3.3 Histology
Appendix Table A.3 details the histology (types and stages) of the patient samples
used by each study. As may be seen, the majority of studies were heterogeneous
with respect to the types of cancer included. However, 23 of the 42 studies used at
least 80% serous samples, suggesting that the majority of information contributed to
the gene signatures of these studies is related to the mechanisms and pathways in
serous cancer. It is important to identify the histologies of patient samples: although
treatment is currently the same across types, response to chemotherapy has been
found to vary [166, 150, 68]. It therefore may be advisable for future studies to
include histological information when developing models predicting chemotherapy
response.
2.3.4 Chemotherapy
Appendix Table A.6 lists the chemotherapy treatments undergone by patients in
each study. The 10 papers labelled NS did not specify the regimen applied, though
the patients did have chemotherapy. These cohorts cannot therefore be assumed
to be homogeneous with respect to patient chemotherapy treatment. All studies
that specified the chemotherapy regimen undergone by patients noted at least one
platinum-based treatment. Of these, 24 included patients treated with a platinum-
taxane combination and 10 with a cyclophosphamide-platinum combination. It is
important to note that 19 of the 42 papers stated the population was heterogeneous
with regards to chemotherapy treatments and, of those that did, only 8 included
patient treatment history as a feature of the study. The aims of the majority of the
studies were to identify genes of which the expression may be used to predict survival
time, or prognosis. As already noted, the presence of resistance to the chemotherapy
agent administered will dramatically affect the survival of a patient. It is therefore
reasonable to expect the gene signatures identified to include genes responsible for
chemoresistance, which will depend on the mechanism of action of the drug. Using
a heterogeneous cohort in terms of chemotherapy treatment may then be causing
problems with the identification of a minimal predictive gene set.
2.3.5 End-point to be Predicted
As may be expected, there was variation between the end-point chosen by studies
for prediction. Popular end-points include overall survival, progression-free survival
and response to chemotherapy. The endpoints considered by each study may be
found in Appendix Table A.6. Of these some are clinical endpoints, such as overall
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survival, others use non-clinical endpoints, such as response to chemotherapy, many
of which are considered to be surrogates for overall survival. For cancer studies,
overall survival is considered to be the most reliable and is the variable that is of
most interest when considering the effect of an intervention.
2.3.6 Model Development
Within this review, many different modelling techniques were used to identify an
explanatory gene signature to predict patient outcome. The most popular was
Cox proportional hazards regression, which was applied by 17 studies. This was
closely followed by hierarchical clustering, which was used by 11 studies. All other
methods were used by 8 or fewer studies. In total 24 different types of modelling
techniques were applied, ranging from statistical tests such as Student’s t test and
the Mann-Whitney U test, to logistic regression and ridge regression. Table 2.2 lists
the modelling techniques identified and the number of studies that employed them.
It is of interest that most of the techniques applied are forms of classification. These
methods result in samples being assigned to groups, such as ‘good prognosis’ and
‘poor prognosis’. Whilst this may be useful in some settings, for a clinically-applicable
tool a regression technique may be more appropriate as it will provide a value, such as
a likelihood of relapse, rather than simply a class. Techniques in Table 2.2 capable of
a numeric prediction include logistic and linear regression, Cox proportional hazards
regression, and ridge regression.
Jointly with the modelling methods identified above, 23 of the 42 studies
implemented Kaplan-Meier curves to visualise the survival of the patient classes
identified by the models. This enables the difference in survival between classes,
for example ‘good prognosis’ and ‘poor prognosis’, to be seen and assessed. The
application of a log-rank test assesses the separation of the curves and identifies
whether there is a statistically significant difference in survival distribution between
the classes. It should be noted that, although this gives an idea of separation of
classes achieved by the model, the model results must still be compared with known
outcomes to check positive and negative predictive power. This step was missing in
several papers, such as Gillet et al. [51], where the p-value returned by the log-rank
test is given as the measure of model success.
It is important to highlight the difference between prognostic and predictive
models. A prognostic model is one capable of predicting prognosis, such as survival
time, using patient information and biomarkers and does not vary between different
treatment options. In contrast, a predictive model is one able to predict the effect
of a treatment on patient prognosis [121, 153]. It is therefore clear that, although
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Table 2.2: Key Modelling techniques applied by studies in the review.
Technique Number of papers
Cox proportional hazards regression 17
Hierarchical clustering 11
Principal components analysis 8
Student’s t test 7
Scoring algorithm 6
Support Vector Machines 5
Correlation coefficients 5
Mann-Whitney U test 5
χ2 test 5
ROC analysis 5
Class prediction 4
Logistic regression 3
Linear regression 3
AIC gene selection 2
Concordance index 1
Pathway interaction networks 1
ANOVA 1
Expression threshold identified 1
Gene set enrichment analysis 1
Linear discriminant analysis 1
ISIS bipartitioning 1
Gaussian mixture modelling 1
Significance analysis of microarrays 1
Ridge regression 1
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prognostic models may be useful for research purposes and when only one treatment
option is available (such as the standard platinum-taxane combination), predictive
models have a much greater part to play in stratified medicine where the aim is to
identify the most appropriate treatment on a patient-by-patient basis. In order for a
model to be predictive, the effects of multiple treatments must be considered and
the response compared with the biomarker status. Classification of the studies as
prognostic or predictive may be seen in Appendix Table A.5. Of the papers identified
by this review, only a minority considered the effects of chemotherapy treatment on
the predicted outcome and hence could be considered predictive. Glaysher et al. [54]
and Vogt et al. [161] produced separate models for various treatments, allowing the
effects of different drugs and combinations to be compared. Both studies applied
drugs in vitro to cultured tissue to measure response to chemotherapy. This was
combined with gene expression measurements to form the model training data
set. In this way the same patient samples may be used to create a set of models
predicting response to a variety of drugs. These models are therefore predictive
rather than prognostic. Alternatively, models may be trained on sets of patients split
by treatments undergone, which would lead to treatment-specific models predicting
response to the particular drug. This method was used by Jeong et al. [76], Ferriss
et al. [42], Williams et al. [165] and Matsumura et al. [98]. Additionally, the use of a
model variable specifying patient treatment history could allow these models to be
combined onto one using a single training set of all patients. The model may then be
passed a variable specifying the drug of interest for resistance prediction. A simple
version of this method was implemented by Crijns et al. [32], who included a feature
for whether a patient was treated with paclitaxel. It is clear that the integration of
patient chemotherapy treatment into these models is underused, and it is likely to
be beneficial for this to be incorporated into future research.
2.3.7 Genes Identified
Of the 42 papers in this review, 32 provided full or partial lists of the genes identified
by their models. Of the remainder, it was common that the gene sets were large
or that the genes were not explicitly identified by the model, as is the case with
modelling techniques such as principal components analysis.
In total across the papers, 1298 unique genes were selected by models and of
these 93.53% were found by only one paper. The most commonly chosen gene was
selected by only four papers. Table 2.3 shows the numbers and percentages of genes
chosen by one to four papers.
A list of the genes identified by the papers in the review may be found in
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Table 2.3: Numbers and percentages of genes featured in the gene sets of various
numbers of papers.
Number of papers
identifying a gene
Number of genes Percent of genes
1 1214 93.53%
2 78 6.01%
3 5 0.385%
4 1 0.08%
Appendix Table A.7.
It is clear that the gene sets selected by the studies are very different and
there is very little overlap. The genes chosen by two or more studies may be seen
in Appendix Table A.8. Many of these genes are known to have links to cancer,
which may suggest that these genes are therefore implicated in ovarian cancer. It
is possible that, although the genes selected varied, they in fact represent similar
mechanisms. This could occur if there are large sets of highly covariate genes
representing particular cellular processes and the genes in the signatures were simply
random selections from these gene sets. The same gene being selected by multiple
papers would then be unlikely, although the same information contribution would
be made. It may then be more informative to assess and compare the mechanisms
controlled by the genes chosen as part of the models.
2.3.8 Gene Set Enrichment
The gene sets reported by the studies identified in this review were assessed to identify
whether certain biological pathways and mechanisms featured more prominently
according to the genes selected. As detailed in Methods section 2.2.5, the genes
selected by the studies are compared to the set of all genes and their associated
pathways in the KEGG database. Pathways identified more commonly than in the
full population are considered enriched.
In order to explore the differences between chemotherapy treatments, studies
were grouped by chemotherapy treatments recieved by the patients. The two groups
identified were ‘platinum and taxane’, and ‘other treatments’ (such as platinum,
cyclophosphamide and combinations). Studies that did not specify the chemotherapy
treatments used were excluded. Studies falling into the ‘platinum and taxane’ group
were Han et al. [61], Kang et al. [78], Gillet et al. [52], Skirnisdottir and Seidal
[145], Schlumbrecht et al. [139], Yoshihara et al. [170], Denkert et al. [37], Hartmann
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et al. [63], Iba et al. [72], and Kamazawa et al. [77]. Studies falling into the ‘other
treatments’ group were Obermayr et al. [120], Obermayr et al. [120], Yan et al. [169],
Netinatsunthorn et al. [115], and Helleman et al. [66]. The results of the gene set
enrichment using the KEGG system may be seen in Figures 2.2a and 2.2b. From
the plots, it may be seen that both groups identify several cancer-related pathways
relevant to the drug mechanisms of action.
It is informative to consider the KEGG terms in the context of the mechanisms
of action of the chemotherapy drugs applied. Both groups contain patients treated
with platinum single agents or platinum-containing combinations. It should therefore
be expected that processes associated with the mechanism of action of platinum
will be enriched. Once activated, the platinum binds to DNA and results in the
formation of monoadducts, intra-strand crosslinking, inter-strand crosslinking and
protein crosslinking. This DNA structure change affects the ability of the DNA to
be unwound and replicated, resulting in the triggering of the G2/M DNA damage
checkpoint and cell cycle arrest. The affected cell will attempt DNA repair and,
if unsuccessful, undergo apoptosis [152]. Expected KEGG terms therefore include
those relating to apoptosis and DNA damage.
From Figure 2.2a, KEGG pathways highlighted for this group of studies
include ten cancer-specific terms and six cancer-related terms. Here italics denote a
KEGG term. The ErbB signalling pathway has been found to influence proliferation,
migration, differentiation and apoptosis in cancer [27] and overexpression of ERBB1
and ERBB2 have been implicated in head and neck and breast cancers. The
neurotrophin signalling pathway is known to trigger MAPK and PI3K signalling,
affecting differentiation, proliferation and development, and survival, growth, motility
and angiogenesis respectively [151]. Altered expression of genes in this pathway has
been found to correlate with poorer survival in colon, breast, lung and prostate
cancers. Changes in expression of genes relating to focal adhesion, which is responsible
for attachment of cells to the extracellular matrix, have been implicated in cancer
migration, invasion, survival and growth [100]. The TGF-beta signalling pathway
also regulates many cellular processes, including proliferation, cellular adhesion and
motility, coregulation of telomerase function, regulation of apoptosis, angiogenesis,
immunosuppression and DNA repair [41]. The p53 signalling pathway has many
varied links to cancer. This pathway many be triggered by various stress signals and
can result in several responses, including cell cycle arrest, apoptosis, the inhibition
of angiogenesis and metastasis, and DNA repair [87]. Finally, nucleotide excision
repair is known to promote cancer development when both up and down regulated.
Down-regulation is thought to increase susceptibility to mutation formation and
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(a) Gene set enrichment networks for studies assessing ovarian cancer patients treated with
platinum and taxane.
Figure 2.2: Network maps of the 30 most enriched KEGG pathways. Node marker
size signifies the number of genes in this category, and the thickness of edges indicate
the Jaccard similarity coefficient between categories. Node markers are coloured
according to adjusted p-value as reported by the hypergeometric test, where darker
red denotes more highly significant.
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(b) Gene set enrichment networks for studies assessing ovarian cancer patients treated with
treatments other than platinum and taxane.
Figure 2.2: Network maps of the 30 most enriched KEGG pathways. Node marker
size signifies the number of genes in this category, and the thickness of edges indicate
the Jaccard similarity coefficient between categories. Node markers are coloured
according to adjusted p-value as reported by the hypergeometric test, where darker
red denotes more highly significant.
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hence the formation of cancer [119], whereas up-regulation has been found to correlate
with resistance to platinum as the DNA damage caused by the chemotherapy agent
is repaired [96].
The first group of studies considered patients treated with taxanes in addition
to platinum. Taxanes act by stabilising tubulin, preventing the microtubule structure
formation required for mitosis. This results in cell cycle arrest at the G2/M DNA
damage checkpoint and apoptosis. Mechanisms for taxane resistance are, however,
not well understood. Two suggested mechanisms include the increased expression
of multidrug transporters, and changes in the expression of the β-tubulin isoforms
[47]. Neither of these mechanisms seem to be enriched in the platinum and taxol
group. In addition to the single-agent effects of platinum and taxanes, there is an
additional synergistic effect [75]. However, this effect is also not well studied and
hence the mechanisms by which this occurs are not clear.
The second group, as seen in Figure 2.2b, was composed of studies applying
chemotherapy treatments other than platinum and taxanes. This group is hetero-
geneous with respect to chemotherapy treatment, and mainly consists of studies
reporting treatment as ‘platinum-based’. The other drug explicitly mentioned by
studies in this group is cyclophosphamide. This drug is an alkylating agent and acts
to form adducts in DNA [59]. This DNA damage triggers the G2/M DNA damage
checkpoint, resulting in DNA repair or apoptosis. This suggests that the same DNA
repair mechanisms related to platinum treatment are also relevant to cyclophos-
phamide. For this group, the KEGG pathway analysis shows that the gene set is
enriched with 14 pathways related to cancer, in addition to two general cancer-related
terms. The mTOR signalling pathway is downstream to the PI3K/AKT pathway
and regulates growth, proliferation and survival [124]. The MAPK signalling pathway
controls the cell cycle, and has been found to contribute to the control of proliferation,
differentiation, apoptosis, migration and inflammation in cancer [38]. The chemokine
signalling pathway has been found to regulate growth, survival and migration in
addition to its role in inflammation [67]. Angiogenesis and vasculogenesis are known
to be regulated by the VEGF signalling pathway [84], which is already the target of
treatments such as bevacizumab. Purine metabolism is required for the production
and recycling of adenine and guanine, and hence is required for DNA replication.
This process is the target of chemotherapies such as methotrexate. The term drug
metabolism – other enzymes is partially cancer related; this term refers to five drugs:
azathioprine, 6-mercaptopurine, irinotecan, fluorouracil and isoniazid. Of these,
two are chemotherapy treatments; irinotecan is a topoisomerase-I inhibitor and
fluorouracil acts as a purine analogue. Also featuring in Figure 2.2b are apoptosis,
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ErbB signalling pathway, focal adhesion, neurotrophin signalling pathway, B cell
receptor signalling pathway and Jak-STAT signalling pathway, all of which are known
to be related to cancer.
Overall, the gene sets appear to be enriched for cancer-related resistance
mechanisms [30], though very few of the terms were considered to be statistically
significantly enriched. However, when combined there is little evidence from this
analysis to suggest that the signatures are capturing chemotherapy-specific mecha-
nisms in addition to more general survival pathways. The DNA repair terms may
suggest a response to platinum-based treatment, though the down-regulation of these
mechanisms is also related to cancer development and resistance in general [19].
It is likely that, due to the varying reliability suggested by the bias analysis and
the reported model development techniques, the signal-to-noise ratio of informative
genes is low when the gene signatures are combined, preventing the identification of
processes of interest.
2.3.9 Model Predictive Ability
Sensitivity and Specificity
The comparison of the success of the various models is difficult, particularly due to the
fact that many papers report different metrics as measures of model accuracy. Many
of these are also incomplete, not providing enough information to fully describe
the model. Ideally, models should be applied to an independent set of samples
with known outcomes and performance measures on this data set reported. For
classification models an informative set of measures would be positive predictive
value (PPV), negative predictive value (NPV), specificity and sensitivity:
Sensitivity =
ntrue positive
ntrue positive + nfalse negative
Specificity =
ntrue negative
ntrue negative + nfalse positive
PPV =
ntrue positive
ntrue positive + nfalse positive
NPV =
ntrue negative
ntrue negative + nfalse negative
where ntrue positive is the number of true positive predictions, nfalse positive is the
number of false positive predictions, ntrue negative is the number of true negative
predictions and nfalse negative is the number of false negative predictions.
Together these provide information on true positive and negative rates as well
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as false positive and false negative rates, all of which are important when assessing
the performance of a model.
Using the sensitivity and specificity the positive and negative likelihood ratios
may be calculated and, using the prevalence of the condition in the test population,
the probability of a patient having the condition based on the test results may
be found, as in the equations below. The likelihood ratios are the ratio of the
probabilities of a patient testing positive (or negative), given that they have the
disease or not.
LR+ve =
P (Test + |Condition+)
P (Test + |Condition−) =
sensitivity
1− specificity
LR-ve =
P (Test− |Condition+)
P (Test− |Condition−) =
1− sensitivity
specificity
P (Condition + |Test+) =
P (Condition+)
1−P (Condition+) · LR+ve
P (Condition+)
1−P ( Condition+) · LR+ve + 1
P (Condition + |Test−) =
P (Condition−)
1−P (Condition−) · LR-ve
P (Condition−)
1−P (Condition−) · LR-ve + 1
These post-test probabilities are much easier to interpret and incorporate
the prevalence of the condition. It should be noted that in order for the test to be
applied in a clinical situation the pre-test probabilities used, P (Condition+) and
P (Condition−), should be correct for the population of patients to whom the test
will be applied. Here the sample prevalence (the proportion of subjects having
the condition) from each study was used for convenience. However, it would be
informative to recalculate P (Condition + |Test+) and P (Condition + |Test−) for
the general population of ovarian cancer patients, as this would provide a better
comparison between models.
Table 2.4 details the post-test probabilities of patients having a condition
based on a positive or negative test result from the models developed by studies
in this review. The papers appearing here are those that supplied sensitivity and
specificity and the numbers of patients with and with without the condition, or
alternative information allowing these to be calculated such as numbers of true and
false positives and negatives.
From the table it may be seen that there is a great variety between the success
of the models. For example, Kamazawa et al. [77] and Hartmann et al. [63] both
achieved P (Condition + |Test+) = 0.95 on their respective samples of the population.
This means that if a patient tests positive, there is a 95% probability that they
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are positive for the condition in question, which in these cases are ‘responding to
chemotherapy’ and ‘poor prognosis’ respectively. In contrast, Obermayr et al. [120],
Helleman et al. [66] and Gevaert et al. [50] only achieved P (Condition + |Test+) of
between 0.20 and 0.40. These results suggest that the tests are not able to predict
the outcome of a patient any better than a random choice, and in the case of tests
in the region of 0.20 it is likely that most patients are simply assigned to the same
class.
The ability of tests not to commit type II errors and give false negatives is
also important. Ferriss et al. [42] and Hartmann et al. [63] both achieved well in
this regard, with P (Condition + |Test−) = 0.07 and P (Condition + |Test−) = 0.05
respectively. Several studies, by contrast, had very poor probabilities of false
negatives; Obermayr et al. [120], Helleman et al. [66] and Gevaert et al. [50] all have
P (Condition + |Test−) > 0.5, which suggests that these models give a false negative
more often than a random assignment.
Kamazawa et al. [77] and Selvanayagam et al. [142] both achieved extremely
impressive prediction abilities, as may be seen by the very large P (Condition+|Test+)
and very small P (Condition + |Test−) values. However, these studies exemplify
why care must be taken in assessing the predictive ability of models. Both studies
calculated sensitivity and specificity based on only training set results and hence
there is no way to judge the generalisability of the models. There is a tendency
for models to perform better on the training set than any following independent
data set to which it is subsequently applied. Secondly, the training set used by
Selvanayagam et al. [142] is extremely small at eight patients and has a 50 : 50 ratio
of chemoresistant to chemosensitive patients. This sample is not representative of the
population and hence the values of P (Condition+|Test+) and P (Condition+|Test−)
will be skewed by unrepresentative P (Condition+) and P (Condition−).
Overall, the most successful model of this group is that by Hartmann et al. [63]
as it makes predictions with good reliability and has been validated on an independent
data set. The least successful models were Obermayr et al. [120], Helleman et al.
[66] and Gevaert et al. [50]. These studies suffered from low ability to identify true
positives and high probability of false positives, resulting in poor predictive ability.
Hazard Ratios
It is common for studies of survival to quote hazard ratios, comparing the results
of clusters identified by classification models or relative-risk models such as Cox
proportional hazards regression. These ratios represent the ratio of the probability of
an event occurring to a patient in either of the two groups. The event is often death,
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but could also be recurrence for example. The studies listed in Table 2.5 supplied
hazard ratios as measures of predictive ability. The hazard ratios vary from 0.23 to
4.6 with the majority around 2 to 3. A hazard ratio that is not equal to 1 suggests
that the variable has predictive ability, and a ratio of 4, for example, suggests that
a member of the high-risk group is 4 times as likely to die within the study period
than a member of the low-risk group. The study with the highest hazard ratio is
Spentzos et al. [147], with HR = 4.6. This is closely followed by Raspollini et al. [128]
with HR = 0.23 and Skirnisdottir and Seidal [145] with HR = 4.12. The confidence
intervals on the hazard ratios of all the studies are large and, with the exception of
Spentzos et al. [147], at the lowest edge the hazard ratio is very close to 1. This
suggests that, although all these hazard ratios were found to be significant, some
were close to not reaching the arbitrary α = 5% significance level. Most notable are
Roque et al. [131], Schlumbrecht et al. [139], and Denkert et al. [37]. These models
would need further investigation to determine their predictive ability. Of the papers
in this group, Spentzos et al. [147] appears to have the best predictive ability when
classifying patients into two clusters with significantly different survival times.
Linear Regression
Two papers reported the success of a model assessed using linear regression: Glaysher
et al. [54] and Kang et al. [78]. These studies plotted the predicted values or model
score against the measured values and applied linear regression to obtain a line of best
fit. The R2 or R2adj of this line is then calculated to assess the discrimination of the
model and represents the proportion of the variance in the dependant variable that is
explained by the independent variable. R2adj also accounts for the number of variables
and the sample size. Glaysher et al. [54] achieved R2 = 0.901 (R2adj = 0.836) for a
model predicting resistance to cisplatin using gene expression via cross-validation and
Kang et al. [78] achieved R2 = 0.84 for a model predicting recurrence-free survival in
the data set on which it was derived. These values suggest a good level of predictive
ability, both in terms of calibration and discrimination, with the model by Glaysher
et al. [54] achieving the better predictions.
Cox Proportional Hazards Models
When studies identified by this review applied the Cox proportional hazards model
to predict patient outcome, it was common for the main analysis of the model to be
assessing whether the gene signature was found to be significant and whether the
signature was an independent predictor. However, the application of this model to
37
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an independent data set was much less common. As may be seen from Appendix
Table A.6, the success of many models was judged using the significance of covariates
including the gene signature in the model. It is likely that this model was not applied
to external data sets due to subtleties in what the model predicts when compared to
methods such as linear regression. Whereas in linear regression the survival times
are predicted directly, Cox proportional hazards regression predicts hazard ratios.
Royston and Altman [133] developed techniques for the external validation of Cox
proportional hazards models by application to an independent data set. These
rely on having at least the weights of the variables included in the linear predictor,
and ideally the baseline survival function. The first allows the assessment of the
discriminatory power of a model, whereas the second is also required to allow the
calibration of the model to be assessed. Royston and Altman [133] are of the opinion
that the inclusion of a log-rank test p-value is not informative, due to the irrelevance
of the null hypothesis being tested, and hence this should not be considered when
judging model performance. An alternative to the log-rank test to compare survival
between groups would be time-dependent ROC curves [64].
Failure to Predict
Of the studies identified by this review, some models failed to achieve significant
predictive ability. These include Lisowska et al. [90], Vogt et al. [161] and Brun
et al. [22]. Of these papers, Vogt et al. [161] and Brun et al. [22] both considered
small numbers of genes when constructing their models. It is possible then that
these models failed because no informative genes were considered. Conversely,
Lisowska et al. [90] applied their modelling technique to over 47000 genes using 127
patients. It is therefore a possibility that genes were selected by their model purely
by chance rather than due to true explanatory ability. This model was tested using
an independent data set. When the model was applied to this data set it performed
poorly, suggesting that the genes chosen did not generalise to the second cohort
of patients. Neither Vogt et al. [161] nor Brun et al. [22] reported measuring the
precision or accuracy of the gene expression measurements. Lisowska et al. [90] used
RT-PCR to measure the expression of 18 genes from the microarray, but the RT-PCR
measurements were carried out on a separate set of samples and hence are not useful
when considering accuracy. It is therefore unknown whether the gene expression
measurement techniques applied by these studies were sufficiently accurate.
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2.4 Discussion
The papers identified as part of this review tackled the important issue of chemore-
sistance and survival prediction in ovarian cancer via gene or protein expression.
The concept of identifying gene signatures is popular, and requires careful handling
to extract the information required for this to be successful. It was observed that of
the many different tissue preservation techniques applied, the most common were
fresh-frozen and formalin fixed, paraffin embedded tissue. Due to the high quality
expression measurements that may now be achieved with FFPE tissue, this appears
to be the most appropriate choice for research intended to translate into a clinical
setting.
It was found that the majority of the studies included in this review were
heterogeneous with respect to the histological type of the patient cohort. This
suggests that, due to the differing response of different types of ovarian cancer
to chemotherapy, the gene signatures may be identifying different pathways and
mechanisms. However, it should also be noted that although 27 of the 42 studies were
heterogeneous, 12 of these consisted of greater than 80% serous samples. Therefore,
for these studies the inclusion of multiple histological types is likely to have less effect
on the gene signature and mechanisms highlighted could be expected to occur in
serous ovarian cancer. It would be advisable for future studies to include histological
type and grade as model features.
The majority of studies identified by this review attempt to classify patients
into groups with different characteristics, for example ‘poor prognosis’ and ‘good
prognosis’ or ‘chemosensitive’ and ‘chemoresistant’. However, variables such as
response to chemotherapy and prognosis are rarely so well separated into classes;
they are by nature continuous variables. Altman and Royston [11] are clear that
dichotomising continuous variables into categories (such as high-risk vs. low-risk)
should be avoided, as it results in loss of information and may lead to underestimation
of variation and the masking of non-linearity. Arbitrary choices of cutoff values may
further obscure the situation, when the original continuous variable could serve the
same purpose in many models. In terms of a clinical test it therefore may be more
appropriate to apply alternative techniques, such as various types of regression, to
obtain a real valued prediction of patient outcome.
It was noted that the metrics reported as measures of predictive ability vary
between studies. These vary in the amount of information conveyed and hence
care should be taken to use metrics that fully describe the model. Sensitivity and
specificity are commonly reported for classification techniques and, together with the
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numbers of patients in each class in the data set, allow the probabilities of a patient
having the condition of interest given that they have tested positive or negative.
It is the ultimate aim of most classification studies to obtain these probabilities,
as it allows the predictive ability of the test to be assessed and the applicability
of the test to be evaluated. Of the studies reporting sensitivity, specificity and
related information, the best predictive ability was achieved by Hartmann et al.
[63] and the worst by Helleman et al. [66]. It is important to note that from the
sensitivity and specificity the model by Helleman et al. [66] does not appear to be
any worse than some of the others, but these probabilities incorporate the prevalence
of the condition of interest in the test population. It would therefore be highly
informative to recalculate these probabilities using the prevalence of the condition in
the population of ovarian cancer patients. Since some of the test populations were
not representative of the overall population (having so called ‘spectrum bias’), this
would give a much more reliable indication of the predictive ability of the models in
a clinical setting.
One of the main aims of the studies identified was to obtain a ‘gene signature’,
the expression of which can explain and predict the response in the patient. To this
end, the majority of the papers (32 of 42) provided full or partial list of the genes
selected by the modelling process. An analysis of these gene signatures resulted in
the conclusion that the signatures were very dissimilar, with the most commonly
selected gene appearing in only four papers. 93.53% of genes were selected by only
one paper. This seems to indicate that the gene signatures identified were not based
on underlying cellular processes, or at least that the processes being highlighted were
not the same across the papers. It should be noted that many of the studies used
cohorts of patients who were heterogeneous in terms of chemotherapy treatment
and, due to the development of resistance to chemotherapy via gene expression
changes, this may affect the genes found to be explanatory. It may be that several
gene signatures from sub-populations of patients treated with different drugs are
combining and hence reducing the predictive ability of the models.
In order to assess the biological relevance of the genes selected for the gene
signatures, gene set enrichment analysis was carried out. This technique is used to
highlight processes and pathways that are over-represented in the gene signature
compared to the set of all genes for the relevant organism, as defined by the database
in use. For the purposes of this review, two groups of studies were considered: those
where the patients were treated with platinum and taxane, and those where the
patients were treated with other platinum based treatments. These groups were
selected due to the low numbers of studies using a single treatment option. For
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example, there were no studies considering platinum, taxane or cyclophosphamide
as single agents. Following the analysis, 30 KEGG terms were returned for each
group. Of these, each list comprised of approximately half cancer related terms. Of
these the majority were processes often up- or down-regulated in cancer cells, such
as proliferation, apoptosis, and motility and metastasis [62]. It is unclear whether
the change in regulation of these processes is further altered in response to specific
chemotherapy treatments. However, one process worthy of additional consideration
is DNA repair. DNA repair is known to be an important mechanism in cancer, both
though cancer development when down-regulated or mutated [119] and resistance
to DNA damaging chemotherapy when up-regulated [96]. Therefore, the strong
presence of DNA repair terms may suggest the presence of platinum resistance
pathways in the gene signatures. Although the combined gene signatures appear
not to include predictive chemotherapy-specific information, they may be capable
of providing prognostic information. It is also thought that some studies, such as
Glaysher et al. [54], may include genes relevant to additional chemotherapy-specific
processes which are ‘drowned out’ when combined with other signatures.
2.5 Conclusions
It is clear that the prediction of response to chemotherapy in ovarian cancer is
an ongoing research problem that has been attracting attention for many years.
However, although many studies have been published, a clinical tool is still not
available. Progress within the field suggests that the development of a predictive
model is possible.
There is great variability between the approaches and success of existing
studies in the literature, and there have been very high levels of variation in the
genes identified as explanatory. If more care is taken when selecting the patients for
inclusion to control for treatment history, these gene signatures may be simplified
and models able to predict response to treatment may be developed.
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Chapter 3
Gaussian processes for survival
data with right-censoring:
Theory
In this chapter three Gaussian process models are presented, capable of handling
right-censored survival data. Here the right-censored time-to-event values, produced
if a subject leaves a study, are modelled as partially missing outcomes, in terms of a
set of known covariates, using Gaussian processes to place priors on the space of all
functions relating the covariates and outcome. Due to their attributes as Gaussian
processes, these models are flexible and probabilistic, making them ideal for handling
noisy and complex data sets such as biomedical data.
3.1 Introduction
The analysis of survival data is an important aspect of medical research. Survival
time is defined as the period from some starting point to the time at which a pre-
defined event occurs. In a medical context, this event is often death, but could
equally be disease relapse or symptom occurrence. The analysis of survival data
often consists of identifying biomarkers capable of predicting survival time, either
prognostically or predictively.
Survival data are often affected by censoring. Right-censoring occurs when a
patient leaves a study, for a reason other than the pre-defined event, so the recorded
time is a lower bound on the survival time rather than an actual survival time. This
censoring reduces the amount of information available in the data set as the outcome
of some patients will not be known. For survival data without censoring, simpler
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statistical methods may be applied for analysis, e.g. regression, but in the presence
of censoring, methods must be able to account for this missing information or the
conclusions will be biased towards shorter survival times. Popular existing models
for survival analysis include Cox proportional hazards regression [29], accelerated
failure time models [163] and more general models modified for survival data, such
as generalised boosted models [138] and Random Survival Forest models [73].
In cancer research, in addition to clinical patient data such as age, stage
and grade, large amounts of molecular data are now often available. For example
The Cancer Genome Atlas (TCGA) project generated a range molecular data
types including gene expression measurements, somatic mutations and copy number
variations [70]. The information available in these data is likely to be relevant to
patient survival as it represents the processes underlying the action and progression
of the disease. These data are usually high dimensional and relationships between
measured variables are expected to be complex and non-linear. The models applied
to them therefore need to be able to accurately capture and represent this complexity.
Currently in the literature, the majority of studies only apply basic analyses
to these data, with by far the most common model used being Cox proportional
hazards regression [29]. This model defines the hazard of a patient at time t to
be λ(t|x) = λ0(t) exp(xβ), where x are the covariates for the patient, β are the
model coefficients, and λ0(t) is the baseline hazard. This model does not require the
baseline hazard to be known, and the model is simply fitted for β. Due to the lack
of knowledge concerning the baseline hazard, predictive ability is often reported as
hazard ratios - the ratio of hazards for two groups - as the baseline hazard cancels.
This model makes assumptions about the data and relationships to the target
value, one of which is the ‘proportional hazards’ assumption. As may be seen from
the form of the hazard above, any time dependence is present via the baseline hazard.
The proportional hazards assumption therefore requires that the effect of a feature
on the hazard function is multiplicative and, unless specified otherwise, constant over
time. This assumption is not necessarily true; features such as tumour grade and
hormone receptor status have been found to have time-varying effects [16, 15]. In the
case of molecular measurements, when analysing a lung cancer gene expression data
set Dunkler et al. [39] identified genes with both converging or diverging hazards.
These observations suggest that, although the Cox proportional hazards model is
effective under the required assumptions, alternative models are required in the case
of more complex data.
Here Gaussian processes have been chosen as the basis for a survival model
due to their flexibility. These models place priors on the space of functions relating
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covariates to outcome, and hence are flexible and probabilistic, allowing them to
effectively deal with noisy and complex data sets. In this way, very few assumptions
are made about the form of the relationship between data and target, allowing the
method to be applicable in many contexts.
Censored survival times may be considered to be missing, but with information
known about their minimum possible value. In order to apply Gaussian processes
to survival data, three models have been developed to learn values for the censored
survival times, incorporating information from the censored samples, resulting in a
training set composed of both censored and uncensored samples. Hence these models
allow many more samples to be retained, using the data set to its best advantage.
3.2 Gaussian process regression
Gaussian process regression is a well researched topic, providing a comprehensive
toolbox of methods suitable for model fitting in many varied contexts. A Gaussian
process is a collection of random variables for which the joint distribution between
any finite subset is Gaussian. A Gaussian process is completely defined via its
covariance and mean functions, k(x,x′) and m(x), and a random function f(x) may
be written f(x) ∼ GP(m(x), k(x,x′)) [127].
It is assumed that for some unknown, underlying function f , y = f(x) + 
where  ∼ N (0, σ2n).
It may then be observed that for any finite set of points X, the Gaussian
process on the latent function values f defines the joint distribution
p(f |X) = N (f |µ,K) (3.1)
where µ = m(X) and Ki,j = k(xi,xj) [104].
Using a Gaussian likelihood and prior, the marginal posterior probability
distribution of the noisy target values may be calculated as
p(y|X) =
∫
p(y|f , X)p(f |X) df (3.2)
=
∫
N (y|f , σ2nI)N (f |µ,K) df (3.3)
= (2pi)−
n
2 |K + σ2nI|−
1
2 exp
(
−1
2
(y − µ)>(K + σ2nI)−1(y − µ)
)
(3.4)
.
Model training involves inferring the hyperparameters θ that maximise the
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marginal posterior probability distribution.
The joint distribution of the noisy observed target values and the latent
function values for the test data is [104]:(
y
f∗
)
∼ N
((
m(X)
m(X∗)
)
,
(
K(X,X) + σ2nI K(X,X∗)
K(X∗, X) K(X∗, X∗)
))
(3.5)
Following training on training targets and data, y and X, predictions yˆ∗ may
therefore be made using unseen data X∗ as such [127]:
yˆ∗ = m(X∗) +K(X,X∗)>(K(X,X) + σ2nI)
−1(y −m(X)) (3.6)
V[y∗] = K(X∗, X∗)−K(X,X∗)>(K(X,X) + σ2nI)−1K(X,X∗) + σ2I (3.7)
The choice of the mean and covariance functions may be guided by the
structure of the data. For Gaussian processes applied here and in Chapter 4, unless
stated otherwise the chosen forms are the zero mean function and the squared
exponential covariance function:
m(xp) = 0 (3.8)
ky(xp,xq) = σ
2
f exp
(
− 1
2l2
|xp − xq|2
)
+ σ2nδpq (3.9)
where σ2f , σ
2
n and l are function variance, noise variance and length scale hyperpa-
rameters, and xp and xq are the data for the p
th and qth samples respectively.
As seen above, for the squared exponential covariance function seen in Equa-
tion 3.9, the hyperparameters are the function variance, noise variance, and length
scale. These hyperparameters may be considered to represent different aspects of the
data. Firstly, the function variance hyperparameter determines how far the function
may vary from the mean. Secondly, the noise variance hyperparameter determines
the noise level in the model. Lastly, the length scale hyperparameter represents the
characteristic length scale of the model, that is, the speed at which y may vary with
x. These hyperparameters therefore determine the characteristics of the functions
described by the Gaussian process. Similarly, other covariance and mean functions
have their own associated hyperparameters, but these are not considered here.
3.3 Gaussian processes for survival
Three Gaussian process models have been developed for right-censored survival
times. Here censored survival times are considered to be missing values for which
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lower bounds are known. Given inferred missing values, the task is then reduced to
regression using a full data set with no missing survival times. This approach utilises
the information contained in both the censored and uncensored samples to impute
an underlying, non-censored data set.
GPS1 - In this model censored target values are assumed to be unknown
parameters, which are inferred subject to a known minimum target value for each
censored case.
GPS2 - This model involves the same censored target learning as GPS1, but
censored target values are assumed to have higher noise variance than uncensored
samples. For these samples an extra hyperparameter is incorporated to model this
uncertainty as an additional source of Gaussian noise.
GPS3 - As GPS2, except the additional source of Gaussian noise is taken
from the predictive distribution for each censored target value, rather than being
learned as an additional hyperparameter. This results in different additional noise
contributions for each of the censored samples.
3.3.1 GPS1
The training targets for censored samples are considered to be missing, with the
censored value being the minimum possible value, and hence the aim of this model is
to infer these missing values as parameters and learn updated values for the censored
training targets using the whole training set. In this way the censored samples may
still be included in the training set of the model, allowing prediction to incorporate
information from all censored and uncensored samples.
The training data set S consists of, for each sample, the data x, such as
clinical or molecular measurements, the target y, the time to event such as survival
time to death, and the event flag e, where 1 denotes event occurred and 0 that it did
not. The training set of targets and data, S, is partitioned by two subsets consisting
of censored and uncensored samples, Se=0 and Se=1. These two subsets are treated
differently by the algorithm. The uncensored samples remain unchanged throughout
the algorithm, as their final event times are known, and for the censored samples
updated target values are learned.
A Gaussian process is trained using the training targets and data S and
used to predict yˆe=0, the new learned values corresponding to the censored training
targets ye=0. In this way, the new target values for the training set incorporate
information from all of S and hence the final model will contain more information
than if the model was only trained on Se=1.
After prediction, the new training target values are considered in the context
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Figure 3.1: Without adjustment, imposing censoring on the predicted distribution
results in a sharp cut-off, whereby all values below the censored value must be
assigned the censored value. Instead, a truncated normal distribution is calculated,
providing new mean a and variance values. The predicted distribution is then a
normal distribution approximating this truncated distribution, by having the same
mean and variance.
of the original censored target values. As GP predictions are distributions fully
specified by the mean and the variance, it is useful to consider the censoring as
truncation of this distribution. The expected value and variance of this normal
distribution A ∼ N(µˆ, σˆ2) truncated at A = c, where c is the corresponding known
censored target value ye=0, are then calculated as
E(A|c < A) = µˆ+ σˆλ(α) (3.10)
V(A|c < A) = σˆ2(1 + δ(α)) (3.11)
where α = c−µˆσˆ , λ(α) =
φ(α)
1−Φ(α) and δ(α) = λ(α)(λ(α)− α). φ(α) are Φ(α) are the
probability density function and cumulative distribution function of the standard
normal distribution respectively, both evaluated at α. The expected value of this
censored distribution is therefore the predicted target value yˆe=0. Illustration may
be seen in Figure 3.1.
This results in an updated target value for each censored training sample,
creating an updated training set consisting of uncensored samples and previously
censored samples with predicted non-censored target values.
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3.3.2 GPS2 and GPS3
The first model, GPS1, simply uses the means of the predicted distributions as the
replacement censored target value. However, this method leads to the underestimation
of the noise variance hyperparameter, which may be seen in Appendix Figure B.1. In
order to combat this two alternative approaches were developed, GPS2 and GPS3.
GPS2 involves including an extra hyperparameter to represent this additional
variance for the censored samples, σc. This additional variance is included only when
considering censored samples, as
ky(xp,xq) = σ
2
f exp
(
− 1
2l2
|xp − xq|2
)
+Hpq, (3.12)
where H is the diagonal noise variance matrix, and
Hpp =
σ2n + σ2c p where e = 0σ2n p where e = 1.
This method learns a single hyperparameter, σ2c , used for all censored training
samples.
GPS3 utilises the variance output by the model when the new training
targets are predicted. This provides a variance per censored training sample, σc,
which are included in the model as
ky(xp,xq) = σ
2
f exp
(
− 1
2l2
|xp − xq|2
)
+Hpq, (3.13)
where H is diagonal, Hpp = σ
2
n + (σ
2
c)p,
σ2c =
V[A|A ∼ N(µˆ, σˆ2), A > c], c ∈ ye=0 p where e = 00 p where e = 1
and (σ2c)p is the pth element of σ
2
c.
3.4 Initialisation
Also implemented are a hyperparameter pre-learning step and hyperpriors. The
censored targets are simply initialised using a GP regression model trained on a
proportion of the uncensored samples to provide initial guesses for yˆe=0 and the
hyperparameters. Identifying a sensible starting point for the hyperparameters may
be used to reduce running times and may aid in the identification of the informative
model regime, rather than very high or very low noise regimes.
Prior to model fitting, the target values are log transformed. This changes the
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possible range of values from (0,∞) to (−∞,∞), and will prevent negative survival
times being considered.
Hyperpriors are implemented to provide information with regards to the
hyperparameter values, using Gamma distributions on the log of the hyperparameters.
After normalisation of each feature to N (0, 1) it is reasonable to expect σ2n and
σ2f to be below 1, and for l to be smaller than the range of the data. Therefore,
the hyperpriors were chosen to be σ2n ∼ G (k = 2, θ = 1), σ2f ∼ G (k = 2, θ = 1) and
l ∼ G (k = 2, θ = d) where d is the 5–95th percentile range of the data X.
Plots of the hyperpriors may be found in Figure 3.2.
3.5 Implementation
All versions of the model have been written in R [126]. The functions and scripts
may be found at https://github.com/kllloyd/Thesis.
3.6 Inference
The algorithm applied for GPS1, GPS2 and GPS3 can be found in Algorithm 3.1.
The original training set is the union of the censored and uncensored subsets,
Se=1 ∪ Se=0, and consists of data X and uncensored and censored targets, ye=1 and
ye=0. Using this training set, updated values for the censored targets are inferred,
yˆe=0. These replacement values are incorporated into the updated training set
Se=1 ∪ Sˆe=0 and used to again predict new censored target values. This process is
repeated until convergence of the log marginal posterior, L.
As with Gaussian process regression, training is carried out via optimisation
of the log marginal posterior with respect to the hyperparameters σ2n, σ
2
f and l. Here
for all Gaussian process models optimisation is implemented using the R function
optim, using the algorithm ‘Nelder-Mead’ [114].
For the Gaussian process for survival algorithms, hyperparameter and cen-
sored training target values are updated alternately, analogously to Expectation
Maximisation. Following hyperparameter learning, updated values for the censored
targets are inferred using the trained GP. Using the updated training set the hy-
perparameters are then learned again, followed by censored target value prediction.
These steps are iterated until the convergence of the log marginal posterior.
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(b) Example hyperprior for length hyperparameter. For this example, the 5–95th percentile
range of the data set was 3.2.
Figure 3.2: Hyperpriors for use with GPS1, GPS2 and GPS3.
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Algorithm 3.1: Gaussian process for survival
Data: Se=1 ∪ Se=0, S∗, tolerance, mean function m, covariance function
k
Result: test targets y∗
1 begin
2 Sˆe=0 ← Se=0
3 t← 1
4 while targetValueChange > tolerance do
5 train GP (m, k), training set = Se=1 ∪ Sˆe=0
6 predict new target values µˆ and variances σˆ2, test set = Sˆe=0
7 y˜ ← E[A|A ∼ N(µˆ, σˆ2), A > c], c ∈ ye=0
8 targetValueChange← |Lt−1 − Lt|
9 yˆe=0 ← y˜
10 t← t+ 1
11 predict values for test targets y∗, test set = S∗
3.7 Illustration
The results of censored target learning using GPS1 may be found in Figure 3.3. For
illustration purposes, a small synthetic data set was generated in 1 dimension (100
training samples, 50 test samples) and then censored non-informatively, with 40%
of training samples being censored. Figure 3.3 shows training set target values pre-
and post censoring, and post learning. These learned target values would later be
used as the training set for test set prediction. It is clear that GPS1 learned the
pre-censoring target values successfully, with good matching between pre-censoring
and post-learning values. Of particular interest is the far right of the data range,
where the Gaussian process is informed mostly by censored target values, the largest
of which is providing information about the minimum value for the adjacent points.
The hyperparameters learned by this model may be seen in Figure 3.4.
Although the fit may be seen to be good in Figure 3.3, the hyperparameters learned
do not match the generating hyperparameters very well. This is likely due to the
uncertainty introduced by the censoring; the noise introduced by the censoring may
be interpreted as variation in the underlying hyperparameters, leading to variation
in the possible values selected.
To illustrate the effect of repeated hyperparameter learning and censored
training target prediction, Figure 3.5 shows a sequence of plots of intermediate states
whilst training a GPS model, using a one-dimensional synthetic dataset. These plots
were selected to be representative of early, middle and late stages of the process.
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Figure 3.3: Plot of training set data against training set targets. Target values before
and after censoring and after learning are shown. The mean ±2× standard deviation
of predictions are also shown.
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Figure 3.5: A sequence of plots showing intermediate stages of the training set data
and targets whilst training GPS models.
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Figure 3.5: A sequence of plots showing intermediate stages of the training set data
and targets whilst training GPS models.
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3.8 Conclusions
Three Gaussian process models have been developed for survival data, and infer
survival times for censored training set samples. These models will allow the flexibility
and non-linearity of Gaussian process models to be utilised when analysing complex
medical data sets, such as gene expression and clinical covariates in cancer survival.
These models will be investigated in Chapter 4, using synthetic and real data
sets, in parallel with other models for comparison.
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Chapter 4
Gaussian processes for survival
data with right-censoring:
Numerical Experiments
Following the development of the Gaussian process models for survival data in
Chapter 3, in this chapter these models have been applied to both synthetic and real
data. Experiments using synthetic data allow model testing, and the application
of the models to cancer molecular, clinical and survival data demonstrate their
applicability to real, noisy, biomedical data. Other commonly used models were also
applied to the same data for comparison.
4.1 Introduction
Chapter 3 detailed three Gaussian process models for right-censored survival data.
These models were developed to extend the toolbox of Gaussian process methods
applicable for regression to survival data, which would otherwise require censored
samples to be removed from the training set.
As observed in Chapter 2, a relatively small range of models are commonly
applied to survival data. In the context of comparison with the Gaussian process
for survival models developed here, several models were selected, either due to
popularity or suitability. These models are detailed in Section 4.2.6. One of the
most popular is Cox proportional hazards regression [29]. This model makes the
simplifying assumption that the hazard is proportional to the exponential of a linear
combination of the model features [40]. The hazard for a subject at time t may be
calculated as λ(t|x) = λ0(t) exp(xβ) where x are the covariates for the subject, λ0
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is the baseline hazard, and β are the fitted coefficients. When considering hazard
ratios, a common measure of covariate predictive ability, this allows the baseline
hazard function to be ignored as it cancels. However further analysis, such as using
the model predictively, which requires the baseline hazard function to be known may
be problematic, requiring additional assumptions to be made.
The Cox proportional hazards model may also be combined with elastic
net regularisation [144]. For this method, conditions on the l1 and l2 norms are
imposed on the model coefficients, β, and these coefficients are then estimated
as βˆ = argmin
β
(‖y − Xβ‖2 + λ2‖β‖2 + λ1‖β‖1) where X is the covariate data
and y are the target values. λ1 and λ2 are mixing weightings and are selected to
prioritise either the ridge or the LASSO term. This technique allows the regression
coefficients to be shrunk or set to zero, with the aim of minimising overfitting
and identifying informative features when modelling high dimensional data. When
applied in combination with a Cox proportional hazards model, this technique may
be applied to survival data.
Similarly to the Cox proportional hazards model, the accelerated failure
time (AFT) model relies on a baseline hazard, but covariates are also assumed to
accelerate the time to failure [163] as the baseline hazard is also a function of the
covariates: λ(t|x) = λ0 (θ(β,x)t) θ(β,x). θ(β,x) is commonly chosen to have the
form θ(β,x) = exp(xβ)
Gradient boosting machines (GBM) may also be applied to censored data.
These methods utilise a series of additions to a weak model, chosen to minimise a
loss function equivalently to gradient descent [46]. This forms an ensemble of weak
models to create an overall strong learner. When Cox proportional hazards is chosen
to be the base model, the GBM allows a more complex model to be built around
this basic form.
Random Forest models may also be used to model survival data. These
models create ensemble predictions using a large number of decision trees learned
on random subsets of the available features [20]. Random forests for regression can
only be applied to uncensored samples; however, a version for survival data has also
been developed [73]. Due to its high reliability and generalisability, Random Forest
is utilised for many different contexts, and hence is very important for comparison
here. Similarly the Cox proportional hazards model, due to its popularity, is another
important comparison method.
When developing new models, it is important to consider how they perform
on a variety of data. When investigating the predictive ability of the model, data
in regimes corresponding to real life data must be investigated. In this chapter,
58
synthetic data will be used to investigate the success of the Gaussian process for
survival models in various regimes. Synthetic data is especially useful, due to known
‘ground truth’: the true values of the survival of the test samples, the pre-censoring
survival times of the censored training samples, and the underlying hyperparameters
used for data generation. These known values may then be compared to the learned
and predicted values output by the model, allowing the fit to be assessed.
As these models were developed to deal with survival data, it is expected that
a proportion of training samples will be censored. Due to underlying assumptions,
for some models it is often assumed that censoring is non-informative, that is, there
is no relationship between survival and probability of censoring. To implement
non-informative censoring on synthetic data, this requires that samples are selected
randomly for censoring, and that a randomly generated value is used to replace the
survival time for that sample.
Following model testing on synthetic data, models should always then be
applied to real life data. Due to the cleanness and simplicity of synthetic data,
models may achieve higher predictive ability than would be seen in real data. It is
important to note that model predictive ability may also be inflated by unnoticed
bias in choices for the generative model, such as parameter and function selection.
In this chapter, the models are therefore also applied to a selection of real data sets,
consisting of survival, clinical and molecular measurements from cancer patients.
Code and functions to run the experiments detailed in this chapter are
available at https://github.com/kllloyd/Thesis.
4.2 Methods
4.2.1 Synthetic data
Synthetic survival data were drawn from a Gaussian process with predefined hy-
perparameter values. A squared exponential covariance function and a zero mean
function were used with hyperparameters set as in Table 4.1. These hyperparameters
were selected to provide nonlinear trends, changing on a reasonable length scale,
when considered per feature. Hyperparameters denoted with a * in Table 4.1 were
varied during experiments.
Data, X, were generated uniformly over [0,8] then passed to the Gaussian
process to produce target values, y. Samples for censoring were selected randomly
and the target, y, was set to a censored target value chosen from a truncated normal
distribution, yc ∼ T N (µ = 0, σ = 50, 0 < yc < y), ensuring non-informative censor-
ing. Pre-censoring target values were stored to allow comparison with predictions.
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Table 4.1: Table of parameters for synthetic data
Experiment Dim
# Training
Samples
# Test
Samples
%
Censoring
#
Repeats
Hyperparameters
σ2n σ
2
f l m
1 6 400 50 75 30 0.10 0.7 1.1 0
2 6 500 100 * 30 0.10 0.5 1.1 0
3 6 * 100 75 30 * 0.9 1.1 0
* Run for a selection of values, see Section 4.3.1
Samples were then divided between training and test sets randomly. Each feature
was standardised to have mean 0, standard deviation 1. For experiments involving
repeats the specified number of data sets were generated separately, equivalently to
biological replicates. The number of samples, dimensionality, level of censoring and
number of repeats for each synthetic experiment may be found in Table 4.1.
4.2.2 Yuan et al. [171] cancer data
The GPS models and comparison models were applied to real data, recreating the
analysis applied by Yuan et al. [171] to publicly available molecular and clinical
data from cancer patients. Yuan et al. [171] applied Cox proportional hazards and
Random Survival Forest models, with the feature selection methods outlined below.
Core clinical and genomic/proteomic data, training and test data set splits
and example code were obtained from the Synapse homepage of the project (accession
number syn1710282, doi:10.7303/syn1710282). The example code provided by Yuan
et al. [171] was used to recreate the methods used, with the code being used as
provided when possible, and modifications minimised. The data sets consist of
samples as seen in Table 4.2. This data is a curated version of that generated by
The Cancer Genome Atlas (TCGA) [118, 116, 101, 117]. The six data types are:
• clinical
• somatic copy-number alteration (SCNA)
• DNA methylation (methyl)
• mRNA expression (mRNA)
• microRNA expression (miRNA)
• protein expression (protein)
The cancer types considered are:
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• kidney renal clear cell carcinoma (KIRC)
• glioblastoma multiforme (GBMF)
• ovarian serous cystadenocarcinoma (OV)
• lung squamous cell carcinoma (LUSC)
Table 4.2: Table of sample numbers and data availability for each cancer type, data
from Yuan et al. [171]
Cancer # Samples
# Variables
Clinical SCNA methyl mRNA miRNA protein
KIRC 243 4 69 16 484 20 203 795 166
OV 379 3 109 24 980 17 813 798 165
GBMF 210 3 106 24 980 17 813 533 -
LUSC 121 3 114 - 20 194 829 174
Cox proportional hazards and Random Survival Forest methods were applied
as by Yuan et al. [171], using the R packages survival [155] and randomForestSRC
[73] were used respectively. In addition, feature selection was applied prior to
model training. Univariate Cox Proportional Hazards models were used to identify
significant features and those with a p-value < 0.05 were retained. For the Cox
Proportional Hazards model, a lasso penalty was also applied if more than five
features were remaining. This feature selection was applied as recreated from Yuan
et al. [171], and functions used may be found in the thesis code repository (see
chapter Introduction, Section 4.1).
All models were run on the same 100 cross-validation training and test sets,
as specified by Yuan et al. [171]. For the GP models, each molecular feature was
standardised to have mean 0, standard deviation 1.
4.2.3 Tothill et al. [156] cancer data
A second real data set was obtained using the the R package curatedOvarianData
[48]. This package consists of data from studies assessing aspects of ovarian cancer
using gene expression and data has been prepared to provide a consistent method of
accessing features across studies. Other clinical features are also available in many
data sets. The data set with the largest number of samples, other than TCGA, was
utilised.
This data set was GSE9891, generated by Tothill et al. [156]. Clinical features
were selected to be grade, stage and age at diagnosis, as these features have an
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Table 4.3: Table of sample numbers and data availability, data from Tothill et al.
[156]
Data Type # Samples # Variables
Clinical 274 3
mRNA 285 19 816
Clinical + mRNA 274 19 819
acceptably low proportion of missing data. The available numbers of samples and
dimensionality of each data type can be found in Table 4.3.
For this gene expression data set, subsets of genes were identified for use in
the models, as the full data set was prohibitively large. Information on these two gene
sets, Ovarian Cancer Gene Set (OCGS), and Systematic Review Gene Set (SRGS),
may be found in Section 4.2.4 below. These gene sets are applied as a filtering step
prior to model fitting for all models. Following gene name standardisation to the
HUGO system [57], only features with names corresponding to those in the gene set
were retained.
4.2.4 Gene sets
In the context of cancer data, studies and measurement techniques are becoming
increasingly high dimensional. Whilst this provides more information per patient,
data sets such as gene expression microarrays can be prohibitively large (∼ 20000
features) and hence some feature filtering is useful prior to model fitting. Here two
separate gene sets are considered, the Ovarian Cancer Gene Set (OCGS) and the
Systematic Review Gene Set (SRGS). Both gene sets were developed using prior
knowledge from published studies and are hoped to provide genes relevant to cancer
survival.
The first gene set, OCGS, was derived from a study by Glaysher et al. [54]
for which a custom TaqMan gene expression microfluidic array was developed to
explore resistance to chemotherapy in ovarian cancer. The genes selected were
biologically motivated and were selected to be associated with various functions
relevant in cancer: apoptosis, proliferation, pumps and detox, and DNA repair. A
small number of housekeeping genes were also included for comparison. The gene
set OCGS comprises of 97 genes included in the TaqMan array.
The second gene set, SRGS, was developed using the results of the systematic
review by Lloyd et al. [92], also detailed in Chapter 2. The systematic review inves-
tigated the literature concerning the prediction of patient response to chemotherapy
in ovarian cancer via statistical methods. The study resulted in a list of genes found
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to be predictive by various published studies. The genes in SRGS were chosen to
be those selected as predictive by two or more papers. This gene set consists of 84
genes.
There is a small overlap of eight genes between the two gene sets: APAF1,
BAD, FASLG, HSPD1, SLC29A1, ABCC1, ABCC2, ABCC6, ERBB2, ERBB3,
TP53 and VEGFA.
The genes comprising OCGS and SRGS may be found in Tables 4.4 and 4.5.
Both of these gene sets will be used for feature filtering with the Tothill et al. [156]
cancer data set.
4.2.5 Gaussian process for survival models
The experiments here investigate the Gaussian process for survival models, as
detailed in Chapter 3: GPS1, GPS2, and GPS3. These models are extensions of
Gaussian process regression to apply to right-censored data and here will be applied
to the synthetic and real data sets along with other, standard models for comparison.
Unless stated otherwise, these models are applied with squared exponential covariance
function and zero mean function. Starting hyperparameter values were either random
or not equal to the generating hyperparameters.
As outlined in Chapter 3:
• GPS1: Gaussian process for survival data with no noise hyperparameter
correction
• GPS2: Gaussian process for survival data with noise hyperparameter correc-
tion, implemented as an additional learned hyperparameter
• GPS3: Gaussian process for survival data with noise hyperparameter cor-
rection, implemented using the predicted variance of each training target
prediction
These models will be subsequently referred to as GPS1, GPS2, and GPS3 respectively.
4.2.6 Comparison methods
Other methods were also applied to the same data for comparison. All models were
applied in R. The models used, with R functions and corresponding packages, were:
• AFT: Accelerated failure time, survreg (survival, Therneau and Grambsch
[155])
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Table 4.4: Genes contained in OCGS
Apoptosis Proliferation Pumps and
Detox
DNA Repair Housekeeping
AKT1 APC ATP7B ATM TYMS
AKT2 TUBB3 ABCG2 BRCA1 HPRT1
AKT3 PTGS2 CES1 ERCC1 HMBS
APAF1 EGFR CES2 ERCC2 SDHA
BAD ERBB2 NT5C2 MGMT TBP
BAX ERBB3 DPYD MLH1
BCL2 ERBB4 FPGS MSH2
BCL2L1 HIF1A H2AFX MSH6
BID MKI67 GCLC RAD51
CFLAR CDKN2A GCLM TOP1
FAS CDKN1A GSTP1 TOP2A
FASLG CDKN1B SLC29A1 TOP2B
HSPD1 TP53 SLC29A2 XPA
HSPA1A VEGF ABCB1 XRCC1
HSPA1L ABCC1 XRCC5
HSP90AA1 ABCC2 XRCC6
HSP90AB1 ABCC3
HSP90B1 ABCC4
BIRC2 ABCC5
IGF1 ABCC6
IGF1R ABCC8
IGF2 MVP
IGF2R UMPS
IGFBP1 RRM1
IGFBP2 SOD1
DNAJC15 TAP1
MCL1 TAP2
FRAP1 ABCB4
NFKB1
PIK3CA
PTEN
STAT3
BIRC5
BIRC4
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Table 4.5: Genes contained in SRGS
AADAC CPE FN1 MMP1 SNX7
ABCB1 CXCR4 FOXA2 MUTYH SRC
ABCB10 CXCR7 GNPDA1 MYCBP TCF15
ACTR3B CYP51A1 GUCY1B3 NBN TGFB1
AGR2 DAP HDAC1 NCOA1 TIAM1
AKAP12 DFNB31 HDAC2 NDST1 TIMP1
ALDH9A1 DGKZ HMGCS1 NFIB TOP2A
ANXA3 EFNB2 HSPB7 PCF11 TP53
AOC1 EHF IGFBP5 POLH TRIM27
ARHGDIA EPHB2 IL6 PSAT1 TUBB4A
B4GALT5 EPHB3 ITGAE RBM39 VEGFA
BAX ERCC8 LBR RFC3 XPA
BRCA2 ETS1 LGR5 RPL36 YWHAE
CD38 FADS2 LRIG1 S100A10 ZMYND11
CES2 FASLG LSAMP SDF2L1 ZNF12
CHIT1 FGFBP1 MARK4 SIVA1 ZNF200
COL3A1 FILIP1L MECOM SLC1A3
• Cox PH: Cox proportional hazards regression, coxph (survival, Therneau and
Grambsch [155])
• GBM: Gradient boosting machine, gbm (gbm, Ridgeway [130])
• Coxnet: Cox proportional hazards with elastic-net penalisation, coxph (sur-
vival, Therneau and Grambsch [155]), glmnet (glmnet, Friedman et al. [45],
Simon et al. [144])
• RF: Random Forest for regression with censored samples removed, rfsrc (ran-
domForestSRC, Ishwaran et al. [73])
• RSF: Random Forest for survival, rfsrc (randomForestSRC, Ishwaran et al.
[73])
• GP: Gaussian process regression, applied only to uncensored samples (i.e. the
censored samples were discarded)
• GPR1: Gaussian process regression, applied to all samples, with censored
training times replaced by the median uncensored value
• GPR2: Gaussian process regression, applied to all samples, with censored
training times replaced by values drawn from U(c,max(y)), where c ∈ ye=0
is the corresponding censored target time and y are the training set survival
times.
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These models will be subsequently referred to as AFT, Cox PH, GBM, Coxnet, RF,
RSF, GP, GPR1 and GPR2 respectively.
For each repeat or bootstrap the same data or subset of the data were used
for all models.
4.2.7 Assessing predictive ability: concordance index
Model predictive ability was assessed via the concordance index, which compares the
rank order of predictions and the rank order of the measured values and incorporates
censoring [149]. Two survival times may be ordered if either of two cases are true:
both times are uncensored, or the uncensored survival time is smaller than the
censored survival time. For each pair of orderable times, the ordering of the predicted
times is compared to the ordering of the known times and a contribution to the
sum is made if the orders match. The total is normalised by the number of possible
comparisons between pairs, |E|.
c index =
1
|E|
∑
tiuncensored
∑
tj>ti
1tˆi<tˆj (4.1)
where ti and tj are known survival times corresponding to samples i and j, tˆi and tˆj
are predicted survival times similarly, 1a<b is the indicator function
1a<b =
1 a < b0 otherwise and |E| is the number of pairs of times which may be ordered.
Here, for synthetic data, comparisons are carried out between the predicted
target values and the uncensored targets stored before censoring was applied. When
considering real data, the uncensored values are unknown and so the predicted target
values are compared to the measured data, including the censoring.
The concordance index was calculated in R using the function concor-
dance.index from the package survcomp [140].
Statistical tests were carried out to test for differences in model predictive
ability. To accompany these results, Cohen’s d effect size was also computed. This is
a measure of the difference in means between two sets of data and is normalised by
the appropriate measure of variance. For paired samples this takes the form:
d =
mean(z1 − z2)
sd(z1 − z2) . (4.2)
where z1 and z2 are paired predictions by two models and the functions calculating
the mean and standard deviation are applied to the difference between the two
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vectors.
Statistical tests were carried out in R using the function t.test, which is a
base function. Cohen’s d effect size was calculated in R using the function cohensD
from the package lsr [113].
4.3 Results and Discussion
4.3.1 Synthetic data
Synthetic data were generated as described in the Methods section of this chapter.
GPS1, GPS2, GPS3, GP regression applied only to uncensored samples, and the
selection of six comparison models were applied to the data. All models were
applied to identical data sets, with the same training-test split of samples. For each
experiment the data parameters were as found in Methods Table 4.1.
Experiment 1
For comparison between models, Figure 4.1 shows the concordance index of pre-
dictions made by the various models when applied to the same 30 six-dimensional
synthetic data sets consisting of 400 training samples and 50 test samples, with 75%
censoring (see Methods Table 4.1 for details).
It is clear that AFT, Cox PH and GBM perform poorly, with GBM having
very low predictive ability. This is likely to be due to the presence of complex
non-linear relationships in the data, which, with the exception of GMB, these models
cannot account for. Random Survival Forest does slightly better, but is still not
performing well. Importantly, the Gaussian process for survival models GPS1, GPS2
and GPS3 have noticeably higher mean concordance index than the less flexible
models. The spread in values is also marginally smaller, suggesting that these models
train and predict more reliably. The Gaussian process model trained on only the
uncensored samples (GP) has a lower mean concordance index, to be expected as
the high level of censoring results in a small training set. For comparison, Gaussian
process regression was also carried out according to GPR1 and GPR2, with censored
training targets assigned new values before training. These methods can be seen
to be better than non-informative, but the resulting bias in the training set causes
the predictive ability of these methods to be inferior to removal of the censored
samples in this context, outweighing the benefit of the inclusion of a greater number
of samples. This suggests that the GPS models perform better than simple censored
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Figure 4.1: Experiment 1. Concordance index of test set predictions. Accelerated
failure time, Cox proportional hazards, Cox proportional hazards with elastic-net
penalisation, gradient boosting machine, Random Survival Forest, Gaussian process
trained on only the uncensored samples, GPR1, GPR2, GPS1, GPS2 and GPS3 were
applied to the same 30 synthetic data sets, generated using the same hyperparameter
values. Boxplots show the median and first and third quartiles, with the whiskers
marking 1.5 times the interquartile range from the box.
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Figure 4.2: Experiment 1. Plot of pre-censoring versus predicted test target values
for GPS3. Error bars show one standard deviation as calculated using the variance
reported for each test sample by the model. y = x line is marked in grey for reference.
This replicate had a concordance index value of 0.8.
training target imputation.
As this experiment involved running the models on many replicates of the
data, it may be informative to consider the predictions produced by one model.
Figure 4.2 shows the log survival times predicted by GPS3 for a single replicate from
Figure 4.1 against the pre-censoring test set target values. The error bars depict one
standard deviation, as calculated using the variance reported for each prediction by
the model. The y = x trend may be seen clearly, though the error bars suggest that
there is substantial uncertainty in these values on the part of the model.
Experiment 2
Figure 4.3 shows how predictive ability as measured by concordance index changes
as the proportion of the training set that is censored is varied. As detailed in
Methods Table 4.1, six dimensional data were generated with 500 training samples
and 100 test samples. For each level of censoring, 30 data sets were generated to
which all five models were applied.
69
ll l l
l
l l
0.01
0.1
0.3
0.5
0.7
0.9
0.98
0.4
0.5
0.6
0.7
0.8
Proportion of Training Set Censored
Concordance Index
G
P
G
PS1
R
F
RSF
Co
x PH
Figure 4.3: Experiment 2. Concordance index of test set predictions. GPS1, Gaussian
process trained on only the uncensored samples, Cox proportional hazards, Random
Forest trained on only the uncensored samples and Random Survival Forest were
applied to the same 30 synthetic data sets, generated using the same parameter
values, as the proportion of samples censored was changed. Boxplots show the
median and first and third quartiles. For clarity, whiskers were not plotted.
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It may be seen that, although the Gaussian process model trained on only
the uncensored samples is not able to predict accurately at high levels of training
set censoring, GPS1 has a much greater ability to extract useful information from
the censored samples in this situation. Both GP and GPS1 fare better than the
Random Forest models at low censoring levels, though the survival models retain
better predictive ability as the censoring level rises. Of the survival models in this
experiment, Cox proportional hazards is the least successful.
Experiment 3
Medical data often contain high noise levels, and data sets are often limited in size,
both due to sample availability and running costs. It is therefore of importance that
the GPS models retain effectiveness in these circumstances. It was expected that the
GPS models are likely to have their training and predictive ability affected by the
data noise levels and the size of the training set. As these models work with censored
data, the number of training samples is expected to be additionally important, as
the number of uncensored samples will be smaller than the total number.
A series of data sets were therefore generated with varying values of the
noise hyperparameter, σ2n, and the number of training samples, as detailed in
Methods Table 4.1. 30 repeats were carried out for each cell. GPS3 was selected
to be representative of the GPS models, as they were observed to provide similar
results up to this point. GPS3 was chosen due to the inclusion of the additional
noise term, unlike GPS1, and the observed lower computational time than GPS2.
Random Survival Forest and Cox proportional hazards were selected as comparison
models due to their frequent implementation and generally good predictive ability.
Figure 4.4a shows the mean concordance index for test targets from each
generated synthetic data set, following prediction using the GPS3 model. It is clear
that for low numbers of training samples and high noise levels the model does not
perform well, but the concordance index values rise as these change. For low noise
and larger numbers of samples the concordance index values achieved are respectable.
For comparison, Figure 4.4b shows the same data fitted using the Random Survival
Forest model. It is clear that this model was much less successful, with all cells
showing lower mean concordance index than for the GPS3 model. When fitted using
the Cox proportional hazards model, these values were lower still, with no cells
having mean value above 0.65 (see Appendix Figure C.1).
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0.63 0.66 0.65 0.69 0.69 0.71 0.72
0.61 0.64 0.64 0.67 0.69 0.69 0.70
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(a) GPS3
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Figure 4.4: Experiment 3. Mean concordance index values as generating noise
variance hyperparameter and number of training samples are varied. a) Model fitted
was GPS3. b) Model fitted was Random Survival Forest.
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4.3.2 Yuan et al. [171] cancer data
The Gaussian process models were also applied to data obtained from Yuan et al.
[171], as outlined in Methods 4.2.2. These data are a curated version of the TCGA
data for four cancer types: kidney renal clear cell carcinoma (KIRC), glioblastoma
multiforme (GBMF), ovarian serous cystadenocarcinoma (OV) and lung squamous
cell carcinoma (LUSC). Here, the clinical data alone for all four cancers and the
molecular data with and without clinical data for KIRC were chosen to be run, due
to Yuan et al. [171] achieving good results on these data sets. Cox proportional
hazards and Random Survival Forest models were also run, as in Yuan et al. [171].
Using the training-test sample splits as defined by Yuan et al. [171], all models
were applied to the data via 100-fold cross validation. This results in a set of test set
predictions per model, per fold, and hence 100 concordance index values per model.
The resulting concordance index values for the models applied to the various
cancers and platforms may be seen in Figures 4.5 and 4.6. The boxplots show
the median and first and third quartiles, with the whiskers marking 1.5 times the
interquartile range from the box.
It may be seen that, whilst the Gaussian process model trained on only the
uncensored samples fails to train a predictive model, the survival models GPS1,
GPS2 and GPS3 have predictive ability comparable with that of the Cox proportional
hazards and Random Forest for survival models.
4.3.3 Tothill et al. [156] cancer data
The selection of models were also applied to ovarian cancer clinical and mRNA
expression data obtained from Tothill et al. [156] using the R package curatedOvar-
ianData [48] (See Methods 4.2.3 for more details). 50 subsets of the data containing
200 training and 50 test samples were run by applying Monte Carlo cross validation,
whereby the required number of samples are held out at random, and repeated for
the required number of folds. This produced 50 concordance index values per model.
The models were applied to the mRNA data from Tothill et al. [156] using
one of two gene sets, OCGS or SRGS. The resulting concordance index values may
be found in Figures 4.7a and 4.7c. The models were then also run on data comprising
of both mRNA expression data as selected by the gene set and clinical features, and
may be found in Figures 4.7b and 4.7d.
When we consider the case of OCGS and no clinical variables in Figure 4.7a,
it may be seen that, whereas the concordance index results of the accelerated failure
time, Cox proportional hazards and Cox proportional hazards model with elastic-net
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(a) KIRC, clinical data
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(b) OV, clinical data
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(c) GBMF, clinical data
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(d) LUSC, clinical data
Figure 4.5: Yuan et al. [171] data, cancers with clinical data
penalisation models are somewhat distributed around 0.5, and the Random Survival
Forest and Gaussian process without censored samples models are only marginally
better, GPS1, GPS2 and GPS3 outperform all the other models. It is thought that
this is a combination of non-linearity and ability to handle high dimensional data.
It was considered whether there is a statistical difference between the results
of the GPS models and the models used for comparison in Figure 4.7a. The results of
paired Wilcoxon signed rank tests applied to the concordance index values calculated
for each model may be found in Table 4.6. The null hypothesis was µ1 = µ2 with
a two sided alternative, µ1 6= µ2. The Holm correction was applied control the
familywise error rate.
Cohen’s d represents the effect size as measured by the difference between
the means of two groups. As a rule of thumb, values of d around 0.01 are considered
very small, 0.8 is medium, and 2 is considered to be extremely large [137]. Although
many of the tests were highly significant (α = 0.05), the effect size as measured
by the Cohen’s d values suggest that that the models fall into two groups, AFT,
Cox PH, Coxnet, GP and RSF vs GPS1, GPS2 and GPS3. The values here suggest
that there is a large difference between the concordance index values for models in
the first group versus the second group, and that there is much less within-group
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(a) KIRC, SCNA data
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(b) KIRC, SCNA and clinical data
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(c) KIRC, mRNA data
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(d) KIRC, mRNA and clinical data
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(e) KIRC, miRNA data
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(f) KIRC, miRNA and clinical data
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(g) KIRC, proteomic data
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(h) KIRC, proteomic and clinical data
Figure 4.6: Yuan et al. [171] data, KIRC with molecular data
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(a) mRNA expression data from gene set OCGS
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(b) mRNA expression from gene set OCGS and clinical data
Figure 4.7: Tothill et al. [156] data, concordance index of test set predictions.
GP, GPS1, GPS2, GPS3, Cox proportional hazards, accelerated failure time, Cox
proportional hazards with elastic-net penalisation and Random Survival Forest were
applied. a) Symbols show whether a model was significantly different from each
other model (α = 0.05): § - AFT, ¢ - Coxph, ∆ - Coxnet, U - RSF, ♦ - GP,  -
GPS1, 0 - GPS2, † - GPS3. See Table 4.6 for full details of statistical tests.
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(c) mRNA expression data from gene set SRGS
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(d) mRNA expression from gene set SRGS and clinical data
Figure 4.7: Tothill et al. [156] data, concordance index of test set predictions.
GP, GPS1, GPS2, GPS3, Cox proportional hazards, accelerated failure time, Cox
proportional hazards with elastic-net penalisation and Random Survival Forest were
applied. a) Symbols show whether a model was significantly different from each
other model (α = 0.05): § - AFT, ¢ - Coxph, ∆ - Coxnet, U - RSF, ♦ - GP,  -
GPS1, 0 - GPS2, † - GPS3. See Table 4.6 for full details of statistical tests.
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variation. GP and RSF may be considered to form an intermediate group, but there
is still a large difference in effect size between these models and the GPS models.
Within the GPS group, there is little difference between the models, and this was
not found to be statistically significant.
Considering Figure 4.7c, in the case of SRGS when clinical features were
excluded, all models resulted in similar concordance index values centred around 0.65
with ranges around 0.4–0.75. The median concordance index for the GPS models
were marginally higher. When clinical features were included (see Figure 4.7d),
there was very little difference in the concordance index values for any models. This
suggests that the gene set SRGS is informative, to some extent. However, the large
variation in concordance indices achieved between cross-validation folds indicates
that the models are not reliably successful, suggesting that this gene set may not be
informative for all samples.
4.4 Conclusions
The modelling of right-censored survival data in medicine is a widespread and
valuable task. The increasing availability of complex, noisy biomedical data is both
a challenge and an opportunity in this regard. New modes of measurement can
potentially lead us to new biological and medical insights, providing opportunities
for future progress. However, the structure underlying such data types can be more
complex than standard methods can fully capture, challenging the abilities of these
methods.
This then requires the development of new statistical methods, to use these
data to their best advantage. Here this challenge is addressed and the following
contributions are made.
• Three models adapting GP regression to right-censored survival data are
presented
• It is shown that all three GP models for survival equal or exceed the performance
of a range of existing models on both synthetic and a range of real data sets
• This opens up the full toolkit of Gaussian process models to analyse survival
data
The Gaussian process modelling framework had already demonstrated its
efficacy in a wide range of data modelling contexts, including many biomedical
applications. The models presented here extend that framework, providing new ways
78
T
ab
le
4.
6:
R
es
u
lt
s
of
st
at
is
ti
ca
l
te
st
s
ap
p
li
ed
to
F
ig
u
re
4.
7a
.
P
ai
re
d
W
il
co
x
on
si
gn
ed
ra
n
k
te
st
,
H
1
:
µ
1
6=
µ
2
(i
.e
.
th
e
d
is
tr
ib
u
ti
on
m
ea
n
s
of
th
e
co
n
co
rd
an
ce
in
d
ex
va
lu
es
fo
r
tw
o
m
o
d
el
s
ar
e
n
ot
eq
u
al
),
H
ol
m
m
u
lt
ip
le
te
st
in
g
p
-v
al
u
e
co
rr
ec
ti
on
ap
p
li
ed
.
W
is
th
e
te
st
st
at
is
ti
c,
C
I
is
th
e
5–
95
%
co
n
fi
d
en
ce
in
te
rv
al
,
an
d
p
is
th
e
re
su
lt
in
g
p
-v
al
u
e.
d
is
th
e
C
oh
en
’s
d
eff
ec
t
si
ze
.
p
-v
al
u
es
in
b
ol
d
ar
e
si
g
n
ifi
ca
n
t
a
t
th
e
5
%
le
v
el
.
C
ox
P
H
C
ox
n
et
R
S
F
G
P
G
P
S
1
G
P
S
2
G
P
S
3
A
F
T
p
=
4
.7
6
.×
1
0
−
3
(W
=
3.
19
,
C
I=
0.
00
–0
.0
1,
d
=
0.
58
)
p
=
4
.5
8
.×
1
0
−
5
(W
=
5.
10
,
C
I=
0.
01
–0
.0
2,
d
=
0.
93
)
p
=
1
.4
5
.
×
1
0
−
3
(W
=
3
.7
0
,
C
I=
0
.0
2
–
0
.0
8
,
d
=
0
.6
8
)
p
=
3
.6
9
.
×
1
0
−
4
(W
=
4
.2
6
,
C
I=
0
.0
3
–
0
.1
0
,
d
=
0
.7
8
)
p
=
2
.3
6
.×
1
0
−
9
(W
=
9
.5
0
,
C
I=
0
.0
9
–
0
.1
4
,
d
=
1
.7
3
)
p
=
2
.3
6
.×
1
0
−
9
(W
=
9
.4
2
,
C
I=
0
.0
9
–
0
.1
4
,
d
=
1
.7
2
)
p
=
3
.3
6
.×
1
0
−
9
(W
=
9
.7
3
,
C
I=
0
.0
9
–
0
.1
4
,
d
=
1
.7
8
)
C
ox
P
H
p
=
5
.6
5
×
1
0
−
5
(W
=
4.
99
,
C
I=
0.
00
–0
.0
1,
d
=
0.
91
)
p
=
4
.6
5
×
1
0
−
3
(W
=
3
.2
2
,
C
I=
0
.0
2
–
0
.0
7
,
d
=
0
.5
9
)
p
=
1
.2
2
×
1
0
−
3
(W
=
3
.7
9
,
C
I=
0
.0
3
–
0
.0
9
,
d
=
0
.6
9
)
p
=
5
.8
6
×
1
0
−
9
(W
=
8
.8
2
,
C
I=
0
.0
8
–
0
.1
3
,
d
=
1
.6
1
)
p
=
6
.9
2
×
1
0
−
9
(W
=
8
.6
8
,
C
I=
0
.0
8
–
0
.1
3
,
d
=
1
.5
8
)
p
=
5
.4
3
×
1
0
−
9
(W
=
8
.9
5
,
C
I=
0
.0
8
–
0
.1
3
,
d
=
1
.6
3
)
C
ox
n
et
p
=
9.
8
2.
×
1
0
−
3
(W
=
2
.8
3
,
C
I=
0
.0
1
–
0
.0
7
,
d
=
0
.5
2
)
p
=
2
.4
6
.
×
1
0
−
3
(W
=
3
.4
9
,
C
I=
0
.0
2
–
0
.0
9
,
d
=
0
.6
4
)
p
=
9
.5
7
.×
1
0
−
9
(W
=
8
.4
3
,
C
I=
0
.0
8
–
0
.1
3
,
d
=
1
.5
4
)
p
=
1
.2
0
.×
1
0
−
8
(W
=
8
.2
9
,
C
I=
0
.0
8
–
0
.1
3
,
d
=
1
.5
1
)
p
=
8
.5
0
.×
1
0
−
9
(W
=
8
.5
3
,
C
I=
0
.0
8
–
0
.1
3
,
d
=
1
.5
6
)
R
S
F
p
=
4.
1
3
×
1
0
−
1
(W
=
0
.9
1
,
C
I=
-0
.0
2
–
0
.0
5
,
d
=
0
.1
7
)
p
=
3
.3
6
×
1
0
−
5
(W
=
5
.2
7
,
C
I=
0
.0
4
–
0
.0
9
,
d
=
0
.9
6
)
p
=
8
.8
2
×
1
0
−
5
(W
=
4
.8
0
,
C
I=
0
.0
4
–
0
.0
9
,
d
=
0
.8
8
)
p
=
4
.5
7
×
1
0
−
5
(W
=
5
.0
9
,
C
I=
0
.0
4
–
0
.0
9
,
d
=
0
.9
3
)
G
P
p
=
5.
6
7
×
1
0
−
3
(W
=
3
.0
7
,
C
I=
0
.0
2
–
0
.0
8
,
d
=
0
.5
6
)
p
=
4
.9
7
×
1
0
−
3
(W
=
3
.1
4
,
C
I=
0
.0
2
–
0
.0
8
,
d
=
0
.5
7
)
p
=
4
.9
7
×
1
0
−
3
(W
=
3
.1
4
,
C
I=
0
.0
2
–
0
.0
8
,
d
=
0
.5
7
)
G
P
S
1
p
=
7.
0
3
×
1
0
−
1
(W
=
-0
.4
2
,
C
I=
-0
.0
1
–
0
.0
0
,
d
=
0
.0
8
)
p
=
7.
0
3
×
1
0−
1
(W
=
-0
.4
6
,
C
I=
0
.0
0
–
0
.0
0
,
d
=
0
.0
8
)
G
P
S
2
p
=
7.
8
7
×
1
0−
1
(W
=
0
.2
7
,
C
I=
0
.0
0
–
0
.0
0
,
d
=
0
.0
5
)
79
to handle censored survival data, and in the process get more out of the data sets
being used.
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Chapter 5
Gaussian process feature
selection
5.1 Introduction
As cancer research progresses, molecular measurements such as gene expression,
miRNA expression and DNA sequencing are producing increasingly high dimensional
data sets. These data sets are often have p n, where p is the number of features
measured and n is the number of samples. For example, of the studies included
in the R package curatedOvarianData, which was used in Chapter 4, the average
number features is 15 046, but 52% of the studies included fewer than 100 samples,
and the largest was 578 samples [48]. This ‘curse of dimensionality’ [17] can cause
many different computational and statistical obstacles.
When data sets are high dimensional, it is common for analysis to involve
feature selection. This process involves the identification of a subset of features from
the whole data set that contain the majority of the information. This subset may
then be used to reduce the dimensionality of the problem, or to inform conclusions
about underlying processes in the data. Feature selection procedures fall into three
main categories [58]: filtering, wrapper or embedded. Filtering procedures involve
pre-fitting analysis to identify informative features, and all other features are removed
prior to model fitting. Wrapper methods involve the generation of features subsets
and fitting using a model as a black box. A score is then used to rate the success
of the feature subset. Wrapper procedures are often applied to feature subsets
methodically, such as using forward selection or backwards elimination. Common
scores include Akaike information criterion (AIC) and Bayesian information criterion
(BIC). Embedded methods are those inherent to the model fitting procedure. These
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methods run on the whole data set and may produce a measure of feature importance.
Examples include Random Forest [20] and elastic net penalisation for generalised
linear models [45].
Gaussian processes were selected as the basis for this work due to their
flexibility and ability to deal efficiently with high-dimensional data. It is often
noted that for Gaussian process regression computational complexity is O(n3) due
to inversion of the n× n covariance matrix [14]. However, the dimensionality of the
data set also contributes to the runtime complexity. For example, given the squared
exponential covariance function, each element is computed as the dot product of two
vectors of length p, which has complexity O(p). For this reason, it is also important
that the dimensionality of the input data is not prohibitively large.
The ability to include prior knowledge into statistical machine learning tech-
niques is an important benefit of these methods, particularly in high-dimensional
contexts [69]. This may be implemented via the use of priors or by guiding fea-
ture selection [85], and may allow, for example, the integration of feature-specific
knowledge or the expectation that the number of non-zero parameters is likely to be
small [45]. The integration of prior knowledge is expected to encourage a model to
favour a biologically relevant regime and hence improve model fitting. In the case of
high-dimensional gene expression data, in Chapter 4 the feature set was restricted
to lists of genes deemed to be relevant to cancer and resistance to chemotherapy.
The identification of a subset of features thought to be biologically relevant allowed
the size of the feature space to be reduced, using prior knowledge to select features
thought to be informative.
Feature selection in biological contexts is often considered to be useful for
understanding relationships and mechanisms of action. For Gaussian processes this
is a lesser researched area. Sparse Gaussian process models have been popular,
but these are more often applied to reduce the size of the sample space rather
than dimensionality [125]. The most basic form of feature selection for Gaussian
processes is via the automatic relevance determination (ARD) covariance function.
This kernel, which is a generalisation of the squared exponential kernel, has a length
hyperparameter per dimension [127]. This allows the length hyperparameters of
uninformative features to take very large values, effectively making the relationship
of the target with that feature constant. However, in high dimensional contexts, this
kernel results in very large numbers of hyperparameters. It is often unlikely that
the data set provides enough samples to learn so many hyperparameters adequately,
resulting in poor fitting due to lack of information, and resulting in strong reliance
on the priors. Simultaneously, the large number of hyperparameters suggests that
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the model is susceptible to overfitting, as with the high number of degrees of freedom
introduced by large numbers of parameters in statistical models such as linear
regression.
In the literature, a selection of other methods have been implemented to
provide more complex feature selection for Gaussian processes. Several of these involve
placing priors, such as the spike-and-slab prior [49], on parameters in variations
of the ARD covariance function [89, 135, 136]. These models have the benefit of
being straightforward to implement: a simple change of covariance function and the
application of priors. However, they still use very large numbers of hyperparameters
in contexts such as gene expression. As a feature selection technique for anisotropic
data, Zhou and Suter [172] applied a Fourier transform before clustering features
and applying feature selection from a frequency perspective. This process allows
the simple squared exponential kernel to be applied, however the results of the
feature selection are not easily interpretable. Other studies have used Gaussian
processes as a basis for more involved feature selection methods [122, 123, 26]. For
example, Pichara and Soto [122] developed a form of local feature selection using
many instances of Gaussian process regression to guide feature inclusion. For each
feature, a score was calculated at each data point and a Gaussian process model
fitted to this score. For each test case, these pre-computed Gaussian processes are
then used to determine which features are to be included in the predictive model.
This method benefits from the ability for features to be included or discarded flexibly,
as may be highly relevant in medical contexts. However, training one model per
feature plus one model per test case may become very computationally intensive.
Here two separate feature selection techniques for Gaussian processes have
been developed. Firstly, a modification of the ARD covariance kernel has been
established to include prior knowledge about relationships in the data. This kernel
assigns a length hyperparameter to groups of features, allowing the number of
hyperparameters to be kept small. This kernel will be referred to as Informed ARD
(IARD) and is detailed in Section 5.2. Secondly, an ensemble method has been
developed to allow random subsets of the feature space to be used to generate
ensemble predictions for test cases that indirectly involve all features. This model
will be referred to as Random Subset Feature Selection (RSFS) and may be found in
Section 5.3.
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5.2 Informed ARD
For Gaussian processes the most widely accepted embedded feature selection method
is the automatic relevance determination (ARD) covariance kernel [127]:
k(xp,xq) = σ
2
f exp
(
−1
2
(xp − xq)>M(xp − xq)
)
(5.1)
where M = diag(l)−2.
Here there is a length hyperparameter per feature, which is fitted to be
appropriate for each feature. Small values suggest a fast-changing trend, whereas
large values represent a flatter, tending towards constant, response. Therefore,
features with length hyperparameters tending towards large values are effectively
being discounted from the model.
However, in situations where the number of features is large or the number
of samples is small, learning values for a length hyperparameter per feature may be
problematic. Simultaneously this type of model is prone to overfitting, due to the
inclusion of many hyperparameters, and heavy reliance on the mean function, due
to not having enough information per feature to adequately learn hyperparameter
values.
It was therefore proposed that a version of ARD be developed that was
capable of incorporating prior knowledge about the grouping of features. In this
way the number of length hyperparameters may be reduced, but the flexibility and
feature selection properties of ARD are retained. This method will be referred to as
Informed ARD, or IARD.
5.2.1 IARD1
The Informed ARD kernel has a basic structure the same as ARD:
k(xp,xq) = σ
2
f exp
(
−1
2
(xp − xq)>M(xp − xq)
)
(5.2)
where M = diag(l)−2.
However, the two differ in their assignation of length hyperparameters l for
each feature.
The full set of features, F , is expected to be split into a number of indexed
subsets, F1, . . . , Fn, which may be overlapping. These are not necessarily a partition,
but must cover F . Each subset of features suggests that the elements of the subset
are similar in some way, and hence it is reasonable for them to be assigned the same
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length hyperparameter.
Example 1
In the simplest case, of two disjoint subsets covering F , the resulting
length hyperparameters may be seen below. Here the two subsets of
hyperparameters are assigned one of two different values.
All	features F	

f1,	f2,	f3,	f4,	f5,	f6,	
f7,	f8,	f9	
	
	
Feature	subset F2	
f3,	f5,	f6,	f8,	f9		->	hyperparameter λ2	
	
	
Feature	subset F1	
f1,	f2,	f4,	f7					 ->	hyperparameter	λ1		
	
	
Therefore		l	=	(λ1, λ1, λ2, λ1, λ2, λ2, λ1, λ2, λ2)		
f1,	f2,	f3,	f4,	
f5,	f6,	f7,	f8,	
f9	
Matters become a little more complicated when the feature subsets are
not disjoint. Now, for each feature, contributions must be considered from each
subset containing it. Simply, the length hyperparameter for each feature becomes
a combination of the length hyperparameters of the subsets to which the feature
belongs.
The IARD kernel is constructed as a product of squared exponential kernels,
one kernel per feature subset, each with their own length hyperparameter, λj . For
each feature, each kernel is either on or off, depending on its inclusion in that
particular feature set.
kIARD(xp,xq) =
n∏
j=1
kj(xp,xq) (5.3)
= σ2nf exp
1
2
(xp − xq)>
 n∑
j=1
Mj
 (xp − xq)
 (5.4)
where there are n feature subsets, Mj = λ
−2
j I, and λj is the length hyperparameter
for feature subset j, associated with squared exponential kernel j.
So, given indexed feature subsets F1, . . . ,Fn ⊆ F with corresponding length
hyperparameters λ1, . . . , λn, the IARD length hyperparameter for feature i is:
1
l2i
=
∑
j∈Ji
1
λ2j
(5.5)
where Ji is the index set of subsets of F containing feature i.
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Example 2
In the case of three subsets covering F but with non-empty inter-
section, the resulting length hyperparameters must be calculated. For each
feature, the length hyperparameters of the subsets to which it belongs are
summed to result in the length hyperparameter for that feature.
All	features F
f1,	f2,	f3,	f4,	f5,	f6,	
f7,	f8,	f9	
	
	
Feature	subset F2	
f3,	f5,	f6,	f8									->	hyperparameter λ2	
	
	
Feature	subset F1	
f1,	f2,	f4,	f7					 ->	hyperparameter	λ1		
	
	
Therefore		
Feature	subset F3	
f1,	f3,	f6,	f8,	f9		->	hyperparameter λ3	
	
	
1
l12
=
1
λ1
2 +
1
λ3
2 ,
1
l22
=
1
λ1
2 ,
1
l32
=
1
λ2
2 +
1
λ3
2 ,
1
l42
=
1
λ1
2 ,
1
l52
=
1
λ2
2 ,
1
l62
=
1
λ2
2 +
1
λ3
2 ,
1
l72
=
1
λ1
2 ,
1
l82
=
1
λ2
2 +
1
λ3
2 ,
1
l92
=
1
λ3
2
f1,	f2,	f3,	f4,	
f5,	f6,	f7,	f8,	
f9	
5.2.2 IARD2
Where feature subsets are not disjoint, the intersection will link more than one,
possibly unrelated, subsets together. Consider the case where one subset contains
some some informative and some non-informative features, and another contains just
some informative features, with the intersection containing a number of informative
features. The non-informative features will push the length hyperparameter of the
first subset to large values, which will have to be compensated for by the length
hyperparameter of the second subset, making it smaller than ideal for the informative
features.
In order to address this issue, a pre-processing step has been developed to
convert the feature subsets to a partition of the original set of features.
For each combination of intersections between the feature subsets, a new
feature subset is created, with a maximum of
∑n
i=1
n!
i!(n−i)! possible new disjoint
subsets. This allows the length hyperparameters of the intersections between feature
subsets to vary more flexibly.
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Example 3
Here the conversion from covering sets to a partition is applied to
three subsets covering F but with non-empty intersection, as in Example 2.
New feature subsets are defined, along with new length hyperparameters,
to allow extra flexibility to the intersection between feature sets.
All	features F
f1,	f2,	f3,	f4,	f5,	f6,	
f7,	f8,	f9	
	
	
Feature	subset F2	
f3,	f5,	f6,	f8									->	hyperparameter λ2	
	
	
Feature	subset F1	
f1,	f2,	f4,	f7					 ->	hyperparameter	λ1		
	
	
Therefore		
l1	=	γ4	
l2	=	γ1	
l3	=	γ5	
l4	=	γ1	
l5	=	γ2	
l6	=	γ5	
l7	=	γ1	
l8	=	γ5	
l9	=	γ3	
	
Feature	subset F3	
f1,	f3,	f6,	f8,	f9		->	hyperparameter λ3	
	
	
New	feature	subset G2	=	F2	-	(F1UF3)	
f5																			->	new	hyperparameter	γ2	
	
	
New	feature	subset G1	=	F1	-	(F2UF3)	
f2,	f4,	f7			 ->	new	hyperparameter	γ1		
	
	
New	feature	subset G3	=	F3	-	(F1UF2)	
f9													->	new	hyperparameter	γ3	
	
	New	feature	subset G4	=	F1UF3	
f1					      ->	new	hyperparameter	γ4		
	
	New	feature	subset G5	=	F2UF3	
f3,	f6,	f8			->	new	hyperparameter	γ5		
	
	
f1,	f2,	f3,	f4,	
f5,	f6,	f7,	f8,	
f9	
5.3 Random Subset Feature Selection
During feature selection processes, it is often difficult to select a single best model or
subset of features, and this approach is often found to give suboptimal results. The
use of Bayesian model averaging (BMA) allows this to be avoided, as many possible
models are combined. During BMA, many possible models are fitted. For each model,
test set predictions are made and the model posterior calculated. For each test set
sample, the predictions are then combined to produce ensemble predictions using
contributions from all the models. To generate ensemble predictions, predictions are
averaged, weighted by the posterior of each model.
Here a method, Random Subset Feature Selection, is investigated whereby
BMA is combined with a randomised algorithm for feature subset selection.
Given a data set D = (X, y), it is expected that of the full set of features F
there is some subset of features F∗ that are informative. In order to identify this
informative subset of features, random subsets of features, Fˆ , are considered and
their utility assessed.
It may be considered that, during feature selection, features are designated
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as ‘on’ or ‘off’. In a model space containing all possible feature sets, this results in(
n
k
)
= n!k!(n−k)! possible models, where n is the full number of features and k is the
number of features in the subsets. This number quickly becomes prohibitively large
to cover exhaustively, and hence the space must be sampled. Here the sampling is
chosen to be random, drawing data subsets from the set of all data subsets with the
given number of features without replacement.
Algorithm 5.1: Algorithm to implement Random Subset Feature Selec-
tion
Data: Data set D with features F , model, subsetDimension,
nFeatureSubsets
Result: BIC per feature subset Fˆ
1 begin
2 Make a list of all possible subsets, s.t. |Fˆ | = subsetDimension,(
# features
subsetDimension
)
combinations
3 for i← 1 to nFeatureSubsets do
4 Randomly select a feature subset Fˆ ⊂ F
5 Train model on data subset Dˆ containing features Fˆ
6 Calculate BIC and test set predictions
7 Compile results from all feature subsets to assess informativeness of
each feature
8 Calculate ensemble predictions, c index etc.
Here the form of the BIC used is
BICmodel = −2 log p(y|X) + d log(n) (5.6)
where d is the number of features in Dˆ, n is the number of samples, and log p(y|X)
is the posterior output by the model trained on the targets and data, y and X.
This form of the BIC balances the number of features against the fit of the
model to the data. In the simple case investigated here the number of features is
static, and so the BIC is proportional to the model posterior.
To investigate the informativeness of each feature, the model posterior is
marginalised over all models containing the chosen feature. In this case,
P (f |D) =
∫
P (f |M,D)P (M |D)dM
∼
∑
Fi3f
exp(−BICi) (5.7)
where f is the chosen feature of interest and BICi is the BIC calculated for feature
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set Fi. By comparing the posterior marginalised for each feature, feature importance
may be assessed.
For each subset of features, the BIC and test set predictions are calculated.
These may be used to generate ensemble predictions, in which BIC is used to create
weighted averages of the predictions from each feature subset. wi = exp(−BICi) is
rescaled such that
∑
iwi = 1, and used as weightings such that for each test sample
yensemble =
nFeatureSubsets∑
i=1
wi · y∗i (5.8)
where y∗i is the predicted target value for a test sample in feature subset i.
5.4 Methods
5.4.1 Comparison models and abbreviations
The full list of models and abbreviated names for this chapter are listed here. Where
relevant, the R package from which the function used is also listed.
• GP: GP regression with only the uncensored samples, and censored samples
removed
• GPS3SqExp: GP for survival data (GPS3) with a squared exponential
covariance function
• GPS3ARD: GP for survival data (GPS3) with an ARD covariance function
• GPS3IARD1: GP for survival data (GPS3) with an IARD1 covariance
function
• GPS3IARD2: GP for survival data (GPS3) with an IARD2 covariance
function
• GPS3SqExpRSFS: GP for survival data (GPS3) with a squared exponential
covariance function and random subset feature selection
• GPS3BICForward: GP for survival data (GPS3) with a squared exponential
covariance function with forward selection of features
• GPS3BICBackward: GP for survival data (GPS3) with a squared exponen-
tial covariance function with backwards elimination of features
89
• RF: Random Forest for regression with censored samples removed, rfsrc (ran-
domForestSRC, Ishwaran et al. [73])
• RSF: Random Forest for survival, rfsrc (randomForestSRC, Ishwaran et al.
[73])
• Coxph: Cox proportional hazards, coxph (survival, Therneau and Grambsch
[155])
• Coxnet: Cox proportional hazards with elastic-net penalisation, coxph (sur-
vival, Therneau and Grambsch [155]), glmnet (glmnet, Friedman et al. [45],
Simon et al. [144])
• StepCoxph: Cox proportional hazards with stepwise forward selection of
features, coxph (survival, Therneau and Grambsch [155]), stepAIC (MASS,
Venables and Ripley [157])
• FilterCoxph1: Cox proportional hazards with univariate filter-based feature
selection using Random Forest and repeated cross validation, coxph (survival,
Therneau and Grambsch [155]), sbf (caret, Kuhn [86])
• FilterCoxph2: Cox proportional hazards with filter-based feature selection
using univariate Cox proportional hazards regression and p-value threshold of
0.05, coxph (survival, Therneau and Grambsch [155])
As in Chapter 4, these models are all applied to the same data sets, for
all repeats. GPS3 is the Gaussian process for survival model with noise variance
correction implemented using the predicted variance of each training target prediction,
as detailed in Chapter 3. Where not explicitly stated, RSFS is always applied to
GPS3 with the squared exponential covariance function.
Forward selection and backwards elimination procedures involve the use of
addition or removal of features from the model. For example, for forward selection,
a single feature is added and some measure of the model fit, such as the BIC, is
computed. The scores for the addition of each possible variable are compared and
the best-performing feature is added to the model. This procedure is continued
iteratively until the addition of variables no longer confers improvement in the score,
and the resulting feature set is used for the final model. Backwards elimination is
performed similarly, but features are removed iteratively from the full feature set,
rather than added to an empty set.
In order to compare different feature selection methods, some comparison
methods also include feature selection. Explicit feature selection is present in
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GPS3BICForward, GPS3BICBackward, Coxnet, StepCoxph, FilterCoxph1 and Filter-
Coxph2. Due to their mechanisms, implicit feature selection is present in GPS3ARD,
GPS3IARD1, GPS3IARD2, GPS3SqExpRSFS, RF and RSF.
5.4.2 Synthetic Data
In order to test the effectiveness of the Informed ARD kernel and the RSFS procedure
for feature selection, a series of synthetic data experiments have been carried out.
Synthetic data were created using a Gaussian process generatively with zero mean
function and ARD covariance function with hyperparameters as detailed in Table 5.1.
The listed proportion of samples were censored randomly to a value drawn
from yc ∼ T N (µ = 0, σ = 50, 0 < yc < y), ensuring non-informative censoring.
Pre-censoring target values were stored to allow comparison with predictions.
The letter following the experiment number indicates which model is being
investigated: ‘I’ for Informed ARD, ‘R’ for RSFS.
5.4.3 Tothill et al. [156] data
As in Chapter 4, the Tothill et al. [156] data set, accessed via the R CuratedOvar-
ianData package [48], was used to test the feature selection procedures on real data.
This data set contains survival, clinical and gene expression data from ovarian cancer
patients. Here two combinations of molecular and clinical features were used, as seen
in Table 5.2. For molecular features, three different options were used: two gene sets,
SRGS and OCGS, and adding a random set of 50 genes from the full data set. This
applies the filtering feature selection step of including a set of genes thought to be
relevant, to reduce the dimensionality of the data set. By including random genes,
some data with unknown levels of information are also introduced. All models were
run on the same set of features.
5.5 Results
5.5.1 Synthetic Data
Experiment 1IR
It is of interest to compare the predictive ability of the two feature selection methods
detailed here. Synthetic data was generated as detailed in Table 5.1. The results
of applying the range of models to the synthetic data may be seen in Figure 5.1.
Each model was applied to all 50 data repeats and the boxplots show the resulting
concordance index values.
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Figure 5.1: Experiment 1IR. Concordance index of test set predictions. Models were
applied to the same 50 synthetic data sets, generated using the same hyperparameter
values. Boxplots show the median and first and third quartiles, with the whiskers
marking 1.5 times the interquartile range from the box.
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Figure 5.2: Experiment 1IR. The BIC values for each GP model. Lower BIC is more
successful. Models were applied to the same 15 synthetic data sets, generated using
the same hyperparameter values. Boxplots show the median and first and third
quartiles, with the whiskers marking 1.5 times the interquartile range from the box.
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Table 5.2: Table of data from Tothill et al. [156] used for each experiment.
Reference Molecular Features Clinical Features Dimension
OCGS+Clin+Rand OCGS, Random grade, stage, age 150
SRGS+Clin+Rand SRGS, Random grade, stage, age 137
From Figure 5.1 the predictive abilities of the range of models may be
compared, using the concordance index values achieved for the test set predictions.
One of the best performing models here was GPS with IARD1, with mean concordance
index of 0.63 (sd = 0.03). GPS3IARD2 was also successful with mean of 0.63 (sd
= 0.04). GPS3SqExpRSFS (mean = 0.63, sd = 0.05) was considered slightly less
successful due to larger variation in the range of values.
When considering only the Gaussian process models, other factors may be
considered to directly compare the models. Firstly, the trade off between model
predictive ability and model complexity may be assessed by considering the BIC. For
each GPS model in Figure 5.2, the BIC was calculated as
BICmodel = −2 log p(y|X) + d log(n) (5.9)
where d is the number of hyperparameters included in the model, n is the number
of samples, and log p(y|X) is the log posterior output by the model trained on the
targets y and data X. Recall that the models aim to maximise the log posterior,
and hence here a lower BIC is preferable.
Figure 5.2 therefore suggests that the ARD model has not been very successful
given the large number of hyperparameters used. When the BIC results are combined
with the concordance index results in Figure 5.1, the IARD and RSFS models appear
to be a good compromise of high concordance index and low BIC. GPSurvBICForward
appears to have achieved a low BIC, but the concordance index values were not
particularly high. As this model used the BIC for feature selection scoring, it is
therefore likely that this model is overfitted.
Secondly, Figure 5.3 shows the hyperparameter values chosen by each GP
model. The boxplots corresponding to each model are grouped and the same colour,
with the models ordered as in the plot title and separated by black lines. The
number of hyperparameters per model varies, hence so do the number of boxplots.
The hyperparameters of the Gaussian process used to generate the data are marked
in grey on the plot, and their values may be found in Methods Table 5.1. As the
generating GP used a zero mean function and an ARD covariance function, there
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are one function variance, one noise variance and 20 length hyperparameters. These
generating hyperparameter values may be used as a comparison for the fitted values
displayed by the boxplots, as these give an impression of the qualities of the data
identified by each model.
The most basic GPS model, GPS3SqExp, used a squared exponential covari-
ance function and hence fitted one function variance, one noise variance and one
length hyperparameter. This model may be seen to select length hyperparameter
values in the middle of the range of values used by the generating model. However,
according to Figure 5.1, the concordance index values achieved by this model were
low. It is probable that this model could not fit the complexity of the data using a
single length hyperparameter. Similarly to all the GPS models, GPS3SqExp both
underestimated the function variance hyperparameter and overestimated the noise
variance hyperparameter. This commonly occurred with the GPS models, and is
likely due to the additional noise introduced via the censoring. Although the GPS3
model includes a term to account for this, it has not been unusual for GPS models
to attribute this additional noise to the noise variance hyperparameter.
The GPS3ARD model fitted 20 length hyperparameter values, and used
the same kernel as the GP used to generate the data. However, this model also
performed poorly. From Figure 5.3, it may be seen that a large number of runs
chose approximately the same values for all the length hyperparameters, and there
appears to be even less variation in the values selected for the function and noise
variance hyperparameters. It seems likely that the GPS3ARD model failed to learn
effectively, and relied heavily on the initial hyperparameter values. This may be due
to the large number of hyperparameters, given the number of training samples.
Due to the imposed structure of the generated data, the length hyperparameter
groups for IARD1 were four sets: F1 = {1, 2, 3, 4, 5, 6}, F2 = {4, 5, 6, 7, 8, 9, 10, 11, 12},
F3 = {11, 12, 13, 14, 15} and F4 = {16, 17, 18, 19, 20}. For IARD2, these sets became
F1 = {16, 17, 18, 19, 20}, F2 = {11, 12}, F3 = {13, 14, 15}, F4 = {4, 5, 6}, F5 =
{7, 8, 9, 10} and F6 = {1, 2, 3}, as the intersections were turned into two additional
sets. From Figure 5.3 we notice that both IARD models fit a gene set with a
longer length hyperparameter. This represents the feature list containing the non-
informative features. By setting the length hyperparameter corresponding to this
list at a large value, the models are able to effectively set it as a constant, with very
little variation on the scale of the X data.
As the RSFS model is an ensemble model, single-run values are of less interest
in this situation. For reference, the RSFS model resulted in chosen length hyperpa-
rameters with median 4.3 and first and third quartiles of 2.9 and 6.0 respectively,
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Figure 5.3: Experiment 1IR. Log hyperparameter values chosen by each GP model.
Models were applied to the same 50 synthetic data sets, generated using the same
hyperparameter values. Boxplots show the median and first and third quartiles, with
the whiskers marking 1.5 times the interquartile range from the box. Hyperparameters
used to generate data are marked in grey (see Methods Table 5.1 for values).
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which are comparable with that of the informative features, x1 to x15.
A group of models commonly incorporated with feature selection are the Cox
proportional hazards models. Here, the basic Cox proportional hazards model does
not have feature selection included, but the Coxnet model involves embedded feature
selection, StepCoxph applies forward selection of features as a wrapper method,
and FilterCoxph1 and FilterCoxph2 both include filtering of features prior to Cox
proportional hazards model fitting. It is interesting to note that all of these models
achieve similar ranges of concordance index values. When the features retained
by these models are considered, those selected by StepCoxph, FilterCoxph1 and
FilterCoxph2 vary. FilterCoxph1 and FilterCoxph2 retain features more evenly, and
FilterCoxph2 in particular fails to discard features and removes features with longer
length scales as often as the non-informative features. StepCoxph placed a strong
emphasis on features x1 to x8, and x12 to x20 were retained rarely. Coxnet was found
to be less strict, with most features being retained on all runs. These results may be
found in Appendix Figure D.1.
Also shown in Appendix Figure D.1, GPSurvBICForward and GPSurvBICBack-
ward resulted in similar trends in retained features, with GPSurvBICForward heavily
favouring x1 to x7, and rarely retaining features x16 to x20. GPSurvBICBackward,
as a greedy method, tended to include more features but x13 to x20 were again
retained less often.
Unlike the models with more explicit feature selection, the Random Forest
methods do not remove features from the model. However, features are assigned a
calculated importance value and these may be used to estimate which features carry
the most information. In this case, RF does not appear to differentiate well between
features, but RSF assigned features x1 to x7 the highest importance. These results
may be found in Appendix Figure D.2.
As described in Methods Section 5.3, exp(−BIC) output by GPS3SqExpRSFS
may be marginalised to provide a marginalised probability for each feature. This may
be considered analogous to the importance value output by Random Forest models.
Appendix Figure D.3 shows that for this experiment the marginalised probabilities
for the variables are quite similar, with very little trend. It is therefore likely that
many models were given the same weighting and found to be equally important.
Experiment 2R
It was considered what effect the number of unique models has on the predictive
ability of the resulting ensemble predictions. For this reason, data was generated
as in Table 5.1 and GPS3SqExpRSFS was fitted with differing numbers of feature
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Figure 5.4: Experiment 2R. Boxplots of concordance index values for ensemble pre-
dictions as the number of subsets of features are varied. Models are GP, GPS3SqExp,
and GPS3SqExpRSFS. Each boxplot represents 99 repeats. GP and GPS3SqExp
were applied to each repeat. GPS3SqExpRSFS was applied to each repeat for varying
numbers of boostraps.
subsets, where for each subset the GPS3SqExp model was applied to a randomly
selected subset of the full set of features. Following the creation of 1000 feature
subsets, smaller samples were taken randomly without replacement to provide the
other sets of feature subsets. Ensemble predictions were then generated for each set
of feature subsets. For comparison, GP and GPS3SqExp were also run on the same
data, and all models were applied to each repeat. Figure 5.4 shows the results of 99
repeats of each number of feature subsets.
Statistical tests were carried out to quantify the statistical significance and
effect size between models for each number of feature subsets. Two sample Wilcoxon
rank sum tests were applied to the concordance index values for each model. The null
hypothesis was µ1 = µ2 with a one sided alternative, µ1 < µ2. The Holm correction
was applied control the familywise error rate. Cohen’s D effect size was calculated
similarly, between the concordance index values for the models.
The results may be seen in Table 5.3. The first block compares GP and
GPS3SqExp. From the first block of values, it may be seen that the concordance
index results for GP versus GPS3SqExp are statistically different (α = 0.05), but
the effect size as represented by Cohen’s D is quite small, suggesting that the two
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GP/GPS3SqExp
W statistic 95% CI P-value Cohen’s D
7083 0.02–∞ 2.0×10−6 0.79
GPS3SqExp/GPS3SqExpRSFS
# feature subsets W statistic 95% CI P-value Cohen’s D
5 3009 -0.07–∞ 1.0×10−0 0.81
25 5898 0.005–∞ 4.2×10−2 0.25
50 6151 0.01–∞ 1.2×10−2 0.35
100 6248 0.01–∞ 8.1×10−3 0.40
200 6242 0.01–∞ 8.1×10−3 0.45
400 6148 0.01–∞ 1.2×10−2 0.44
600 6415 0.02–∞ 2.2×10−3 0.55
800 6521 0.02–∞ 9.1×10−4 0.62
1000 6630 0.02–∞ 3.4×10−4 0.62
Table 5.3: Table of results statistical tests comparing concordance index values of
different models, for different numbers of feature subsets
models do not achieve very different concordance indices.
The second block compares GPS3SqExp to GPS3SqExpRSFS. As seen in
Figure 5.4, GPS3SqExpRSFS does not achieve as good concordance index values as
the other models when 5 feature subsets are used. However, the results for 25 to
1000 subsets are more interesting. It may be seen that the models are statistically
different (α = 0.05), though again the effect sizes are still modest. However, they
may be seen to rise as the number of feature subsets is increased. This suggests
that the GPS3SqExpRSFS model achieved higher predictive ability than GP and
GPS3SqExp and, additionally, increasing the number of feature subsets improved
the predictive ability, though only slightly.
As the number of feature subsets was increased it was expected that the
concordance index of predictions would converge, as a larger number of possible
models were sampled. However, it may be seen from Figure 5.4 that this failed to
occur. On inspection of the models for each subset, it seems a small number of
models are dominating the weightings, which may be seen in Appendix Figure D.4.
This is likely due to the inflation caused by exp(−BIC) for the smallest BIC values.
This results in a small number of highly weighted models, and hence the increase
in the number of models included is not able to add information to the ensemble
predictions. For comparison, the predictions made by GPS3SqExpRSFS were also
weighted uniformly and these results may be found in Appendix Figure D.5. There
it may be seen that, using uniform weighting, there is a slight improvement in
concordance index as the number of feature subsets rises, compared to the exp(−BIC)
99
weighted version.
It is therefore suggested that the procedures for both the model selection and
ensemble generation could be improved. The model selection procedure used here
was random selection, and could be improved by some guidance to aid identification
of possibly informative models. This method could, for example, blend random and
stepwise sampling to further explore models similar to those with low BIC.
Experiment 3R
To investigate the Random Subset Feature Selection method more thoroughly, it was
proposed to experiment with changing the dimensionality of the data. When gener-
ating data, both the dimensionality of the data and the number of non-informative
features are set. For this experiment, these are both varied. The length hyperparam-
eters were drawn randomly from G(k = 2, θ = 3). As the number of features was
increased, the number of feature subsets for the RSFS model was also increased to
be approximately 10 times the dimensionality of the data.
For comparison, GP regression with only uncensored samples and GPS3 with
squared exponential kernel were also run. Each model was applied to all 50 repeats.
Figure 5.5 shows, for each model, an interpolated surface created using the median
value from each set of repeats.
For reference, Appendix Figure D.6 shows the results of the RSFS model,
with boxplots showing the concordance index of the model predictions as the total
dimensionality and the number of non-informative dimensions changes.
As may be seen in Figure 5.5, the GPS3SqExpRSFS model appears to have
higher concordance index values for the higher dimensionality combinations than GP
and GPS3SqExp, suggesting that the GPS3SqExpRSFS model is achieving better
predictive ability.
It is interesting to note that for all models, for a set number of features,
model predictive ability seems to be better when a greater proportion of features are
non-informative. The RSFS feature selection method operates by fitting a GPS model
to small subsets of features. In Experiment 2R we saw that the ensemble predictions
were dominated by small numbers of highly weighted models. Combined, these
two factors suggest that few features are contributing to each feature subset, and
also to the ensemble, resulting in low numbers of informative features contributing
effectively to the overall model. For data sets with small numbers of informative
features, this should have little effect on overall predictive ability, but, for large
numbers, the ensemble predictions are unlikely to extract information from enough
features to represent the complexity of the data. The predictive ability of the RSFS
100
0.5
0.6
0.7
0.8
0.9
C Index
10 20 30 40 50 60 70
20
40
60
80
100
No. of non−informative dimensions
To
ta
l n
o.
 
o
f d
im
en
sio
ns
(a) GP regression with censored samples removed (GP)
0.5
0.6
0.7
0.8
0.9
C Index
10 20 30 40 50 60 70
20
40
60
80
100
No. of non−informative dimensions
To
ta
l n
o.
 
o
f d
im
en
sio
ns
(b) GP for survival data (GPS3SqExp)
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Figure 5.5: Experiment 3R. Results of running models on synthetic data with
changing total number of dimensions (y axis) and number non-informative dimensions
(x axis). Interpolated surface created using the median concordance index values
from each set of repeats. Colour represents median concordance index, as shown in
the scale.
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feature selection method therefore is most effective at lower numbers of informative
features, given the total number of features in the data set.
It should also be observed that the number of points present on the pre-
interpolation grid here is low, and hence any conclusions drawn here should be
taken with care. The number of samples appears to be a strong limiting factor in
this experiment, and is likely the reason for the lack of predictive ability at high
dimensions.
5.5.2 Tothill et al. [156] data
Following application to synthetic data, the same models were applied to two subsets
of the Tothill et al. [156] ovarian cancer data set, as detailed in Table 5.2. The results
may be found in Figure 5.6.
Overall, the Informed ARD models are achieving equally good concordance
index scores as the next best models. In both cases, GPS3 with the ARD kernel
achieved much lower scores. It is likely that the data sets used here are too high
dimensional for the ARD model to fit well.
Interestingly, the GPS3SqExpRSFS model does not fare well here. It is
suggested that, as in Experiment 2R, the ensemble predictions are being dominated
by a small number of models. These models each contain a small number of features,
which are unlikely to be capable of particularly good predictions alone due to the
nature of expression data. As in Section 5.5.1, further work investigating alternative
model selection and ensemble generation procedures is proposed to improve the
predictive ability of this model.
Although the difference between models for this data set is not immediately
obvious in Figure 5.6, statistical tests were used to assess the differences. Using
the results of the ‘OCGS+Clin+Rand’ data subset in Figure 5.6a, Wilcoxon signed
rank tests applied to the concordance index values calculated for each model were
applied to compare GPS3IARD1, GPS3IARD2 and GPS3SqExpRSFS to the range
of other models. The null hypothesis was µ1 = µ2 with a two sided alternative,
µ1 6= µ2. The Holm correction was applied control the familywise error rate. From
Table 5.4 it may be seen that the majority of tests were found to be significant
(α = 0.05) for all three methods. The effect scores suggest that GPS3IARD1 and
GPS3IARD2 performed most similarly to GPS3SqExp and GPS3BICBackward, and
GPS3SqExpRSFS performed similarly to GP and RF.
When the same statistical tests are applied to the data in Figure 5.6b, where
the SRGS was used, the results are similar, with mostly significant p-values. For
the IARD models, Cohen’s d effect scores averaged 1.77, whereas GPS3SqExpRSFS
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Figure 5.6: Results of running models on subsets of the Tothill et al. [156] data
set as found in Table 5.2. a) Symbols show whether a model was significantly
different from each other model (α = 0.05): § - GPS3IARD1, ¢ - GPS3IARD2, ∆ -
GPS3SqExpRSFS. See Table 5.4 for full details of statistical tests.
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averaged lower with 1.16 (not shown).
It should be observed that, given the results of Experiment 3R above, it
is likely that the data here are too high-dimensional for the number of samples
available. Whilst the common situation of n << p is often the motivation behind
feature selection, methods will be limited by the sparsity of samples and lack of
information with which to identify useful features and predictive ability suffers as a
result.
5.6 Conclusions
As medical testing procedures become increasingly complex, the molecular measure-
ments produced are becoming higher dimensional. Data such as gene expression and
DNA sequencing may routinely provide 20 000 dimensional data. When it comes
to analysis, this high dimensional data can prove problematic, both in terms of
computational power and time.
Feature selection is often used to reduce the dimensionality of a data set and
identify informative features. In Chapter 4 filter feature selection methods were
applied, both using pre-defined feature sets and univariate Cox proportional hazards
models. However, these methods are restrictive and are unlikely to capture complex
relationships between features.
For Gaussian processes, the ARD covariance function is capable of implement-
ing embedded feature selection via a change of covariance function. This covariance
function assigns a hyperparameter per dimension, which allows uninformative features
to effectively be set as constant. However, when applied to high-dimensional data,
this method is prone to poor fitting due to the large numbers of hyperparameters
used.
In this chapter, two feature selection procedures for Gaussian processes
have been proposed and investigated. In order to address the large number of
hyperparameters required for the GP ARD kernel, the IARD kernel has been designed
to incorporate prior knowledge about relationships between features. Each group
of related features are therefore assigned the same length hyperparameter, thereby
reducing the total number of hyperparameters. This feature selection procedure has
the benefit of being easily integrated, by a simple change of covariance function.
Secondly, an ensemble model utilising Bayesian model averaging using ran-
domly selected feature subsets has also been developed as a wrapper method for
Gaussian process models. This model, GPS3SqExpRSFS, allows the space of models
to be randomly sampled, and produces ensemble predictions weighted using the BIC.
104
Table 5.4: Results of statistical tests applied to Figure 5.6a. Paired Wilcoxon signed
rank test, H1 : µ1 6= µ2 (i.e. the distribution means of the concordance index values
for two models are not equal), Holm multiple testing p-value correction applied. W is
the test statistic, CI is the 5–95% confidence interval, and p is the resulting p-value.
d is the Cohen’s d effect size. p-values in bold are significant at the 5% level.
GPS3IARD1 GPS3IARD2 GPS3SqExpRSFS
RF p value = 3.44× 10−6
(W statistic = 5.90,
CI = 0.055–0.113,
d = 1.08)
p value = 3.44× 10−6
(W statistic = 5.90,
CI = 0.055-0.113,
d = 1.08)
p value = 5.38× 10−1
(W statistic = 0.66,
CI = -0.021-0.041,
d = 0.12)
RFSurvival p value = 1.08× 10−13
(W statistic = 14.09,
CI = 0.2–0.267,
d = 2.57)
p value = 1.08× 10−13
(W statistic = 14.09,
CI = 0.2-0.267,
d = 2.57)
p value = 3.03× 10−11
(W statistic = 10.95,
CI = 0.13-0.189,
d = 2)
Coxph p value = 2.51× 10−11
(W statistic = 11.05,
CI = 0.154–0.223,
d = 2.02)
p value = 2.51× 10−11
(W statistic = 11.05,
CI = 0.154-0.223,
d = 2.02)
p value = 4.06× 10−6
(W statistic = 5.83,
CI = 0.074-0.154,
d = 1.06)
FilterCoxph1 p value = 1.99× 10−14
(W statistic = 15.46,
CI = 0.23–0.3,
d = 2.82)
p value = 1.99× 10−14
(W statistic = 15.46,
CI = 0.23-0.3,
d = 2.82)
p value = 1.09× 10−10
(W statistic = 10.3,
CI = 0.153-0.228,
d = 1.88)
FilterCoxph2 p value = 2.71× 10−14
(W statistic = 15.15,
CI = 0.189–0.249,
d = 2.77)
p value = 2.71× 10−14
(W statistic = 15.15,
CI = 0.189-0.249,
d = 2.77)
p value = 1.18× 10−8
(W statistic = 8.24,
CI = 0.109-0.181,
d = 1.5)
Coxnet p value = 1.71× 10−13
(W statistic = 13.78,
CI = 0.184–0.248,
d = 2.52)
p value = 1.71× 10−13
(W statistic = 13.78,
CI = 0.184-0.248,
d = 2.52)
p value = 1.06× 10−7
(W statistic = 7.31,
CI = 0.102-0.182,
d = 1.34)
StepCoxph p value = 1.86× 10−13
(W statistic = 13.67,
CI = 0.232–0.314,
d = 2.5)
p value = 1.86× 10−13
(W statistic = 13.67,
CI = 0.232-0.314,
d = 2.5)
p value = 1.05× 10−11
(W statistic = 11.50,
CI = 0.164-0.234,
d = 2.1)
GP p value = 3.64× 10−7
(W statistic = 6.78,
CI = 0.048–0.09,
d = 1.24)
p value = 3.64× 10−7
(W statistic = 6.78,
CI = 0.048-0.09,
d = 1.24)
p value = 6.85× 10−1
(W statistic = -0.43,
CI = -0.032-0.021,
d = 0.08)
GPS3SqExp p value = 2.22× 10−1
(W statistic = 1.31,
CI = -0.005–0.024,
d = 0.24)
p value = 2.22× 10−1
(W statistic = 1.31,
CI = -0.005-0.024,
d = 0.24)
p value = 7.29× 10−5
(W statistic = -4.75,
CI = -0.093–0.037,
d = 0.87)
GPS3ARD p value = 2.76× 10−7
(W statistic = 6.90,
CI = 0.085–0.157,
d = 1.26)
p value = 2.76× 10−7
(W statistic = 6.90,
CI = 0.085-0.157,
d = 1.26)
p value = 1.62× 10−2
(W statistic = 2.65,
CI = 0.011-0.083,
d = 0.48)
GPS3BICForward p value = 9.48× 10−08
(W statistic = 7.36,
CI = 0.077–0.137,
d = 1.34)
p value = 9.48× 10−08
(W statistic = 7.36,
CI = 0.077-0.137,
d = 1.34)
p value = 2.67× 10−2
(W statistic = 2.42,
CI = 0.005-0.06,
d = 0.44)
GPS3BICBackward p value = 2.33× 10−1
(W statistic = 1.27,
CI = -0.006–0.024,
d = 0.23)
p value = 2.33× 10−1
(W statistic = 1.27,
CI = -0.006-0.024,
d = 0.23)
p value = 5.36× 10−5
(W statistic = -4.87,
CI = -0.092–0.038,
d = 0.89)
GPS3IARD1 p value = NaN
(W statistic = NaN,
CI = NaN-NaN,
d = NaN)
p value = 5.66× 10−6
(W statistic = 5.69,
CI = 0.048-0.101,
d = 1.04)
GPS3IARD2 p value = 0
(W statistic = NaN,
CI = NaN–NaN,
d = NaN)
p value = 5.66× 10−6
(W statistic = 5.69,
CI = 0.048–0.101,
d = 1.04)
GPS3SqExpRSFS p value = 5.66× 10−6
(W statistic = -5.69,
CI = -0.101– -0.048,
d = 1.04)
p value = 5.66× 10−6
(W statistic = -5.69,
CI = -0.101– -0.048,
d = 1.04)
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This model, unlike the IARD models, does not rely on prior knowledge of the data
set.
These feature selection methods have been applied to synthetic and cancer
gene expression data and have been found to achieve similar predictive ability to
existing methods, such as Coxnet, Random Survival Forest and stepwise feature
selection. These methods therefore merit further investigation and development,
which will be discussed in Chapter 7.
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Chapter 6
REB Array analysis program
Following the development of a qPCR based mutation test for common, actionable
mutations in non-small cell lung cancer, melanoma and colorectal cancer by the
Cree group, a program for results file analysis has been created. The data generated
by this test require analysis prior to the results being clinically accessible, and the
process by which this is done is required to be carried out by non-specialists. The
analysis program detailed here aims to make data analysis and report preparation
simple, fast and reliable, allowing the test to be clinically feasible.
The mutation test was developed as in [81]:
Hugh Kikuchi, Anne Reiman, Jenifer Nyoni, Katherine Lloyd, Richard Savage, Tina
Wotherspoon, Lisa Berry, David Snead, and Ian A Cree. Development and validation
of a TaqMan array for cancer mutation analysis. Pathogenesis, 3 (1):1–8, 2016.
The analysis program was developed by Katherine Lloyd. Ian Cree developed
the REB array, Hugh Kikuchi did the testing with assistance from Jenifer Nyoni and
Anne Reiman, supervised by Lisa Berry, David Snead, and Tina Wotherspoon.
6.1 Clinical Context
Personalised medicine aims to guide treatment choices using testing and measure-
ments of patient disease state and other factors. By identifying treatments with
better predicted outcomes, patient quality of life and survival may be improved, and
unnecessary interventions minimised.
Personalised medicine is an important aim in cancer research, originating
from the inherent heterogeneity of the disease [97]. Due to the observed abnormal
cell responses, cancer is thought to often be triggered by DNA mutations that lead
107
to disregulation of normal cell mechanisms [159], and hence produce the hallmarks of
cancer [62]. Although some research suggests the matter is more complex [34], it is
a working assumption in much of cancer research that understanding the underlying
mutations within a tumour will allow the development and treatment response of
that tumour to be understood. However, techniques to apply this in a clinical setting
are currently lacking.
Currently, with the exception of Sanger sequencing, sequencing techniques
are little-used in a clinical context, due to their high cost in terms of money, time
and expertise. Sanger sequencing is used clinically as a gold-standard test, but cost
per sample suggests that this would not be feasible if mutation testing were to be
widely implemented, as aimed for by the NHS Personalised Medicine Strategy 2016
[1]. Alternative techniques are therefore required to allow the application of genetic
testing in a higher throughput manner. Next generation sequencing techniques, using
instruments such as the IonTorrent (Thermo Fisher Scientific) or Illumina systems,
are becoming increasingly feasible, but due to cost and expertise required are not yet
routinely utilised in practice. During this interim period, it is therefore reasonable
to consider more targeted, well established techniques for clinical mutation testing.
This is particularly true for triage testing, where a fast, reliable test may be used for
the bulk of cases, with next generation sequencing being utilised when required.
One such technique is mutation detection via quantitative polymerase chain
reaction (qPCR) gene expression measurement. When testing for mutations, qPCR
techniques involve DNA extracted from cancer tissue samples, probes with attached
DNA primers, and a polymerase enzyme. The probes consist of a marker, such as a
fluorescent reporter, attached to short lengths of DNA that are complementary to
the mutation of interest. When these probes are added to the extracted DNA, the
complementary sequences adhere and the primer sequences provide a platform for
the polymerase enzyme to replicate the DNA sequence. As the name suggests, the
reaction then cascades, with replication occurring in an exponential fashion as the
number of copies increases. If the mutated gene is present amplification will occur,
whereas if the gene does not have the mutation there should be no replication.
The action of the polymerase enzyme requires a series of different temperatures
for replication to occur, a sequence of which is referred to as a cycle. These cycles
are therefore used as a measure of time. Due to the probe markers, the number of
copies of the sequence may be estimated over time. Using a chosen threshold, the
cycle number at which the marker passed the threshold is identified, referred to as
Ct. For mutation testing, due to the binary nature of the question, a cut-off between
mutation and wild type is required. This is usually pre-defined using validation
108
experiments. If the Ct for a mutation is smaller than the cut-off, the mutation is
judged to be present. As a control, a number of wild type probes should also be
run, to ensure that the DNA is of sufficient quality and quantity for mutations to be
detected if present.
For example, two tests using this technique, the therascreen EGFR RGQ
PCR Kit (Qiagen) and the cobas EGFR Mutation Test (Roche Molecular Systems),
are currently recommended by NICE [107] but these kits are single-genes and hence,
when applied to multiple genes, costs increase.
In clinical contexts, the feasibility of tests is judged by cost in terms of money,
time and expertise. Usually, tests are carried out by biomedical or clinical scientists,
and time per test is ideally minimised. The complexity of the data analysis following
test output being obtained should therefore also kept to a minimum, both to reduce
required expertise and to reduce chances for human error. For a test involving
gene expression measurement, qPCR is carried out and the resulting amplification
measurements are assessed for whether a threshold value was met. This data analysis
is well defined and the same process will be applied to all samples. It is therefore a
good candidate for automation, whereby the person running the test does not come
into contact with the original data further than inputting a file into the analysis
program.
The aim of the analysis program would be to take qPCR machine output,
apply the analysis using pre-defined rules and thresholds, and output results and
reports as required. Details of the experimental methods and data used to develop the
test will be outlined in Section 6.2 below, and the subsequent analysis specification in
Section 6.3. The technical approach taken and examples may be found in Sections 6.4
and 6.5.
6.2 Data
Kikuchi et al. [81] developed and validated a multi-gene qPCR-based test for ac-
tionable mutations relevant to the treatment of colorectal cancer, lung cancer and
melanoma. This test aims to maximise information gained whilst simultaneously
minimising cost and method complexity.
The genes of interest were EGFR, BRAF, NRAS and KRAS, and the mu-
tations considered have actionable consequences in terms of treatment. NICE
recommends the testing of EGFR for all non-small cell lung cancer patients, to
assess the utility of prescribing EGFR inhibitors such as gefitinib, erlotinib or os-
imertinib [108, 106, 111]. For BRAF V600 mutation positive metastatic melanoma,
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EGFR BRAF
Exon 19 del c.1799T>A
c.2573T>G, c.2572 2573CT>AG c.1798 1799GT>AA
c.2369C>T c.1798 1799GT>AG
c.2582T>A c.1799 1800TG>AT
c.2303G>T
c.2156G>C
c.2155G>A
c.2155G>T
c.2125G>A
c.2126A>C
c.2311 2312insGCGTGGACA
c.2319 2320ins9
KRAS NRAS
c.35G>A c.37G>C
c.35G>T c.34G>T
c.38G>A c.34G>A
c.34G>T c.38G>A
c.34G>A c.182A>T, c.181 182CA>TT
c.35G>C c.35G>A
c.34G>C c.181C>A
c.436G>A c.182A>G, c.181 182CA>AG
c.37G>T c.38G>T
c.183A>C c.35G>T
c.182A>T c.183A>T
c.37G>C c.183A>C
c.35G>C
c.37G>T
c.37G>A
c.38G>C
Table 6.1: Mutations included on the TaqMan array card, by gene.
NICE recommend a range of BRAF inhibitors including dabrafenib and vemurafenib
[110, 109]. It has also been suggested that mutations in KRAS, NRAS, BRAF are
predictive of resistance to EGRF inhibitors in colorectal cancer [154]. The mutations
tested by Kikuchi et al. [81] for the genes of interest are listed in Table 6.1.
Following DNA extraction from FFPE biopsy tissue, gene expression mea-
surements were carried out using TaqMan microfluidic array cards, which carry out
qPCR in 8 sets of 48 wells. Using these cards, the expression of 44 mutations for
7 samples (plus a no-template control) may be measured. In order to test for a
mutation, probes corresponding to the mutation of interest are used. If the muta-
tion is present in the loaded DNA the probe binds to it, resulting in a measurable
florescence response indicating that the mutation is expressed in the sample. For
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each sample, the remaining 4 wells test for a wild type reference per gene, used to
check run quality.
As this is a qPCR technique, the presence or absence of a mutation is judged
based on when florescence in a well passes a threshold value. The cycle number
of this event is referred to as the threshold cycle, or Ct. The threshold value may
vary between probes, and is usually set at 3–5 times of the standard deviation of
the signal noise above background. The measurement of gene expression using the
TaqMan array produces a file containing time course florescence measurements and
Ct values for each well.
6.3 Specification
Following the development and validation of the physical methods and materials, for
the purposes of the Kikuchi et al. [81] paper, analysis was carried out in Excel (by
HK). However, it was decided that this approach was not optimal if the test was to
be used in a clinical setting. Instead a dedicated software program was designed for
data analysis and report generation.
With input from clinical pathologists (IC and DS), program requirements
were determined to be:
• Analysis was required to be carried out in an automated fashion, requiring
little user input or tuning
• To conclude that a mutation is present in a sample, the following conditions
must be met:
– The card no-template control must be negative (all wells Ct > 36.5)
– All four sample reference wells must have Ct ≤ 35
– The well for the particular mutation must have Ct < 36.5
• A report was to be produced for each sample, detailing extraction techniques
and mutations present
The subsequent program was designed and written by KL.
6.4 Techniques
R [126] was selected as a suitable programming language for the analysis. Once
the analysis was written to specification, the shiny [24] package was used to create
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an interface with which the user can interact, without requiring knowledge of the
language. This package allows the creation of standalone, interactive pages capable of
functions such as uploading files, presenting data, plotting and outputting files. The
package knitr [168] was then used to create PDF reports for each sample containing
the requested information.
The program was designed to run as a standalone program in Windows, to
open like any other program and to prevent users having to interact with the R
console. Running the program starts R and runs the script, and Chrome is started
to present the output. When Chrome is closed, R is also closed. The program uses
portable versions of R, Chrome and Miktex to enable it to be self-contained and
installation to be simply copying over the folder.
In the context of the clinical test under development, gene expression mea-
surements were carried out on a ViiA 7 Real-Time PCR System (Thermo Fisher
Scientific). This machine has accompanying software which allows the data produced
by runs to be downloaded in a variety of file types. Here .txt was selected as the
most suitable, and the analysis was written to read from this file type.
When the program is started, the user is required to locate the appropriate
file and upload it to the program. The analysis is then applied automatically. The
original file is not altered. When required, the analysis results may be downloaded
as a zipped file containing a .pdf report per sample.
The program was written to run on Windows 7 Professional, and has also
been tested on Windows XP. The program contains Google Chrome Portable 2.3.0.0,
Miktex Portable and R Portable 3.1.2 loaded with the shiny [24], knitr [168] and
xtable [33] packages. For generating the PDF reports, the LATEX packages amsmath,
multicol, framed and geometry are used.
6.5 Program
When started, the program appears as in Figure 6.1.
As per the instructions, a .txt file produced by the ViiA 7 Real-Time PCR
machine is then uploaded. Figure 6.2 shows the Summary tab for one such file.
This tab compiles the data from all 7 samples, reporting no-template control status,
wild type reference status and any present mutations. If no mutations are detected,
mutations are labelled as wild type (WT).
Figure 6.3 shows the contents of a Sample tab. These tabs give a more
detailed view of the results for each sample. Time course florescence measurements
are plotted for each gene with a line for each mutation. Also present is a small table
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Figure 6.1: Screenshot of program before selecting file
summarising which mutations passed the Ct threshold for each gene.
In addition to the on-screen output, a summary report for each sample is also
produced. On clicking the Download Reports button, the reports are generated and
then downloaded as a zipped file. Figure 6.4 shows an example report.
6.6 Future generalisations
This approach of developing automated analysis software becomes increasingly
important as the complexity of the analysis rises. For example, the movement from
qPCR to next generation mutation testing will likely necessitate such software to
allow mutation reporting to be feasible within clinical constraints.
Hamblin et al. [60] investigated the appropriateness of setting up a next
generation sequencing-based EGFR mutation test for clinical use. As the sequencing
platform was the Ion Torrent Personal Genome Machine (Thermo Fisher Scientific),
this study utilised the built-in Torrent Suite software for data analysis. This study
implemented targeted sequencing using the Ion AmpliSeq Cancer Hotspot Panel
(Thermo Fisher Scientific; 46 genes, 189 amplicons), which limits the segments
of DNA that are sequenced to those corresponding to the provided primers for
amplicon library construction. Here the regions sequenced are 46 genes known to
be relevant to cancer. On completion of sequencing, data is passed to the Torrent
Suite software, which provides the facility to apply standard or modified analysis
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Figure 6.2: Screenshot of Summary tab. Table 1 shows the run status for each
sample. Table 2 shows the mutation status for each mutation on the array, for each
sample.
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Figure 6.3: Screenshot of Sample 6 tab. Table shows a summary of the mutations
present in each gene. Plots show the change in measured fluorescence over time for
each gene. Threshold values for each mutation are marked in the same line style as
the corresponding time-series.
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Supplementary Report
Sample Reference: H13-22380
Run Date: 2014-10-26
Molecular Results
Gene CT Base.Change Protein.Mutation Interpretation
1 EGFR Ref* 30.521
2 EGFR 31.691 c.2582T>A L861Q Mutant
3 BRAF Ref* 30.272
4 BRAF WT
5 KRAS Ref* 30.055
6 KRAS WT
7 NRAS Ref* 30.909
8 NRAS WT
* The Ref (reference) result is a control for the wild-type gene.
Genotyping Result
Mutation detected as in the above table.
Testing was carried out using the REB Taqman Array on diagnostic paraffin embedded material selected for testing.
This test uses castPCR
TM
, amplifying targeted mutations in exons 18–21 of EGFR; codons 12, 13, 61 and 146 of KRAS;
codons 12, 13 and 61 of NRAS; and codon 600 of BRAF. 95% of known mutations are covered. Results are considered
reliable down to a concentrate of 2% neoplastic cells. However, at levels as low as this it may be worth considering
re-testing of additional material if the result is negative.
Result Interpretation
Mutations detected in EGFR (c.2582T>A; L861Q).
(Pathologist to add note of clinical significance)
1
Figure 6.4: Example report for Sample 6.
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workflows. The results of this workflow were lists of the mutations present, sorted into
categories: Tiers 1 to 4. Tiers 1 and 2 are known, actionable mutations and known,
non-actionable but clinically relevant mutations respectively. Tier 3 mutations are
those linked to malignancies, e.g. in My Cancer Genome, COSMIC, ccBioPortal or
peer-reviewed literature. Tier 4 mutations have not been previously described. The
Tier 1 and 2 mutations are those of interest in a clinical setting. Tier 3 mutations
may be of interest if clinical trials are available, and this platform presents the
opportunity to test for mutations that are unlikely to be present on qPCR-based
tests.
Use of the Torrent Suite software clinically would likely be problematic due
to the involved nature of the platform, with the investigation of Tier 3 and Tier
4 mutations requiring the user to access databases. As a simplistic analysis, the
inclusion of a .bed file containing a list of mutations of interest would limit the
analysis, but other mutations are then lost from the analysis. Clinically, it is
important that all present mutations are retained if possible, to allow for treatment
research progress.
It is proposed that a second, automated program capable of analysing the
results of the Torrent Suite software would greatly improve the clinical applicability
of this platform. As the list of mutations of clinical relevance could be pre-defined by
a clinician, software capable of extracting these from the list of mutations present in
a sample would greatly reduce the specialist knowledge required by the data analyst,
and still allow the full list of detected mutations to be retained. As with the qPCR
program, clinical reports may then be generated including only the information
relevant for the clinician, whilst a full list of mutations is stored elsewhere.
It should also be noted that the list of interesting mutations need not be
static. For this type of implementation, it would be highly beneficial for the list to be
able to be altered as actionable mutations with targeted therapies, NICE guidelines
and available clinical trials change.
For these reasons, software capable of applying well-defined post-Torrent
Suite analysis without altering the original data file, applying up to date clinical and
NICE guidelines, could be highly beneficial when preparing reports for clinical use.
6.7 Conclusions
With the introduction of personalised medicine the analysis of data following clinical
tests, both for single platform and more complex multi-platform combinations, may
be expected to greatly increase. For example, the analysis required following next
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generation sequencing can be highly in-depth. Similarly, the implementation of a
predictive score to aid treatment choices would be likely to involve complex models
and statistics. Thus, at the point of contact with the user in a clinical context, it
would not be reasonable to expect these analyses to be attempted by hand. It is
therefore suggested that an automated approach should be taken, whereby programs
taking the output from testing procedures and producing results and reports are
utilised.
The benefits of this automated approach are two-fold. Firstly, the specialist
knowledge required for the analysis to be carried out is greatly reduced, with little
to no interactivity between the method applied and the user. This enables any
requirements or standards that need to be met to be integrated into the program,
hence ensuring that they are always satisfied. Unlike with the use of more general
tools, for which knowledge of applicability and best use are required, an automated
analysis tool designed specifically for the data generated by a clinical test could be
trusted to implement the pre-decided, appropriate analysis for every sample.
Secondly, the added separation between user and analysis also reduces the
chance of user error. The use of read-only files removes the risk of data being
overwritten, and the automation of the analysis ensures that all steps of the process
are applied. The ability to transfer results automatically to a report without any
transcribing by the user again removes an opportunity for user error.
Here a program was developed to provide analysis following mutation testing.
Given the well-defined nature of this analysis, with set cut-off values and a pre-
determined list of mutations, this was well suited to an automated program, with
no user input required. The production of clinical standard reports, containing all
required information, allows the program to be used by a biomedical scientist to
produce reports suitable for use by clinicians.
It is proposed that this approach, using programs designed to apply highly
specific analyses tailored to the data generated, could greatly aid clinical practice as
medical tests and models increase in complexity.
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Chapter 7
Conclusion
Cancer research has made great strides in improvements to diagnosis, treatment and
understanding. However, much of this progress is slow to enter clinical practice or
be utilised to highest benefit.
Personalised medicine for cancer is now becoming a feasible aim, with mutation
testing and guided treatments starting to be implemented in clinical practice. In
order to continue this progress as cancer research becomes increasingly data-rich,
tools capable of modelling the high-dimensional data generated as part of molecular
clinical tests must therefore be developed, in order to use these data to their best
advantage. The ability to apply these tools in a clinical setting would then allow
personalised medicine to be used to aid diagnosis and guide treatment decisions.
As seen in Chapter 2, there is currently very little consensus in the literature
concerning the prediction of patient response to chemotherapy via gene expression,
though many studies have concluded that it is a worthy and feasible goal. The
range of laboratory and modelling techniques also vary significantly, and hence so do
the data available. Following collation from the studies fulfilling the search criteria,
a list of 84 genes identified as predictive by at least two studies was constructed.
However, the models used to provide the analysis and predictions were often found
to be basic, with strong emphasis on traditional methods such as Cox proportional
hazards regression.
Accordingly, three Gaussian process models were developed for survival data
in Chapter 3. Gaussian processes were selected due to their suitability for medical
data: they are flexible, probabilistic, and model noisy data effectively. Right-censored
data may be considered to consist of survival times where for censored samples the
survival time is partially missing, and hence the censored times form lower bounds
on the true values. The models apply a Gaussian process prior to the set of all
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functions relating features to outcome, and infer values for the true values of the
censored survival times. In this way, the underlying unmeasured survival times are
imputed using information from all available samples, and the resulting model may
be used for prediction using unseen samples.
These models were investigated using both synthetic and real data in Chap-
ter 4. Initially the models were tested with right-censored synthetic data created
using Gaussian process regression generatively, on which the Gaussian process for
survival (GPS) models outperformed the comparison models in terms of predictive
ability as measured via concordance index. These results are encouraging, but should
be considered in the context of the synthetic data on which they were obtained. The
use of Gaussian processes to generate the data means there is an inherent ability for
a Gaussian process-based model to fit the data successfully. Additionally, synthetic
data form an idealised version of real life data, and are unlikely to include the same
levels of complexity and noise present in real data.
Subsequently, the models were applied to molecular data from cancer patients,
from two sources. Firstly, the analysis by Yuan et al. [171] of the TCGA data
sets for kidney renal clear cell carcinoma, glioblastoma multiforme, ovarian serous
cystadenocarcinoma and lung squamous cell carcinoma were recreated, with the
addition of the GPS models. This data set consisted of clinical data as well as
molecular data from six platforms. The GPS models were found to achieve as good
predictive ability as the Cox proportional hazards and Random Survival Forest
models, with concordance index values taking similar ranges to these comparison
models for all data considered.
Secondly, the models were applied to the gene expression data generated by
Tothill et al. [156]. This data set consists of clinical and gene expression measurements,
and the GPS models were applied along with a range of comparison models. Here,
the list of features was restricted to either of two gene sets, derived from biological
pathway knowledge or Chapter 2. Again, the GPS models were found to equal or
outperform all other tested models. When applied to gene set OCGS and clinical
features, the GPS models were found to achieve statistically significantly (α = 0.05)
higher concordance index values than the comparison models, with large Cohen’s d
effect scores.
For the analysis of the Tothill et al. [156] gene expression data, the dimen-
sionality was reduced using the two gene lists. It was therefore proposed that more
informative feature selection procedures would be useful. For Gaussian processes
this is a lesser researched area, with few easily implemented methods being available.
A popular embedded technique for feature selection with Gaussian processes is the
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automatic relevance determination (ARD) covariance function. The implementation
of this technique is simple, only requiring a change of covariance function, but it can
lead to poor fitting due to the large number of hyperparameters required.
In Chapter 5 a modification of the ARD kernel was developed, IARD, to
incorporate prior knowledge of similarity between features, such as may be provided
by the gene lists used in Chapter 4. The kernel is informed of groups within the
features, such as pathways of relevance to the disease, and these are used to reduce
the number of hyperparameters required. A second feature selection procedure was
also developed whereby a wrapper method was applied to Gaussian processes, to
implement Bayesian model averaging with randomly selected feature subsets (RSFS).
These two feature selection methods were applied, along with suitable comparison
methods, to synthetic data and the Tothill et al. [156] data set. IARD and RSFS
were found to achieve similar predictive ability to the existing models and show
promise, though I believe their performance could be improved in the future.
RSFS in particular has displayed areas in which further work would be
beneficial. Experiments in Chapter 5 suggest that, currently, the method of model
averaging when generating ensemble predictions leads to small numbers of highly
weighted models dominating the ensemble, with many models with larger BICs
contributing much less. To an extent this is expected behaviour; it should be hoped
that well-performing models contribute more than lesser-performing models in order
to generate good predictions. However, with RSFS in its current form, too few
models are being retained to adequately cover more complex feature spaces, and
hence predictive ability is suffering. One approach to address this may be the
improvement of the feature subset selection procedure. Currently, RSFS uses random
selection without replacement for feature subset generation. However, this results
in n!k!(n−k)! possible feature subsets, where n is the total number of features and k is
the subset size. For large numbers of features this forms an extremely large model
space, which is likely to be sparsely sampled if the number of feature subsets is not
increased accordingly. A more involved method for feature subset selection could
therefore improve ensemble predictive ability, if feature subsets could be identified
that were more likely to provide good predictions. A possible area for investigation is
the combination of random and stepwise feature selection, whereby promising areas
in model space would be explored more thoroughly before moving on to another
randomly selected area. Another alternative for consideration may be the prevention
of highly correlated features being present in the same feature subset. As features
with high correlation are unlikely to add additional information, the removal of such
subsets would allow more informative subsets to be used.
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RSFS currently uses feature subsets containing a set number of features,
which is determined prior to the model fitting. For simplicity and speed of fitting, in
Chapter 5 this was set to reasonably small numbers, but in reality it may be difficult
to predict a suitable value. For a given dataset, this value needs to be large enough
that inter-feature effects may be captured, but small enough that the underlying
GPS model may fit effectively. An interesting extension to RSFS may therefore be to
investigate how the feature subset size affects ensemble predictive ability, and explore
the widening of the possible feature subset size to multiple values. For example, it
may be of use to consider the inclusion of small, medium and large subsets in varying
ratios, to attempt to capture dynamics between different numbers of features.
For the IARD methods, the underlying technique is performing reasonably
well, as seen when applied to synthetic data. However, for synthetic data, knowledge
of the length hyperparameters used when generating the data may be used to
accurately inform the selection of feature subsets, resulting in good predictive ability.
In reality, this process is quite problematic when being applied to real data. As seen
in Chapter 5, the IARD methods did not perform as well, relative to the comparison
methods, on real data as on synthetic data, and I believe that a lack of effective
feature grouping is at least partially responsible for this effect. When applied to
the Tothill et al. [156] data set, the three feature groups were selected to be the
features in the chosen gene set (OCGS or SRGS), the randomly selected features,
and the clinical features. However, these groups are large and hence the model
was fitting many features with the same length hyperparameters. As further work,
it would be an interesting progression to investigate the application of biological
knowledge when selecting feature groups. The use of databases such as KEGG could
be useful in identifying related genes, as well as the use of existing literature and
expert knowledge. In this way, the feature grouping inherent to IARD could be used
more effectively.
Chapter 6 documents a program developed for the automated analysis of
mutation testing data, using previously existing methods for qPCR data analysis
and clinically guided parameter values. This program, written with the aim of
allowing reproducible, controlled analysis without requiring specialist knowledge, was
designed to provide results and reports for clinical use, and is currently used for this
purpose at University Hospital of Coventry and Warwickshire. As the complexity of
clinical measurement and testing procedures increases, so will the required analysis.
Therefore, the automation of such tasks is likely to become increasingly important.
Whilst the analysis carried out by the program in Chapter 6 is simple, similar
programs capable of applying well-defined, complex analysis to data without input
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from the user would be highly beneficial in the context of personalised medicine.
When a model for the prediction of patient response to chemotherapy is developed,
for example, this is likely to be complex and requiring specific specialist knowledge.
However, for application in a clinical setting to be feasible, this complexity must be
separated from the user, to allow reproducible and efficient application of the tool.
In order to build on the progress made using traditional modelling methods,
further work is likely to require an emphasis on the flexibility and probabilistic
qualities provided by statistical machine learning techniques, to enable the modelling
of highly complex interactions. The Gaussian process for survival models developed
here have been found to perform well in low-dimensional contexts, and hence may
provide a basis for further investigation. However, despite the promise of these
models, the extension to higher dimensional data such as that found in molecular
cancer data sets would require further development in order to be effective as a
clinical tool. The feature selection tools developed here would require further work
to meet this aim, but again have shown promise. Additionally, effective use of
knowledge of the features likely to be important could greatly benefit the choice and
application of relevant models, as the ability to incorporate any prior knowledge is
an advantage of machine learning models. Feature selection procedures capable of
this, as with IARD, could allow the full volume of information provided by existing
cancer research to be put to best advantage.
The actualisation of personalised medicine tools will result in their application
in a clinical context. Whilst this is not yet imminent, parallels may be drawn to
the increasingly involved analysis required to produce actionable recommendations
following tests such as mutation testing. These analyses are required to be carried out
by biomedical or clinical scientists by rote - it would be prohibitive for the analysis
to require detailed knowledge of the methods being applied or for ad hoc tailoring
of the method to be necessary. It is therefore highly preferable for automation of a
precisely defined and accepted analysis to be implemented. The advantages of this
approach are many, from reduction in opportunities for user error, improvement in
reproducibility, to ease of use. When this concept is eventually applied to personalised
medicine, the machine learning tools likely to be implemented will similarly benefit
from being automated, allowing these highly sophisticated methods to be applied
with the same reliability and simplicity as the most basic analyses.
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Appendix A
Chapter 2 Supplementary
Information
Listing A.1: PubMed search terms
(Ovarian Neoplasms[Mesh] OR ((ovarian[tiab] AND cancer[tiab]) NOT medline[sb]) OR ((
ovarian[tiab] AND carcinoma[tiab]) NOT medline[sb]) OR ((ovarian[tiab] AND
cancerous[tiab]) NOT medline[sb]) OR ovarian neoplasm∗[tw] OR ((ovary[tiab] AND
cancer[tiab]) NOT medline[sb]) OR ovary neoplasm∗[tiab])
AND
(”Chemotherapy, Adjuvant”[Mesh] OR ”Antineoplastic Agents”[Mesh] OR chemotherapy[
tiab] OR chemotherap∗[tiab] OR Doxorubicin[tiab] OR Cisplatin[tiab] OR
Carboplatin[tiab] OR taxanes[tiab] OR taxane[tiab] OR Paclitaxel[tiab] OR
vinorelbine[tiab] OR platinum[tiab] OR Antineoplastic Combined Chemotherapy
Protocols/therapeutic use[mesh] NOT molecular targeted therapy[mesh])
AND
(Gene Expression/drug effects[Mesh] OR Gene Expression/genetics[Mesh] OR gene
expression[tiab] OR genetic express∗[tiab] OR upregula∗[tiab] OR downregula∗[tiab]
OR gene regula∗[tiab] OR microarray[tiab] OR microarrays[tiab] OR gene signature∗[
tiab] OR gene expression profiling[mesh] OR microarray analysis[mesh] OR real−time
polymerase chain reaction[mesh] NOT (MicroRNAs[Mesh] OR microRNA[tiab] OR
microRNAs[tiab] OR miRNA[tiab] or protein expression[tw]))
AND
(chemoresistance[tw] OR chemo−resistant[tw] OR chemoresistant[tw] OR chemo−
resistance[tw] OR resistance to chemotherapy[tw] OR (resistance[tiab] AND
chemotherapy[tiab]) OR (resistant[tiab] AND chemotherapy[tiab]) OR drug resistance
[tw] OR chemosensitivity[tw] OR chemosensitive[tw] OR (chemoresponse[tiab] AND
resistance[tiab]) OR (treatment outcome[mesh] AND chemotherapy[tw]) OR gene
expression regulation,neoplastic[mesh])
AND
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((Humans[Mesh] NOT cell line, tumor[mesh] NOT cell line[Mesh] NOT Xenograft Model
Antitumor Assays[Mesh]) OR (Human[Mesh] AND Tumor cells, cultured[Mesh:noexp
] AND (patients[tw] OR patient[tw])) OR ((human[tiab] NOT cell−line[tiab] NOT
cell line[tiab] NOT xenograft[tiab]) NOT medline[sb]) OR ((patients[tiab] NOT cell−
line[tiab] NOT cell line[tiab]) NOT medline[sb]) NOT (animal model[tiab] NOT
medline[sb]))
AND
(Molecular Medicine[mesh] OR molecular diagnostic[tw] OR molecular diagnostic
techniques[mesh] OR (resistance[tw] AND predict[tw]) OR (prognosis[tw] AND
predict[tw]) OR (outcome[tw] AND predict[tw]) OR (outcome[tw] AND prediction[tw
]) OR (prognosis[tw] AND prediction[tw]) OR (relapse[tw] AND prediction[tw]) OR (
relapse[tw] AND predict[tw]) OR (recurrence[tw] AND prediction[tw]) OR (
recurrence[tw] AND predict[tw]) OR (prognostic[tw] AND prediction[tw]) OR (
prognostic[tw] AND predict[tw]) OR (treatment outcome[mesh] AND predict[tw]) OR
(response[tw] AND predict[tw]) OR (response[tw] AND prediction[tw]) OR (
molecular biologic techniques[tw] NOT medline[sb]) OR (molecular biology
techniques[tw] NOT medline[sb]) OR Drug Screening Assays, Antitumor[mesh] OR
predictive value of tests [mesh] OR (molecular biological techniques[tw] NOT medline
[sb]) OR discriminate[tiab] OR differentiate[tiab] OR categorise[tiab] OR categorize[
tiab] NOT imaging[tiab] OR computing methodologies[mesh] OR statistical analysis[
tw] OR statistical modelling[tw] OR machine learning[tw] OR supervised[tiab] OR
unsupervised[tiab] OR algorithms[mesh] OR multiple linear regression[tiab] OR (
regression[tiab] AND analysis[tiab]) OR ((prediction[tiab] OR predictive[tiab] OR
predicting[tiab] OR predicts[tiab] OR predict[tiab] OR predictors[tiab] OR predictor[
tiab]) AND (development[tiab] OR developed[tiab] OR developing[tiab])) OR
predictive value of tests[mesh] OR ((individualised[tiab] OR individualized[tiab] OR
personalised[tiab] OR personalized[tiab] OR stratified[tiab]) AND (treatment[tiab]
OR medicine[tiab] OR chemotherapy[tiab] OR drug choice[tiab])) OR forecasting[
mesh])
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QUADAS-2	[164]	results	and	CEBM	2011	Levels	of	Evidence	[3]		
	
Study	 RISK	OF	BIAS	 APPLICABILITY	CONCERNS	 Level	of	
Evidence	PATIENT	
SELECTION	
INDEX	
TEST	
REFERENCE	
STANDARD	
FLOW	AND	
TIMING	
PATIENT	
SELECTION	
	
INDEX	
TEST	
REFERENCE	
STANDARD	
Jeong	et.	al.	[76]	 J	 J	 J	 J	 J	 J	 J	 2	
Lisowska	et.	al.	[90]	 J	 J	 J	 J	 J	 J	 J	 2	
Roque	et.	al.	[131]	 J	 		?		 J	 J	 J	 J	 J	 2	
Li	et.	al.	[88]	 J	 J	 J	 J	 J	 J	 J	 2	
Schwede	et.	al.	[141]	 J	 J	 J	 J	 J	 J	 J	 2	
Verhaak	et.	al.	[158]	 J	 J	 J	 J	 J	 J	 J	 2	
Obermayr	et.	al.	[120]	 J	 J	 J	 J	 J	 L	 J	 2	
Han	et.	al.	[61]	 J	 J	 J	 J	 J	 J	 J	 2	
Hsu	et.	al.	[71]	 J	 J	 J	 J	 J	 J	 J	 2	
Lui	et.	al.	[91]	 J	 J	 J	 J	 J	 J	 J	 2	
Kang	et.	al.	[78]	 J	 J	 J	 J	 J	 J	 J	 2	
Gillet	et.	al.	[52]	 J	 J	 J	 J	 J	 J	 J	 2	
Ferriss	et.	al.	[42]	 J	 J	 J	 J	 J	 J	 J	 2	
Brun	et.	al.	[22]	 J	 J	 J	 J	 J	 J	 J	 2	
Skirnisdottir	and	Seidal	[145]	 J	 		?	 J	 J	 J	 J	 J	 2	
Brenne	et.	al.	[21]	 J	 J	 J	 J	 J	 J	 J	 2	
Sabatier	et.	al.	[134]	 J	 J	 J	 J	 J	 J	 J	 2	
Gillet	et.	al.	[51]	 J	 J	 J	 J	 J	 J	 J	 2	
Chao	et.	al.	[25]	 L	 J	 L	 J	 J	 J	 L	 3	
Schlumbrecht	et.	al.	[139]	 J	 J	 J	 J	 J	 J	 J	 2	
Glaysher	et.	al.	[54]	 J	 J	 J	 J	 J	 J	 J	 2	
Yan	et.	al.	[169]	 J	 J	 J	 J	 J	 J	 J	 2	
Yoshihara	et.	al.	[170]	 J	 J	 J	 J	 J	 J	 J	 2	
Williams	et.	al.	[165]	 J	 J	 J	 J	 J	 J	 J	 2	
Denkert	et.	al.	[37]	 J	 J	 J	 J	 J	 J	 J	 2	
Matsumara	et.	al.	[98]	 J	 J	 J	 J	 J	 J	 J	 2	
Crijns	et.	al.	[32]	 J	 J	 J	 J	 J	 J	 J	 2	
Mendiola	et.	al.	[103]	 		?	 		?	 J	 J	 J	 J	 J	 2	
Gevaert	et.	al.	[50]	 		?	 J	 J	 J	 J	 J	 J	 2	
Bachvarov	et.	al.	[12]	 L	 J	 J	 J	 J	 J	 J	 3	
Netinatsunthorn	et.	al.	[115]	 J	 J	 J	 J	 J	 J	 J	 2	
De	Smet	et.	al.	[35]	 L	 J	 J	 J	 J	 J	 J	 3	
Helleman	et.	al.	[66]	 J	 J	 J	 J	 J	 J	 J	 2	
Spentzos	et.	al.	[148]	 J	 J	 J	 L	 J	 J	 J	 2	
Jazaeri	et.	al.	[74]	 L	 J	 J	 J	 J	 J	 J	 3	
Raspollini	et.	al.	[128]	 		?	 J	 J	 J	 J	 J	 J	 3	
Hartmann	et.	al.	[63]	 J	 J	 J	 J	 J	 J	 J	 2	
Spentzos	et.	al.	[147]	 J	 J	 J	 J	 J	 J	 J	 2	
Selvanayagam	et.	al.	[142]	 		?	 J	 J	 J	 J	 J	 J	 3	
Iba	et.	al.	[72]	 J	 J	 J	 J	 J	 J	 J	 2	
Kamazawa	et.	al.	[77]	 J	 L	 J	 J	 J	 J	 J	 2	
Vogt	et.	al.	[161]	 J	 J	 J	 J	 J	 J	 J	 2	
JLow	Risk	 LHigh	Risk	 		?	Unclear	Risk		
Table	modified	from	http://www.bris.ac.uk/quadas/resources/	
Figure A.3: Bias assessment, including QUADAS-2 and CEBM levels of evidence.
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Table A.1: Papers included in systematic review with basic journal and study
information. If more than one value is given, the study used multiple different
starting gene-sets or found multiple gene signatures.
Study Journal No.
Samples
No.
Genes in
Study
No. Genes
in Signature
Jeong et al. [76] Anticancer Res. 487 612 388, 612
Lisowska et al.
[90]
Front. Oncol. 127 > 47 000 0
Roque et al. [131] Clin. Exp. Metasta-
sis
48 1 1
Li et al. [88] Oncol. Rep. 44 1 1
Schwede et al.
[141]
PLoS ONE 663 2632 51
Verhaak et al.
[158]
J. Clin. Invest. 1368 11 861 100
Obermayr et al.
[120]
Gynecol. Oncol. 255 29 098 12
Han et al. [61] PLoS ONE 322 12 042 349, 18
Hsu et al. [71] BMC Genomics 168 12 042 134
Liu et al. [91] PLoS ONE 737 NS 227
Kang et al. [78] J. Nat. Cancer Inst. 558 151 23
Gillet et al. [52] Clin. Cancer Res. 80 356 11
Ferriss et al. [42] PLos ONE 341 NS 251, 125
Brun et al. [22] Oncol. Rep. 69 6 0
Skirnisdottir and
Seidal [145]
Oncol. Rep. 105 3 2
Brenne et al. [21] Hum. Pathol. 140 1 1
Sabatier et al.
[134]
Br. J. Cancer 401 NS 7
Gillet et al. [51] Mol. Pharmeceutics 32 350 18, 10, 6
Chao et al. [25] BMC Med. Ge-
nomics
6 8173 NS
Schlumbrecht
et al. [139]
Mod. Pathol. 83 7 2
Glaysher et al.
[54]
Br. J. Cancer 31 91 10, 4, 3, 5, 5,
11, 6, 6
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Table A.1: (continued)
Yan et al. [169] Cancer Res. 42 2 1
Yoshihara et al.
[170]
PLoS ONE 197 18 176 88
Williams et al.
[165]
Cancer Res. 242 NS 15 to 95
Denkert et al. [37] J. Pathol 198 NS 300
Matsumura et al.
[98]
Mol. Cancer Res. 157 22 215 250
Crijns et al. [32] PLoS Medicine 275 15 909 86
Mendiola et al.
[103]
PLoS ONE 61 82 34
Gevaert et al. [50] BMC Cancer 69 ∼ 24 000 ∼ 3000
Bachvarov et al.
[12]
Int. J. Oncol. 42 20 174 155, 43
Netinatsunthorn
et al. [115]
BMC Cancer 99 1 1
De Smet et al. [35] Int. J. Gynecol.
Cancer
20 21 372 3000
Helleman et al.
[66]
Int. J. Cancer 96 NS 9
Spentzos et al.
[148]
J. Clin. Oncol. 60 NS 93
Jazaeri et al. [74] Clin. Cancer Res. 40 40 033,
7585
85, 178
Raspollini et al.
[128]
Int. J. Gynecol.
Cancer
52 2 2
Hartmann et al.
[63]
Clin. Cancer Res. 79 30 721 14
Spentzos et al.
[147]
J. Clin. Oncol. 68 12 625 115
Selvanayagam
et al. [142]
Cancer Genet. Cy-
togenet.
8 10 692 NS
Iba et al. [72] Cancer Sci. 118 4 1
Kamazawa et al.
[77]
Gynecol. Oncol. 27 3 1
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Table A.1: (continued)
Vogt et al. [161] Acta Biochim. Pol. 17 3 0
Table A.2: Papers included in systematic review with tissue information. If more
than one value is given, the study used tissue from multiple sources.
Study Tissue Source % Cancerous
Tissue
Jeong et al. [76]
Lisowska et al. [90] Fresh-frozen NS
Roque et al. [131] FFPE, Fresh-frozen min. 70%
Li et al. [88] FFPE NS
Schwede et al. [141]
Verhaak et al. [158]
Obermayr et al. [120] Fresh-frozen, Blood NS
Han et al. [61]
Hsu et al. [71]
Liu et al. [91]
Kang et al. [78]
Gillet et al. [52] Fresh-frozen min. 75%
Ferriss et al. [42] FFPE min. 70%
Brun et al. [22] FFPE NS
Skirnisdottir and Seidal
[145]
FFPE NS
Brenne et al. [21] Fresh-frozen effusion, Fresh-frozen min. 50%
Sabatier et al. [134] Fresh-frozen min. 60%
Gillet et al. [51] Fresh-frozen effusion NS
Chao et al. [25]
Schlumbrecht et al. [139] Fresh-frozen min. 70%
Glaysher et al. [54] FFPE, Fresh min. 80%
Yan et al. [169] Fresh-frozen NS
Yoshihara et al. [170] Fresh-frozen min. 80%
Williams et al. [165]
Denkert et al. [37] Fresh-frozen NS
Matsumura et al. [98] Fresh-frozen NS
Crijns et al. [32] Fresh-frozen median = 70%
Mendiola et al. [103] FFPE min. 80%
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Table A.2: (continued)
Gevaert et al. [50] Fresh-frozen NS
Bachvarov et al. [12] Fresh-frozen min. 70%
Netinatsunthorn et al.
[115]
FFPE NS
De Smet et al. [35] Not specified NS
Helleman et al. [66] Fresh-frozen median = 64%
Spentzos et al. [148] Fresh-frozen NS
Jazaeri et al. [74] FFPE, Fresh-frozen NS
Raspollini et al. [128] FFPE NS
Hartmann et al. [63] Fresh-frozen min. 70%
Spentzos et al. [147] Fresh-frozen NS
Selvanayagam et al. [142] Fresh-frozen min. 70%
Iba et al. [72] FFPE, Fresh-frozen NS
Kamazawa et al. [77] FFPE, Fresh-frozen NS
Vogt et al. [161] None specified NS
Table A.3: Papers included in systematic review with histology information. Entries
in bold indicate that the study data set was comprised of at least 80% this type.
Study Sub-type Stage
Jeong et al. [76] Serous, Endometrioid, Adenocarci-
noma
I, II, III, IV
Lisowska et al. [90] Serous, Endometrioid, Clear cell, Un-
differentiated
II, III, IV
Roque et al. [131] Serous, Endometrioid, Clear cell, Un-
differentiated, Mixed
IIIC, IV
Li et al. [88] Serous, Endometrioid, Clear cell,
Mucinous, Transitional
II, III, IV
Schwede et al. [141] Serous, Endometrioid, Clear cell,
Mucinous, Adenocarcinoma, OSE
I, II, III, IV
Verhaak et al. [158] NS II, III, IV
Obermayr et al. [120] Serous, Non-serous II, III, IV
Han et al. [61] Serous, Endometrioid, Clear cell,
Mucinous, Mixed, Poorly differen-
tiated
II, III, IV
Hsu et al. [71] NS III, IV
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Table A.3: (continued)
Liu et al. [91] Serous II, III, IV
Kang et al. [78] Serous I, II, III, IV
Gillet et al. [52] Serous III, IV
Ferriss et al. [42] Serous, Clear cell, Other III, IV
Brun et al. [22] Serous, Endometrioid, Clear cell,
Mucinous, Other
III, IV
Skirnisdottir and Seidal
[145]
Serous, Endometrioid, Clear cell,
Mucinous, Anaplastic
I, II
Brenne et al. [21] Serous, Endometrioid, Clear cell,
Undifferentiated, Mixed
II, III, IV
Sabatier et al. [134] Serous, Endometrioid, Clear cell,
Mucinous, Undifferentiated, Mixed
I, II, III, IV
Gillet et al. [51] Serous III, IV, NS
Chao et al. [25] NS NS
Schlumbrecht et al. [139] Serous III, IV
Glaysher et al. [54] Serous, Endometrioid, Clear cell,
Mucinous, Mixed, Poorly differen-
tiated
IIIC, IV
Yan et al. [169] Serous, Endometrioid, Clear cell,
Mucinous, Transitional
II, III, IV
Yoshihara et al. [170] Serous III, IV
Williams et al. [165] Serous, Endometrioid, Undifferenti-
ated
III, IV
Denkert et al. [37] Serous, Non-serous, Undifferenti-
ated
I, II, III, IV
Matsumura et al. [98] Serous I, II, III, IV
Crijns et al. [32] Serous III, IV
Mendiola et al. [103] Serous, Non-serous III, IV
Gevaert et al. [50] Serous, Endometrioid, Mucinous,
Mixed
I, III, IV
Bachvarov et al. [12] Serous, Endometrioid, Clear cell II, III, IV
Netinatsunthorn et al.
[115]
Serous III, IV
De Smet et al. [35] Serous, Endometrioid, Mucinous,
Mixed
I, III, IV
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Table A.3: (continued)
Helleman et al. [66] Serous, Endometrioid, Clear cell,
Mucinous, Mixed, Poorly differen-
tiated
I/II, III/IV
Spentzos et al. [148] Serous, Endometrioid, Clear cell,
Mixed
I, II, III, IV
Jazaeri et al. [74] Serous, Endometrioid, Clear cell,
Mixed, Undifferentiated, Carcinoma
II, III, IV
Raspollini et al. [128] Serous IIIC
Hartmann et al. [63] Serous, Endometrioid, Mixed II, III, IV
Spentzos et al. [147] Serous, Endometrioid, Clear cell,
Mixed
I, II, III, IV
Selvanayagam et al. [142] Serous, Endometrioid, Clear cell, Un-
differentiated
III, IV
Iba et al. [72] Serous, Endometrioid, Clear cell,
Mixed
I, II, III, IV
Kamazawa et al. [77] Serous, Endometrioid, Clear cell III, IV
Vogt et al. [161] NS NS
Table A.4: Papers included in systematic review with gene expression measurement
technique information.
Study Immuno-
histochem-
istry
TaqMan
Array
q-RT-
PCR
Commercial
Microarray
Custom
Microar-
ray
RT-
PCR
Jeong et al.
[76]
7 7 7 3 7 7
Lisowska et al.
[90]
7 7 3 3 7 7
Roque et al.
[131]
3 7 3 7 7 7
Li et al. [88] 3 7 7 7 7 7
Schwede et al.
[141]
7 7 7 3 7 7
Verhaak et al.
[158]
7 7 7 3 7 7
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Table A.4: (continued)
Obermayr
et al. [120]
7 7 3 3 7 7
Han et al. [61] 7 7 7 3 7 7
Hsu et al. [71] 7 7 7 3 7 7
Liu et al. [91] 7 7 7 3 7 7
Kang et al.
[78]
7 7 7 3 7 7
Gillet et al.
[52]
7 3 7 7 7 7
Ferriss et al.
[42]
7 7 7 7 3 7
Brun et al.
[22]
3 7 7 7 7 7
Skirnisdottir
and Seidal
[145]
3 7 7 7 7 7
Brenne et al.
[21]
7 7 3 7 7 7
Sabatier et al.
[134]
7 7 7 3 7 7
Gillet et al.
[51]
7 3 7 7 7 7
Chao et al.
[25]
7 7 7 3 7 7
Schlumbrecht
et al. [139]
3 7 3 7 7 7
Glaysher et al.
[54]
7 3 7 7 7 7
Yan et al.
[169]
3 7 7 7 7 7
Yoshihara
et al. [170]
7 7 3 3 7 7
Williams et al.
[165]
7 7 7 3 7 7
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Table A.4: (continued)
Denkert et al.
[37]
7 7 7 3 7 7
Matsumura
et al. [98]
3 7 3 3 7 7
Crijns et al.
[32]
7 7 3 7 3 7
Mendiola
et al. [103]
7 3 7 7 7 7
Gevaert et al.
[50]
7 7 7 3 7 7
Bachvarov
et al. [12]
7 7 3 3 7 7
Netinatsunthorn
et al. [115]
3 7 7 7 7 7
De Smet et al.
[35]
7 7 7 7 3 7
Helleman
et al. [66]
7 7 3 7 3 7
Spentzos et al.
[148]
7 7 7 3 7 7
Jazaeri et al.
[74]
3 7 7 7 3 7
Raspollini
et al. [128]
3 7 7 7 7 7
Hartmann
et al. [63]
7 7 7 7 3 7
Spentzos et al.
[147]
7 7 7 3 7 7
Selvanayagam
et al. [142]
7 7 7 7 3 7
Iba et al. [72] 3 7 3 7 7 7
Kamazawa
et al. [77]
7 7 3 7 7 7
Vogt et al.
[161]
7 7 7 7 7 3
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Table A.5: Papers included in systematic review with basic modelling information.
If more than one value is given, the study included patients treated with different
treatments.
Study Patient Prior
Chemotherapy
Treatment
Model
accounts
for the
different
chemother-
apies?
Prognostic
or predic-
tive?
Model
Validated?
Jeong et al. [76] Platinum-based 3 Predictive 3
Lisowska et al. [90] Platinum/
Cyclophosphamide,
Platinum/Taxane
7 Prognostic 3
Roque et al. [131] NS 7 Prognostic 7
Li et al. [88] Platinum/
Cyclophosphamide,
Platinum/Taxane
7 Prognostic 7
Schwede et al. [141] NS 7 Prognostic 3
Verhaak et al. [158] NS 7 Prognostic 3
Obermayr et al.
[120]
Platinum-based 7 Prognostic 7
Han et al. [61] Platinum/
Paclitaxel
Prognostic 3
Hsu et al. [71] Platinum/
Paclitaxel +
additional treat-
ments
3 Prognostic 3
Liu et al. [91] NS 7 Prognostic 3
Kang et al. [78] Platinum/Taxane Prognostic 3
Gillet et al. [52] Carboplatin/
Paclitaxel
Prognostic 3
Ferriss et al. [42] Platinum-based 3 Predictive 3
Brun et al. [22] NS 7 Prognostic 7
Skirnisdottir and
Seidal [145]
Carboplatin/
Paclitaxel
Prognostic 7
Brenne et al. [21] NS 7 Prognostic 7
Sabatier et al. [134] Platinum-based 7 Prognostic 3
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Table A.5: (continued)
Gillet et al. [51] NS 7 Prognostic 3
Chao et al. [25] NS 7 Prognostic 7
Schlumbrecht et al.
[139]
Platinum/Taxane Prognostic 7
Glaysher et al. [54] Platinum, Plat-
inum/Paclitaxel
3 Predictive 3
Yan et al. [169] Platinum-based 7 Prognostic 7
Yoshihara et al.
[170]
Platinum/Taxane Prognostic 3
Williams et al. [165] NS 3 Predictive 3
Denkert et al. [37] Carboplatin/
Paclitaxel
Prognostic 3
Matsumura et al.
[98]
Platinum-based 3 Predictive 3
Crijns et al. [32] Platinum,
Platinum/
Cyclophosphamide,
Platinum/
Paclitaxel
3 Prognostic 3
Mendiola et al. [103] Platinum/Taxane Prognostic 3
Gevaert et al. [50] NS 7 Prognostic 3
Bachvarov et al. [12] Carboplatin/
Paclitaxel,
Carboplatin/
Cyclophosphamide,
Cisplatin/
Paclitaxel
7 Prognostic 3
Netinatsunthorn
et al. [115]
Platinum/
Cyclophosphamide
Prognostic 7
De Smet et al. [35] Platinum/
Cyclophosphamide,
Platinum/
Paclitaxel
7 Prognostic 3
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Table A.5: (continued)
Helleman et al. [66] Platinum/
Cyclophosphamide,
Platinum-based
7 Prognostic 3
Spentzos et al. [148] Platinum/Taxane Prognostic 3
Jazaeri et al. [74] Carboplatin/
Paclitaxel,
Cisplatin/
Cyclophosphamide,
Carboplatin/
Docetaxel, Carbo-
platin
7 Prognostic 3
Raspollini et al.
[128]
Cisplatin/
Cyclophosphamide,
Carboplatin/
Cyclophosphamide,
Carboplatin/
Paclitaxel
7 Prognostic 7
Hartmann et al. [63] Cisplatin/
Paclitaxel, Carbo-
platin/Paclitaxel
7 Prognostic 3
Spentzos et al. [147] Platinum/Taxane Prognostic 3
Selvanayagam et al.
[142]
Cisplatin/
Cyclophosphamide,
Carboplatin/
Cyclophosphamide,
Cisplatin/
Paclitaxel
7 Prognostic 3
Iba et al. [72] Carboplatin/
Paclitaxel
Prognostic 7
Kamazawa et al.
[77]
Carboplatin/
Paclitaxel
Prognostic 7
Vogt et al. [161] Etoposide, Pacli-
taxel/Epirubicin,
Carboplatin/
Paclitaxel
3 Predictive 7
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Table A.6: Papers included in systematic review with basic modelling information. If more than one value is given, the study used
multiple different prediction methods or predicted more than one endpoint.
Study Prediction Prediction Method Predictive Ability
Jeong et al. [76] Overall Survival Student’s T test, Hierarchi-
cal clustering, Compound co-
variate predictor algorithm,
Cox proportional hazards re-
gression, Kaplan-Meier curves,
Log-rank test, ROC analysis
‘Taxane-based treatment sig-
nificantly affected OS for pa-
tients in the YA subgroup (3
year rate: 74.4% with tax-
ane vs. 37.9% without taxane,
p=0.005 by log-rank test)’, ‘es-
timated hazard ratio for death
after taxane-based treatment
in the YA subgroup was 0.5
(95% CI = 0.31 − −0.82,p =
0.005)’
Lisowska et al. [90] Chemoresponse, Disease-Free
Survival , Overall Survival
Support vector machines,
Kaplan-Meier curves, Log-
rank test
No genes found to be signifi-
cant in the training set were
significant in the test set, for
chemoresponse, DFS or OS
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Table A.6: (continued)
Roque et al. [131] Overall Survival Kaplan-Meier curves, Log-
rank test, Student’s T test
‘OS was predicted by increased
class III β-tubulin staining
by both tumor (HR3.66, 96%
CI = 1.11–12.1, p = 0.03) and
stroma (HR4.53, 95% CI =
1.28–16.1, p = 0.02)’
Li et al. [88] Chemoresponse (chemoresis-
tant vs. chemosensitive)
Correlation of p-CFL1 stain-
ing and chemoresponse
‘immunostaining of p-CFL1
was positive in 77.3% of
chemosensitive and in 95.9% of
the chemoresistant’ (p = 0.014,
U = 157.5)
Schwede et al. [141] Stem cell-like subtype,
Disease-Free Survival, Overall
Survival
ISIS unsupervised bipartition-
ing, Diagonal linear discrimi-
nant analysis, Gaussian mix-
ture modelling, Kaplan-Meier
curves, Log-rank test
OS (p values): Dressman =
0.0354, Crijns = 0.021, Tothill
= 4.4E − 7
Verhaak et al. [158] Poor Prognosis vs. Good Prog-
nosis
Significance analysis of mi-
croarrays, Single sample
gene set enrichment anal-
ysis, Kaplan-Meier curves,
Log-rank test
Good or Poor prognosis, likeli-
hood ratio = 44.63
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Table A.6: (continued)
Obermayr et al. [120] Disease-Free Survival, Overall
Survival
Kaplan-Meier curves, Cox pro-
portional hazards regression,
χ2 test
‘The presence of CTCs six
months after completion of the
adjuvant chemotherapy indi-
cated relapse within the follow-
ing six months with 41% sen-
sitivity, and relapse within the
entire observation period with
22% sensitivity (85% speci-
ficity)’
Han et al. [61] Complete Response or Progres-
sive Disease
Supervised principal compo-
nent method
349 gene signature: ROC
AUC= 0.702, p = 0.022. 18
gene: ROC AUC= 0.614, p =
0.197.
Hsu et al. [71] Progression-Dree Survival Semi-supervised hierarchical
clustering
Good Response vs. Poor Re-
sponse, p = 0.021
Liu et al. [91] Chemosensitivity, Overall Sur-
vival, Progression-Dree Sur-
vival
Predictive score using
weighted voting algorithm,
Kaplan-Meier curves, Log-
rank Test, Cox proportional
hazards regression
Response of 26 of 35 patients
in an independent data set was
correctly predicted, patients
in the low-scoring group ex-
hibited poorer PFS (HR =
0.43, p = 0.04), ROC AUC
= 0.90(0.86–0.95)
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Kang et al. [78] Overall Survival, Progression-
Free Survival, Recurrence-Free
Survival
Kaplan-Meier curves, Log-
rank test, Cox proportional
hazards regression, Pearson
correlation coefficient
Berchuck dataset: HR = 0.33,
95% CI = 0.13–0.86, p =
0.013; Tothill dataset: HR =
0.61, 95% CI = 0.36–0.99,
p = 0.044
Gillet et al. [52] Overall Survival, Progression-
Free Survival
Supervised principle com-
ponents method, Cox pro-
portional hazards regression,
Kaplan-Meier curves, Log-
rank test
‘An 11-gene signature whose
measured expression signifi-
cantly improves the power of
the covariates to predict poor
survival’(p < 0.003)
Ferriss et al. [42] Overall Survival COXEN coefficient, Mann-
Whitney U test, ROC analy-
sis, Unsupervised Hierarchical
Clustering
Carboplatin: sensitivity =
0.906, specificity = 0.174, PPV
= 60%, NPV = 57% (UVA-55
validation set)
Brun et al. [22] 2-year Disease-Free Survival Student’s T test, Principal
component analysis, Concor-
dance index, Kaplen-Meier
curves, Log-rank test
No genes were found to have
prognostic value
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Table A.6: (continued)
Skirnisdottir and Seidal
[145]
Recurrence, Disease-Free Sur-
vival
χ2 test, Kaplan-Meier curves,
Log-rank test, Logistic regres-
sion, Cox proportional hazards
regression
p53-status (OR = 4.123, p =
0.009; HR = 2.447, p = 0.019)
was a significant and indepen-
dent factor for tumor recur-
rence and DFS.
Brenne et al. [21] OC or MM, Progression-Free
Survival, Overall Survival
Mann-Whitney U test,
Kaplan-Meier curves, Log-
rank test, Cox proportional
hazards regression
Cox Multivariate Analysis:
EHF mRNA expression in pre-
chemotherapy effusions was an
independent predictor of PFS
(p = 0.033, relative risk =
4.528)
Sabatier et al. [134] Progression-Free Survival,
Overall Survival
Cox proportional hazards re-
gression, Pearson’s coefficient
correlation score
Favourable vs. Unfavourable:
‘sensitivity = 61.6%, speci-
ficity = 62.4%, OR = 2.7,
95% CI = 1.7—4.2; p = 6.1×
10−06, Fisher’s exact test’
Gillet et al. [51] Overall Survival, Progression-
Free Survival, Treatment Re-
sponse
Linear regression, Hierarchi-
cal clustering, Kaplan-Meier
curves, Log-rank test
‘6 gene signature alone
can effectively predict the
progression-free survival
of women with ovarian
serous carcinoma (log-rank
p = 0.002)’
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Chao et al. [25] Chemoresistance Interaction and expression net-
works for pathway identifica-
tion, pathway intersections,
betweenness and degree cen-
trality, Student’s T test
No statistical measure avail-
able. Many genes identified
have previously been found ex-
perimentally
Schlumbrecht et al. [139] Overall Survival, Recurrence-
Free Survival
Linear regression, Logistic re-
gression, Cox proportional haz-
ards regression, Kaplan-Meier
curves, Unsupervised cluster
analysis, Log-rank test, Mann-
Whitney U test, χ2 test
‘Greater EIG121 expression
was associated with shorter
time to recurrence (HR =
1.13 (CI = 1.02–1.26), p =
0.021)’, ‘Increased expression
of EIG121 demonstrated a sta-
tistically significant associa-
tion with worse OS (HR =
1.21 (CI1.09–1.35), p <
0.001)’
Glaysher et al. [54] Chemosensitivity AIC gene selection, Multiple
linear regression
Cisplatin: R2adj = 0.836, p <
0.001
Yan et al. [169] Chemosensitivity ANOVA, Student’s T test,
Mann-Whitney U test
‘Immunostaining scores [An-
nexin A3] are significantly
higher in platinum-resistant
tumors (p = 0.035)’
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Yoshihara et al. [170] Progression-Free Survival Cox proportional hazards re-
gression, Ridge regression,
Prognostic index, ROC analy-
sis, Kaplan-Meier curves, Log-
rank test
‘Prognostic index was an inde-
pendent prognostic factor for
PFS time (HR = 1.64, p =
0.0001)’, sensitivity = 64.4%,
specificity = 69.2%
Williams et al. [165] Overall Survival COXEN score, Kaplan-Meier
curves, Student’s T test, ROC
analysis, Spearman’s rank cor-
relation coefficient, Logistic re-
gression, Log-rank test
Carboplatin and Taxol: sen-
sitivity = 77%, specificity =
56%, PPV = 71%, NPV =
78%
Denkert et al. [37] Overall Survival Semi-supervised analysis via
Cox scoring, Principal compo-
nents analysis, Kaplan-Meier
curves, Log-rank test, Cox pro-
portional hazards regression
Duke et al.: ‘clinical outcome
is significantly different de-
pending on the OPI (p =
0.021), with an HR of 1.7 (CI
1.1-–2.6)’
Matsumura et al. [98] Taxane sensitivity, Overall
Survival
Hierarchical clustering,
Kaplan-Meier curves, Log-
rank test
‘Patients in the YY1-High clus-
ter who were treated with pa-
clitaxel showed improved sur-
vival compared with the other
groups (p = 0.010)’
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Crijns et al. [32] Overall Survival Supervised principal com-
ponents method, Cox pro-
portional hazards regression,
Kaplan-Meier curves, Log-
rank test, χ2 test
OSP: (High-risk vs. low-
risk) HR = 1.940, CI =
1.190–3.163, p = 0.008
Mendiola et al. [103] Progression-Free Survival,
Overall Survival
Kaplan-Meier curves, Log-
rank test, AIC-based model se-
lection, ROC curves, Cox pro-
portional hazards regression
OS: sensitivity = 87.2%, speci-
ficity = 86.4%
Gevaert et al. [50] Platin Resistance/Sensitivity,
Stage
Principal component analysis,
Least squares support vector
machines
Platin-Resistance/Sensitivity:
sensitivity = 67%, specificity
= 40%, accuracy = 51.11%
Bachvarov et al. [12] Chemoresistance Hierarchical Clustering, Sup-
port vector machines
No prediction metric applied
Netinatsunthorn et al.
[115]
Overall Survival, Recurrence-
Free Survival
Kaplan-Meier curves, Cox pro-
portional hazards regression
OS: HR = 1.98, 95% CI =
1.28–3.79, p = 0.0138 ; RFS:
HR = 3.36, 95% CI =
1.60–7.03, p = 0.0017
De Smet et al. [35] Stage I vs. Advanced stage,
Platin-sensistive vs. Platin-
resistant
Principal component analysis,
Least squares support vector
machines
Estimated Classification Ac-
curacy: Stage I vs Advanced
Stage = 100%, Platin-sensitive
vs. Platin-resistant = 76.9%
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Helleman et al. [66] Chemoresponse (responder vs.
non-responder)
Class prediction, Hierarchical
clustering, Principal compo-
nent analysis
Test set: PPV = 24%,
NPV = 97%, sensitivity =
89%, specificity = 59%
Spentzos et al. [148] Chemoresponse (pathological-
CR or PD), Disease-Free sur-
vival, Overall Survival
Class prediction analy-
sis, Compound covariate
algorithm, Average link-
age hierarchical clustering,
Kaplan-Meier curves, Log-
rank test, Cox proportional
hazards regression
Cox PH (resistant vs. sensi-
tive): Recurrence HR = 2.7
(95% CI = 1.2–6.1), Death
HR = 3.9 (95% CI =
3.1–11.4)
Jazaeri et al. [74] Clinical response Class prediction 9 most significantly differen-
tially expressed genes, primary
chemoresistant vs. primary
chemosensitive: accuracy =
77.8%
Raspollini et al. [128] Overall Survival (high vs. low) Univariate logistic regression,
χ2 test
COX-2: OR = 0.23, 95%
CI = 0.06–0.77, p = 0.017;
MDR1: OR = 0.01, 95%
CI = 0.002–0.09, p =< 0.0005
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Hartmann et al. [63] Time To Relapse (early
vs.late)
Support vector machine,
Kaplan-Meier curves, Log-
rank test, average linkage
clustering
Accuracy = 86%, PPV =
95%, NPV = 67%
Spentzos et al. [147] Disease-Free Survival, Overall
Survival
Supervised pattern recogni-
tion/class prediction, Kaplan-
Meier curves, Log-rank test,
Cox proportional hazards re-
gression
Unfavourable vs. Favourable
OS : (CPH) HR = 4.6, 95%
CI = 2.0–10.7, p = 0.0001
Selvanayagam et al.
[142]
Chemoresistance (chemoresis-
tant vs. chemosensitive)
Supervised voice-pattern
recognition algorithm (cluster-
ing)
PPV = 1, NPV = 1
Iba et al. [72] Chemoresponse, Overall Sur-
vival
Kaplan-Meier curves, Log-
rank test, Cox propotionate
hazards regression, ROC anal-
ysis, χ2 test, Student’s T test,
Mann-Whitney U test
‘Patients with c-myc expres-
sion of over 200 showed a sig-
nificantly better 5-year sur-
vival rate (69.8% vs. 43.5%)’,
p < 0.05
Kamazawa et al. [77] Chemoresponse (CR or PR vs.
NC or PD)
Defined threshold expression
to divide responders and non-
responders
MDR-1 (all samples): speci-
ficity = 95%, sensitivity =
100%, predictive value = 96%
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Table A.6: (continued)
Vogt et al. [161] Chemoresistance Correlation of AUC from in-
vitro ATP-CVA and gene ex-
pression
All p values for correlation of
drugs and genes were > 0.05
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Table A.7: List of genes reported by studies included in this review. Gene names
have been standardised. Genes in bold were selected by more than two studies.
A1BG CST6 HRASLS NID1 SHFM1
A2M CST9L Hs.120332 NIT1 SHOX
AADAC CT45A6 HS3ST1 NKIRAS2 SIDT1
AAK1 CTA-246H3.1 HS3ST5 NKX31 SIGLEC8
ABCA13 CTNNBL1 HSD11B2 NKX62 SIRT5
ABCA4 CTSD HSD17B11 NLGN1 SIRT6
ABCB1 CUTA HSPA1L NOP5/58 SIVA1
ABCB10 CX3CL1 HSPA4 NOS3 SIX2
ABCB11 CXCL1 HSPA8 NOTCH4 SKA3
ABCB7 CXCL10 HSPB7 NOV SLAMF7
ABCC3 CXCL12 HSPD1 NOX1 SLC12A2
ABCC5 CXCL13 HTATIP2 NPAS3 SLC12A4
ABCD2 CXCR4 HTN1 NPR1 SLC14A1
ABCG2 CYB5B HTR3A NPR3 SLC15A2
ABLIM1 CYBRD1 ICAM1 NPTX2 SLC1A1
ACADVL CYP27A1 ICAM5 NPTXR SLC1A3
ACAT2 CYP2E1 ID1 NPY SLC22A5
ACKR2 CYP3A7 ID4 NRBP2 SLC25A37
ACKR3 CYP4X1 IDI1 NRG4 SLC25A41
ACO2 CYP4Z1 IFIT1 NRP1 SLC25A5
ACOT13 CYP51A1 IGF1R NSFL1C SLC26A9
ACP1 CYSTM1 IGFBP2 NSL1 SLC27A6
ACRV1 CYTH3 IGFBP5 NSMCE4A SLC29A1
ACSM1 D4S234E IGHM NT5C3A SLC2A1
ACSS3 DAP IGKC NTAN1 SLC2A5
ACTA2 DAPL1 IGKV1-5 NTF4 SLC37A4
ACTB DBI IHH NUDT21 SLC39A2
ACTBL3 DCBLD2 IKZF4 NUDT9 SLC4A11
ACTG2 DCHS1 IL11RA NUS1 SLC5A1
ACTR3B DCK IL15 OAS3 SLC5A3
ACTR6 DCTN5 IL17RB OASL SLC5A5
ADAMDEC1 DCTPP1 IL1B ODF4 SLC6A3
ADAMTS5 DCUN1D4 IL23A OGFOD3 SLC7A2
ADIPOR2 DCUN1D5 IL27 OGN SMAD2
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ADK DDB1 IL6 OPA3 SMC4
AEBP1 DDB2 IL8 OR10A3 SMG1
AF050199 DDR1 IMPA2 OR2AG1 SMPD2
AF052172 DDX23 ING3 OR4C15 SNIP1
AFM DDX49 INHBA OR51B5 SNRPA1
AFTPH DEFB132 INPP5A OR51I1 SNRPC
AGFG1 DERL1 INPP5B OR6F1 SNRPD3
AGR2 DFNB31 INSR OR9G9 SNX13
AGT DHCR7 INTS12 OSGEPL1 SNX19
AIPL1 DHRS11 INTS9 OSGIN2 SNX7
AKAP12 DHRS9 IRF2BP1 OSM SOAT2
AKR1A1 DHX15 ISCA1 OXTR SOBP
AKR1C1 DHX29 ISG20 P2RX4 SORBS3
AKT1 DIAPH3 ITGAE PABPC4 SOS1
AKT2 DICER1 ITGB2 PAGR1 SOX12
ALCAM DIRC1 ITGB6 PAH SOX21
ALDH5A1 DKK1 ITGB7 PAK4 SPANXD
ALDH9A1 DLAT ITLN1 PALB2 SPATA13
ALG5 DLEU2 ITM2A PARD6B SPATA18
ALMS1 DLG1 ITM2C PAX6 SPATA4
AMPD1 DLG3 ITPR2 PBK SPC25
ANKHD1 DLGAP4 ITPRIP PBX2 SPDEF
ANKRD27 DLGAP5 JAG2 PBXIP1 SPEN
ANXA3 DMRT3 JAK2 PCF11 SPHK2
ANXA4 DNAH2 JAKMIP2 PCGF3 SPOCK2
AOC1 DNAH7 KCNB1 PCK1 SPTBN2
AP2A2 DNAJB12 KCNE3 PCNA SRC
APC DNAJB5 KCNH2 PCNXL2 SREBF2
API5 DNAJC16 KCNJ16 PCOLCE SRF
APOE DNASE1L3 KCNN1 PCSK6 SRRM1
AQP10 DOCK3 KCNN3 PDCD2 SRSF3
AQP5 DPH2 KCTD1 PDE3A SSR1
AQP6 DPM1 KCTD5 PDGFA SSR2
AQP9 DPP7 KDELC1 PDGFRA SSUH2
ARAF DPYSL2 KDELR1 PDGFRB SSX2IP
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ARAP1 DRD4 KDELR2 PDP1 ST6GALNAC1
AREG DTYMK KDM4A PDSS1 STC2
ARFGEF2 DUSP2 Ki67 PDZK1 STK38
ARHGAP29 DUSP4 KIAA0125 PEBP1 STX12
ARHGDIA DUX3 KIAA0141 PEX11A STX1B
ARL14 DYNLT1 KIAA0226 PEX6 STX7
ARL6IP4 DYRK3 KIAA0368 PFAS STXBP2
ARMC1 E2F2 KIAA1009 PGAM1 STXBP6
ARNT2 ECH1 KIAA1033 PHF3 SUB1
ARPC4 EDF1 KIAA1324 PHGDH SULT1C2
ASAP1 EDN1 KIAA1551 PHKA1 SULT2B1
ASAP3 EDNRA KIAA2022 PHKA2 SUPT5H
ASF1A EDNRB KIAA4146 PI3 SUSD4
ASIP EEF1A2 KIF3A PIC3CD SUV420H1
ASPA EFCAB14 KIFC3 PIGC SV2C
ASPHD1 EFEMP2 KIT PIGR SYNM
ASS1 EFNB2 KLF12 PIK3CG SYT1
ASUN EGF KLF5 PIP5K1B SYT11
ATM EGFR KLHDC3 PITRM1 SYT13
ATP1B3 EHD1 KLHL7 PKD1 TAC3
ATP5D EHF KLK10 PKHD1 TAP1
ATP5F1 EI24 KLK6 PLA2G7 TASP1
ATP5L EIF1 KPNA3 PLAA TBCC
ATP6V0E1 EIF2AK2 KPNA6 PLAU TBP
ATP7B EIF3K KRT10 PLAUR TCF15
ATP8A2 EIF4E2 KRT12 PLCB3 TCF7L2
AUP1 EIF5 KYNU PLEC TENM3
AURKA ELF3 L1TD1 PLEK TEX30
AURKC ELF5 LAMB1 PLIN2 TFF1
AVIL EML4 LAMTOR5 PLS1 TFF3
B3GALNT1 ENC1 LARP4 PMM1 TFPI2
B3GNT2 ENOPH1 LAX1 PMP22 TGFB1
B4GALT5 ENSA LAYN PMVK THBS4
BAG3 ENTPD4 LBR PNLDC1 TIAM1
BAIAP2L1 EPB41L4A LCMT2 PNLIPRP2 TIMM10B
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BAK1 EPCAM LCTL PNMA5 TIMM17B
BASP1 EPHB2 LDB1 POFUT2 TIMP1
BAX EPHB3 LDHB POLH TIMP2
BCHE EPHB4 LGALS4 POLR3K TIMP3
BCL2A1 EPOR LGR5 POMP TKTL1
BCL2L11 ERBB3 LHB POU2AF1 TLE2
BCL2L12 ERCC8 LHX1 POU5F1 TM9SF2
BCR-ABL ERMP1 LIN28A PPAP2B TM9SF3
BEAN ESF1 LINGO1 PPAT TMCC1
BEST4 ESM1 LIPA PPCDC TMED5
BFSP1 ESR1 LIPC PPCS TMEM139
BFSP2 ESRP2 LIPG PPFIA3 TMEM14B
BGN ESYT1 LMO3 PPIC TMEM150A
BHLHE40 ETS1 LMO4 PPIE TMEM161A
BIN1 ETV1 LOC100129250 PPP1R1A TMEM259
BIRC5 EVA1A LOC149018 PPP1R1B TMEM260
BIRC6 EXOC6B LOC1720 PPP1R2 TMEM45A
BLCAP EXTL1 LOC389677 PPP1R26 TMEM50A
BLMH EYA2 LOC642236 PPP2R3C TMPRSS3
BMP8B F2R LOC646808 PPP2R5C TMSB15B
BMPR1A FAAH LOC90925 PPP2R5D TMTC1
BNIP3 FABP1 LPAR6 PPP4R4 TMX2
BOLA3 FABP7 LPCAT2 PPP6R1 TNFRSF17
BPTF FADS1 LPCAT4 PRAP1 TNS1
BRCA1 FADS2 LPHN2 PRELP TOMM40
BRCA2 FAM133A LRIG1 PRKAB1 TONSL
BRSK1 FAM135A LRIT1 PRKCH TOP1
BTN3A3 FAM155B LRRC16B PRKCI TOP2A
BTNL9 FAM174B LRRC17 PRKD3 TOX3
C11orf16 FAM19A4 LRRC59 PROC TP53
C11orf74 FAM211B LRSAM1 PROK1 TP53TG5
C12orf5 FAM217B LSAMP PRPF31 TP73
C16orf89 FAM49B LSM14A PRRX1 TPD52
C17orf45 FAM8A1 LSM3 PRSS16 TPM2
C17orf53 FANCB LSM7 PRSS22 TPP2
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C17orf70 FANCE LSM8 PRSS3 TPPP
C1orf109 FANCF LTA4H PRSS36 TPRKB
C1orf115 FANCG LTB PSAT1 TRA
C1orf159 FANCI LTK PSMB5 TRAF3IP2
C1orf198 FARP1 LUC7L2 PSMB9 TRAM1
C1orf27 FAS LY6K PSMC4 TRAPPC4
C1orf68 FASLG LY96 PSMD1 TRAPPC9
C1QTNF3 FBXL18 LZTFL1 PSMD12 TREML1
C20orf199 FCGBP MAB21L2 PSMD14 TREML2
C2orf72 FCGR3B MAD2L2 PSME4 TRIAP1
C4A FEN1 MAGEE2 PTBP1 TRIM27
C4BPA FEZ1 MAGEF1 PTCH2 TRIM49
C6orf120 FGF2 MAK PTEN TRIM58
C6orf124 FGFBP1 MAMLD1 PTGDS TRIML2
C9orf3 FGFR1OP MANF PTGS2 TRIT1
C9orf47 FGFR1OP2 MAP6D1 PTP4A1 TRMT1L
CA13 FGFR2 MAPK1 PTP4A2 TRO
CACNA1B FHL2 MAPK1IP1L PTPRN2 TRPV4
CACNG6 FILIP1 MAPK3 PTPRS TRPV6
CADM1 FJX1 MAPK8IP3 PWP2 TSPAN3
CALML3 FKBP11 MAPK9 QPRT TSPAN4
CAMK2B FKBP1B MAPKAP1 R3HDM2 TSPAN6
CAMK2N1 FKBP7 MAPKAPK2 RAB26 TSPAN7
CANX FLII MARCKS RAB27B TSR1
CAP1 FLJ41501 MARK4 RAB40B TTC31
CAP2 FLNC MATK RAB5B TTLL6
CAPN13 FLOT2 MB RAB5C TTPAL
CAPN5 FLT1 MBOAT7 RABIF TTYH1
CASC3 FMN2 MCF2L RAC1 TUBB3
CASP9 FMO1 MCL1 RAC3 TUBB4A
CASS4 FN1 MCM3 RAD23A TUBB4Q
CATSPERD FOXA2 MDC1 RAD51 TUSC3
CC2D1A FOXD4L2 MDFI RAD51AP1 UBD
CCBL1 FOXJ1 MDK RANBP1 UBE2I
CCDC130 FOXO3 MDR-1 RANGAP1 UBE2K
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CCDC135 FSCN1 MEA1 RARRES2 UBE2L3
CCDC147 FXYD6 MEAF6 RB1 UBE4B
CCDC167 FZD4 MECOM RBBP7 UBR5
CCDC19 FZD5 MEF2B RBFA UGT2B17
CCDC53 G0S2 MEGF11 RBM11 UGT8
CCDC9 G3BP1 MEST RBM39 UHRF1BP1
CCL13 GABRP METRN RCHY1 UMOD
CCL2 GAD1 METTL13 RER1 UPK1A
CCL28 GALNT10 METTL4 RFC3 UPK1B
CCM2L GAP43 MFAP2 RGL2 UQCRC2
CCNA2 GART MFSD7 RGP1 URI1
CCNG2 GATAD2A MGMT RGS19 USP14
CCT6A GCH1 MINOS1 RHOT1 USP18
CCZ1 GCHFR MKRN1 RHPN2 USP21
CD34 GCM1 MLF2 RIIAD1 UST
CD38 GDF6 MLH1 RIN1 UTP11L
CD44 GFRA1 MLX RIT1 UTP20
CD46 GGCT MMP1 RNF10 UVRAG
CD70 GGT1 MMP10 RNF13 VDR
CD97 GJB1 MMP12 RNF14 VEGFA
CDC42EP4 GLRX MMP13 RNF148 VEGFB
CDCA2 GMFB MMP16 RNF34 VEZF1
CDH12 GMPR MMP17 RNF6 VPS39
CDH19 GNA11 MMP3 RNF7 VPS52
CDH3 GNAO1 MMP7 RNF8 VPS72
CDH4 GNAZ MMP9 RNGTT VTCN1
CDH5 GNG4 MPZL1 RNPEPL1 VTI1B
CDK17 GNG7 MRPL2 ROBO1 WBP2
CDK20 GNL2 MRPL35 ROR1 WBP4
CDK5R1 GNMT MRPL49 ROR2 WDR12
CDK8 GNPDA1 MRPS12 RP13-347D8.3 WDR45B
CDKN1A GOLPH3 MRPS17 RP13-36C9.6 WDR7
CDY1 GPIHBP1 MRPS24 RPA3 WDR77
CDYL2 GPM6B MRPS9 RPL23 WIT1
CEACAM5 GPR137 MRS2 RPL29P17 WIZ
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CEACAM6 GPT2 MSH2 RPL31 WNK4
CEACAM7 GPX2 MSL1 RPL36 WNT16
CEP55 GPX3 MSMO1 RPP30 WT1
CES1 GPX8 MST1 RPS15 WTAP
CES2 GRAMD1B MT1G RPS16 WWOX
CFI GRB2 MTCP1 RPS19BP1 XBP1
CH25H GRK6 MTMR11 RPS24 XPA
CHIT1 GRM2 MTMR2 RPS28 XPO4
CHPF2 GRPEL1 MTPAP RPS4Y1 XYLT1
CHRDL1 GRSF1 MTUS1 RPS6KA2 Y09846
CHRNE GSPT1 MTX1 RPSA YBX1
CHST6 GSTM2 MUS81 RRAGC YIPF3
CHTOP GSTT1 MUTYH RRBP1 YIPF6
CIAPIN1 GTF2E1 MXD1 RRN3 YLPM1
CIB1 GTF2F2 MXI1 RSL24D1 YWHAE
CIB2 GTF2H5 MYBPC1 RSU1 YWHAZ
CIITA GTPBP4 MYC RTN4R ZBTB11
CILP GUCY1B3 MYCBP RXRB ZBTB16
CITED2 GYG1 MYL9 RYBP ZBTB8A
CKLF GYPC MYO1D RYR3 ZC3H13
CLCA1 GZMB MYOM1 S100A10 ZCCHC8
CLCNKB GZMK NANOS1 S100A4 ZEB2
CLDN10 H2AFX NASP S100P ZFHX4
CLIP1 H3F3A NBEA SAMD4B ZFP91
CNDP1 HAP1 NBL1 SASH1 ZFR2
CNKSR3 HBG2 NBN SCAMP3 ZKSCAN7
CNN2 HDAC1 NCAM1 SCARF1 ZMYND11
CNOT8 HDAC2 NCAPD2 SCG2 ZNF106
CNTFR HECTD4 NCAPG SCGB1C1 ZNF12
cofilin1 HES1 NCAPH SCGB3A1 ZNF124
COL10A1 HEY1 NCKAP5 SCNM1 ZNF148
COL21A1 HHIPL2 NCOA1 SCO2 ZNF155
COL3A1 HIF1A NCOR2 SCUBE2 ZNF180
COL4A4 HIP1R NCR2 SDF2L1 ZNF200
COL4A6 HIPK1 NCSTN SEC14L2 ZNF292
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COL6A1 HIST1H1C NDRG2 SELT ZNF337
COL7A1 HK2 NDST1 SEMA3A ZNF432
COX8A HLAA NDUFA12 SENP3 ZNF467
CPD HLADMB NDUFA9 SENP6 ZNF48
CPE HLADOB NDUFAB1 SEPN1 ZNF503
CPEB1 HMBOX1 NDUFAF4 SERPINB6 ZNF521
CRCT1 HMGCS1 NDUFB4 SERPIND1 ZNF569
CREB5 HMGCS2 NDUFS5 SERPINF1 ZNF644
CRYAB HMGN1 NEBL SERTAD4 ZNF71
CRYBB1 HMOX2 NETO2 SETBP1 ZNF711
CRYL1 HNRNPA1 NEUROD2 SF3A3 ZNF74
CRYM HNRNPUL2 NFE2 SF3B4 ZNF76
CSE1L HOPX NFE2L3 SGCB ZNF780B
CSPP1 HOXA5 NFIB SGCG ZYG11A
CSRP1 HOXB6 NFKBIB SGPP1
CSRP3 HPN NFS1 SH3PXD2A
Table A.8: Genes chosen most commonly by studies in review, listed by number of
papers selecting each gene. Gene function and links to cancer obtained via cursory
literature search.
Gene
Symbol
Number
of
studies
Function Expression links to can-
cer in literature
AGR2 4 Cell migration and
growth
Prostate, breast, ovar-
ian, pancreatic
MUTYH 3 Oxidative DNA damage
repair
Colorectal
AKAP12 3 Subcellular compart-
mentation of PKA
Colorectal, lung,
prostate
TP53 3 Cell cycle regulation Breast
TOP2A 3 Required for DNA repli-
cation
Breast, prostate, ovar-
ian
FOXA2 3 Liver-specific transcrip-
tion factor
Lung, prostate
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SRC 2 Regulation of cell
growth
Colon, liver, lung,
breast, pancreatic
SIVA1 2 Pro-apoptotic protein Many cancers
ALDH9A1 2 Aldehyde dehydroge-
nase
Many cancers
LGR5 2 Associated with stem
cells
Cancer stem cells
EHF 2 Epithelial differentiation
and proliferation
Prostate
BAX 2 Apoptotic activator Colon, breast, prostate,
gastric, leukaemia
CES2 2 Intestine drug clearance Colorectal
CPE 2 Synthesis of hormones
and neurotransmitters
FGFBP1 2 Cell proliferation, differ-
entiation and migration
Colorectal, pancreatic
TUBB4A 2 Component of micro-
tubules
ZNF12 2 Transcription regulation
RBM39 2 Steroid hormone
receptor-mediated
transcription
RFC3 2 Required for DNA repli-
cation
GNPDA1 2 Triggers calcium oscilla-
tions in mammalian eggs
ANXA3 2 Regulation of cellular
growth
Prostate, ovarian
NFIB 2 Activates transcription
and replication
Breast
ACTR3B 2 Actin cyctoskeleton or-
ganisation
Lung
YWHAE 2 Mediates signal trans-
duction
Lung, endometrial
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Table A.8: (continued)
CYP51A1 2 Drug metabolism and
lipid synthesis
HMGCS1 2 Cholesterol synthesis
and ketogenesis
ZMYND11 2 Transcriptional repres-
sor
FADS2 2 Regulates unsaturation
of fatty acids
SNX7 2 Family involved in intra-
cellular trafficking
ARHGDIA 2 Regulates the
GDP/GTP exchange
reaction of the Rho
proteins
Prostate, lung,
NDST1 2 Inflammatory response Prostate, breast
AOC1 2 Catalyses degredation of
such as histamine and
spermidine
DAP 2 Positive mediator of pro-
grammed cell death
ERCC8 2 Transcription-coupled
nucleotide excision
repair
GUCY1B3 2 Catalyzes conversion of
GTP to the second mes-
senger cGMP
HDAC1 2 Control of cell prolifera-
tion and differentiation
Prostate, breast, colorec-
tal, gastric
HDAC2 2 Transcriptional regula-
tion and cell cycle pro-
gression
Cervical, gastric, col-
orectal
IGFBP5 2 Cell proliferation, differ-
entiation, survival, and
motility
Breast
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Table A.8: (continued)
IL6 2 Transcriptional inflam-
matory response, B cell
maturation
Many cancers
LSAMP 2 Neuronal surface glyco-
protein
Osteosarcoma
MDK 2 Cell growth, migration,
angiogenesis
Many cancers
MYCBP 2 Stimulates the activa-
tion of E box-dependent
transcription
S100A10 2 Transport of neurotrans-
mitters
Colorectal, lung, breast
SLC1A3 2 Glutamate transporter
NCOA1 2 Stimulates hormone-
dependent transcription
Breast, prostate
TIAM1 2 Modulates the activity
of Rho GTP-binding
proteins
Many cancers
VEGFA 2 Angiogenesis, cell
growth, cell migration,
apoptosis
Many cancers
RPL36 2 Component of ribosomal
60S subunit
LBR 2 Anchors lamina and het-
erochromatin to the nu-
clear membrane
ABCB1 2 ATP-dependent drug ef-
flux pump for xenobiotic
compounds
Many cancers
FASLG 2 Required for triggering
apoptosis in some cell
types
Many cancers
TIMP1 2 Extracellular matrix,
proliferation, apoptosis
Many cancers
161
Table A.8: (continued)
FN1 2 Cell adhesion, motility,
migration processes
Many cancers
TGFB1 2 Proliferation, differenti-
ation, adhesion, migra-
tion
Prostate, breast, colon,
lung, bladder
XPA 2 DNA excision repair Many cancers
ABCB10 2 Mitochondrial ATP-
binding cassette trans-
porter
POLH 2 Polymerase capable of
replicating UV-damaged
DNA for repair
ITGAE 2 Adhesion, intestinal in-
traepithelial lymphocyte
activation
ZNF200 2 Zinc finger protein
COL3A1 2 Collagen type III, occur-
ring in most soft connec-
tive tissues
ACKR3 2 G-protein coupled recep-
tor
EPHB3 2 Mediates developmental
processes
Lung, colorectal
NBN 2 Double-strand DNA re-
pair, cell cycle control
PCF11 2 May be involved in Pol
II release following poly-
merisation
DFNB31 2 Sterocilia elongation,
actin cystoskeletal
assembly
BRCA2 2 Double-strand DNA re-
pair
Breast, ovarian
AADAC 2 Arylacetamide deacety-
lase
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Table A.8: (continued)
CD38 2 Glucose-induced insulin
secretion
Leukaemia
CHIT1 2 Involved in degrada-
tion of chitin-containing
pathogens
CXCR4 2 Receptor specific for
stromal-derived-factor-
1
Breast, glioma, kidney,
prostate
EFNB2 2 Mediates developmental
processes
MECOM 2 Apoptosis, development,
cell differentiation, pro-
liferation
Leukaemia
FILIP1 2 Controls neocortical cell
migration
Ovarian
HSPB7 2 Heat shock protein
LRIG1 2 Regulator of signaling
by receptor tyrosine ki-
nases
Glioma
MMP1 2 Breakdown of extracellu-
lar matrix
Gastric, breast
PSAT1 2 Phosphoserine amino-
transferase
SDF2L1 2 Part of endoplasmic
reticulum chaperone
complex
TCF15 2 Regulation of patterning
of the mesoderm
EPHB2 2 Contact-dependent bidi-
rectional signaling be-
tween cells
Colorectal
ETS1 2 Involved in stem cell
development, cell senes-
cence and death
Many cancers
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Table A.8: (continued)
TRIM27 2 Male germ cell differen-
tiation
Ovarian, endometrial,
prostate
MARK4 2 Mitosis, cell cycle con-
trol
Glioma
B4GALT5 2 Biosynthesis of glycocon-
jugates and saccharides
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Figure B.1: Boxplots of hyperparameter values selected by GPS1 fitted using 100
generated synthetic data sets. The generating hyperparameters are marked in grey.
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Figure C.1: Experiment 3. Mean concordance index values as generating noise
variance hyperparameter and number of training samples are varied. Fitted using
Coxph
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Figure D.1: Experiment 1IR. Frequency plots of variables selected during feature
selection for a range of models. a): StepCoxph b): FilterCoxph1 c): FilterCoxph2
d): Glmnet e): GPSBICBackwards f): GPSBICForwards
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Figure D.2: Experiment 1IR. Boxplots of variable importance reported for each
feature of random forest models. a): RF b): RSF
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Figure D.3: Experiment 1IR. Boxplots of marginalised probability reported for each
feature of GPS3SqExpRSFS.
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(f) 400 feature subsets
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Figure D.4: Experiment 2R. Boxplots plots of GPS3SqExpRSFS model weightings
for the first 10 repeats, using varing numbers of feature subsets.
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Figure D.5: Experiment 2R. Boxplots of concordance index values for ensemble
predictions as the number of feature subsets are varied. Models are GPS3SqExpRSFS
using exp(-BIC) wighting and GPS3SqExpRSFS using uniform weighting of models.
Each boxplot represents 99 repeats. GPS3SqExpRSFS was applied to each repeat
for varying numbers of feature subsets, using the specified weighting for generating
ensemble predictions.
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Figure D.6: Experiment 3R. Results of running GPS3 with RSFS on synthetic data
with changing total number of dimensions and number non-informative dimensions.
Boxplots of concordance index of the model predictions as the total dimensionality
(y axis) and the number of non-informative dimensions (x axis) changes.
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